阅读说明：本技术 异色满基化合物的盐及其结晶形式、制备方法、治疗用途和药物组合物 (Salts of isochroman-based compounds, crystalline forms thereof, processes for their preparation, their use in therapy and pharmaceutical compositions containing them ) 是由 N·N·博格尔 T·哈希祖卡 R·J·普赖特科 J·R·史努尼安 H·S·威尔金森 张海涛 于 2020-03-13 设计创作，主要内容包括：本公开文本涉及(R)-1-(8-氟异色满-1-基)-N-甲基甲胺的盐、其结晶形式及其制备方法,所述盐、其结晶形式可用于治疗CNS障碍。(The present disclosure relates to salts of (R) -1- (8-fluoroisochroman-1-yl) -N-methyl methylamine, crystalline forms thereof, which are useful for treating CNS disorders, and processes for their preparation.)

1. A salt, said salt being:

(R) -1- (8-fluoroisochroman-1-yl) -N-methyl methylamine phosphate (compound 1 phosphate);

(R) -1- (8-fluoroisochroman-1-yl) -N-methylmethanamine l-tartrate (compound 1 l-tartrate);

(R) -1- (8-fluoroisochroman-1-yl) -N-methylmethanamine d-tartrate (compound 1 d-tartrate);

(R) -1- (8-fluoroisochroman-1-yl) -N-methyl methylamine fumarate (compound 1 fumarate);

(R) -1- (8-fluoroisochroman-1-yl) -N-methyl methylamine citrate (compound 1 citrate);

(R) -1- (8-fluoroisochroman-1-yl) -N-methyl methylamine succinate (compound 1 succinate);

(R) -1- (8-fluoroisochroman-1-yl) -N-methyl methylamine glutarate (compound 1 glutarate);

(R) -1- (8-fluoroisochroman-1-yl) -N-methylmethanamine levomalate (compound 1 levomalate);

(R) -1- (8-fluoroisochroman-1-yl) -N-methylmethanemethanesulfonate (compound 1 benzenesulfonate); or

(R) -1- (8-fluoroisochroman-1-yl) -N-methylmethanamine p-toluenesulfonate (compound 1 p-toluenesulfonate);

or a hydrate or solvate thereof.

2. The salt of claim 1, wherein the salt is in a solid form.

3. The salt of claim 1 or 2, wherein the salt is (R) -1- (8-fluoroisochroman-1-yl) -N-methyl methylamine phosphate (compound 1 phosphate).

4. The salt of claim 3, wherein the compound 1 phosphate salt is crystalline.

5. The salt of claim 4, wherein the salt has a characteristic XRPD peak, expressed in 2 θ, selected from 4.6 ° ± 0.2 °, 9.1 ° ± 0.2 ° and 18.2 ° ± 0.2 °.

6. The salt according to claim 4, wherein the salt has at least one characteristic XRPD peak, expressed in 2 θ, selected from 4.6 ° ± 0.2 °, 9.1 ° ± 0.2 °, 15.7 ° ± 0.2 °, 18.2 ° ± 0.2 °, 22.3 ° ± 0.2 °, 22.8 ° ± 0.2 ° and 24.8 ° ± 0.2 °.

7. The salt according to claim 4, wherein the salt has at least two characteristic XRPD peaks expressed in 2 θ selected from 4.6 ° ± 0.2 °, 9.1 ° ± 0.2 °, 15.7 ° ± 0.2 °, 18.2 ° ± 0.2 °, 22.3 ° ± 0.2 °, 22.8 ° ± 0.2 ° and 24.8 ° ± 0.2 °.

8. The salt according to claim 4, wherein the salt has at least three characteristic XRPD peaks expressed in 2 θ selected from 4.6 ° ± 0.2 °, 9.1 ° ± 0.2 °, 15.7 ° ± 0.2 °, 18.2 ° ± 0.2 °, 22.3 ° ± 0.2 °, 22.8 ° ± 0.2 ° and 24.8 ° ± 0.2 °.

9. The salt of any of claims 4-8, wherein the salt has an XRPD pattern with characteristic peaks substantially as shown in figure 6 (figure 6).

10. The salt of any one of claims 4-9, wherein the salt has an endothermic peak at a temperature of about 213 ℃.

11. The salt of any of claims 4-10, wherein the salt has a DSC thermogram substantially as depicted in figure 7 (figure 7).

12. The salt of any one of claims 4-11, wherein the salt has a DVS isotherm substantially as depicted in figure 9 (figure 9).

13. A pharmaceutical composition comprising the salt of any one of claims 1-12 and a pharmaceutically acceptable excipient.

14. A method for treating a neurological or psychiatric disease or disorder in a subject in need thereof, the method comprising administering to the subject an effective amount of a salt according to any one of claims 1-12 or a pharmaceutical composition according to claim 13.

15. The method of claim 14, wherein the neurological or psychiatric disease or disorder is depression, bipolar disorder, pain, schizophrenia or other psychiatric disease, obsessive-compulsive disorder, addiction, social disorders, attention deficit hyperactivity disorder, anxiety disorders, movement disorders, epilepsy, autism, or cognitive diseases or disorders.

16. The method of claim 14, wherein the neurological or psychiatric disease or disorder is depression.

17. The method of claim 16, wherein the depression is Treatment Resistant Depression (TRD), Major Depressive Disorder (MDD), unipolar depression, bipolar depression, or depression associated with another disease or disorder.

18. The method of claim 14, wherein the neurological disease or disorder is selected from alzheimer's disease and parkinson's disease.

19. The method of claim 18, wherein the alzheimer's disease is alzheimer's disease with a surge, alzheimer's disease surge or alzheimer's disease with a surge attack.

20. A method of treating a surge in a subject in need thereof, the method comprising administering to the subject an effective amount of a salt according to any of claims 1-12 or a pharmaceutical composition according to claim 13.

21. A method of treating a stimulus associated with a neurological or psychiatric disease or disorder in a subject in need thereof, the method comprising administering to the subject an effective amount of a salt according to any one of claims 1-12 or a pharmaceutical composition according to claim 13.

22. A process for the preparation of (R) -1- (8-fluoroisochroman-1-yl) -N-methyl methylamine phosphate (compound 1 phosphate) having the structure:

the process comprises reacting (R) -1- (8-fluoroisochroman-1-yl) -N-methylmethanamine (compound 1) having the structure:

with phosphoric acid.

23. A process for the preparation of (R) -1- (8-fluoroisochroman-1-yl) -N-methylmethanamine (compound 1), comprising reacting (R) -1- (8-fluoroisochroman-1-yl) -N-methylmethanamine dibenzoyl-levotartrate (compound 1 dibenzoyl-levotartrate) having the structure:

With B1, wherein B1 is a base.

24. A process for the preparation of (R) -1- (8-fluoroisochroman-1-yl) -N-methylmethanamine dibenzoyl-levotartrate (compound 1 dibenzoyl-levotartrate), which comprises reacting 1- (8-fluoroisochroman-1-yl) -N-methylmethanamine (racemic compound 1) having the structure:

with dibenzoyl-levotartaric acid in the presence of S3, wherein S3 is a solvent.

25. A compound 1 phosphate salt prepared by the process according to claim 22, wherein the compound 1 phosphate salt is crystalline.

Technical Field

The present application relates to salts of (R) -1- (8-fluoroisochroman-1-yl) -N-methyl methylamine (compound 1) and crystalline forms, processes for their preparation, therapeutic uses and pharmaceutical compositions thereof.

Background

Central nervous system diseases and disorders affect a wide range of people with varying degrees of severity. Neurological and psychiatric diseases and disorders include major depressive disorder, schizophrenia, bipolar disorder, Obsessive Compulsive Disorder (OCD), panic disorder, and post-traumatic stress disorder (PTSD), among others. These diseases and disorders affect a person's thought, mood, behavior, and social interactions, and may significantly impair everyday functioning. See, e.g., the Diagnostic and Statistical Manual of Mental Disorders, 4 th edition, American Psychiatric Association (2000) ("DSM-IV-TR"); the Diagnostic and Statistical Manual of Mental Disorders, 5 th edition, American Psychiatric Association (2013) ("DSM-5"). In addition, neuropsychiatric symptoms such as apathy, depression, anxiety, cognitive impairment, psychosis, aggression, agitation, impulse control and sleep disruption are now considered the core impairment of neurological diseases and disorders such as alzheimer's disease and parkinson's disease.

A variety of drugs are currently being developed to treat CNS disorders. For example, (R) -1- (8-fluoroisochroman-1-yl) -N-methyl methylamine, which is reported in U.S. patent No. 10,196,403, incorporated herein by reference in its entirety, may be used to treat CNS disorders. Salts and novel forms of (R) -1- (8-fluoroisochroman-1-yl) -N-methyl methylamine are needed to facilitate the manufacture of safe, effective and high quality pharmaceutical products.

Disclosure of Invention

Provided herein are salts of (R) -1- (8-fluoroisochroman-1-yl) -N-methyl methylamine and crystalline forms thereof. The compound (R) -1- (8-fluoroisochroman-1-yl) -N-methylmethanamine (compound 1) has the following structure:

(Compound 1).

In some embodiments, a process for preparing (R) -1- (8-fluoroisochroman-1-yl) -N-methylmethanamine (compound 1), or a salt or crystalline form thereof, is provided.

In some embodiments, methods of treating CNS disorders using (R) -1- (8-fluoroisochroman-1-yl) -N-methylmethanamine (compound 1), or a salt or crystalline form thereof, are provided.

In some embodiments, there is provided a pharmaceutical composition comprising (R) -1- (8-fluoroisochroman-1-yl) -N-methylmethanamine (compound 1), or a salt or crystalline form thereof, as described herein, and one or more pharmaceutically acceptable excipients.

Drawings

Figure 1 shows an X-ray powder diffraction (XRPD) pattern of compound 1 as the hydrochloride salt form HA.

Figure 2 shows a Differential Scanning Calorimetry (DSC) thermogram of compound 1 hydrochloride form HA.

Figure 3 shows a thermogravimetric analysis (TGA) thermogram of HA as the hydrochloride salt of compound 1.

Figure 4 shows the Dynamic Vapor Sorption (DVS) isotherm of compound 1 hydrochloride form HA.

Figure 5 shows an XRPD pattern of compound 1 hydrochloride form HB.

Figure 6 shows the XRPD pattern of compound 1 phosphate.

Figure 7 shows the DSC thermogram of compound 1 phosphate.

Figure 8 shows a TGA thermogram of compound 1 phosphate.

Figure 9 shows DVS isotherms of compound 1 phosphate.

Figure 10 shows an XRPD pattern of compound 1, levotartrate form LA.

Figure 11 shows the DSC thermogram of compound 1 levotartrate form LA.

Figure 12 shows a TGA thermogram of compound 1 levotartrate form LA.

Figure 13 shows DVS isotherms of compound 1 levotartrate form LA.

Figure 14 shows an XRPD pattern of compound 1, levotartrate form LB.

Figure 15 shows DVS isotherms for compound 1 l-tartrate form LB.

Figure 16 shows the XRPD pattern of compound 1 levotartrate form LC.

Figure 17 shows a DSC thermogram for compound 1 levotartrate form LC.

Figure 18 shows a TGA thermogram of compound 1 levotartrate form LC.

Figure 19 shows DVS isotherms of compound 1 l-tartrate form LC.

Figure 20 shows the XRPD pattern of compound 1 dextrotartrate.

Figure 21 shows DVS isotherms of compound 1 d-tartrate.

Figure 22 shows an XRPD pattern of compound 1 fumarate form FA.

Figure 23 shows the DSC thermogram for compound 1 fumarate salt form FA.

Figure 24 shows a TGA thermogram of compound 1 fumarate form FA.

Figure 25 shows DVS isotherms of compound 1 fumarate form FA.

Figure 26 shows an XRPD pattern of compound 1 fumarate form FB.

Figure 27 shows a DSC thermogram for compound 1 fumarate salt form FB.

Figure 28 shows a TGA thermogram of compound 1 fumarate salt form FB.

Figure 29 shows DVS isotherms for compound 1 fumarate form FB.

Figure 30 shows the XRPD pattern of compound 1 citrate.

Figure 31 shows the DSC thermogram of compound 1 citrate salt.

Figure 32 shows a TGA thermogram of compound 1 citrate salt.

Figure 33 shows DVS isotherms of compound 1 citrate salt.

Figure 34 shows the XRPD pattern of compound 1 succinate salt.

Figure 35 shows the DSC thermogram of compound 1 succinate salt.

Figure 36 shows a TGA thermogram of compound 1 succinate.

Figure 37 shows DVS isotherms of compound 1 succinate salt.

Figure 38 shows the XRPD pattern of compound 1 glutarate salt.

Figure 39 shows DVS isotherms of compound 1 glutarate.

Figure 40 shows an XRPD pattern of l-malate salt of compound 1.

Figure 41 shows the DSC thermogram of l-malate salt of compound 1.

Figure 42 shows a TGA thermogram of compound 1 levorotatory malate.

Figure 43 shows DVS isotherms of l-malate salt of compound 1.

Figure 44 shows the XRPD pattern of compound 1 benzenesulfonate.

Figure 45 shows the DSC thermogram of compound 1 benzenesulfonate.

Figure 46 shows a TGA thermogram of the benzenesulfonate of compound 1.

Figure 47 shows DVS isotherms for compound 1 benzenesulfonate.

Detailed Description

The methods of the present disclosure relate to the use of the compounds and compositions disclosed herein for the treatment of neurological or psychiatric diseases, disorders, or injuries. In some embodiments, the neurological or psychiatric disease or disorder is depression, bipolar disorder, pain, schizophrenia, obsessive-compulsive disorder, neurostimulation, addiction, social disorders, attention deficit hyperactivity disorder, anxiety disorders, movement disorders, epilepsy, autism, alzheimer's disease, parkinson's disease, or cognitive impairment. In one embodiment, the disease or disorder is depression, particularly Treatment Resistant Depression (TRD), Major Depressive Disorder (MDD), unipolar depression, bipolar depression, or depression associated with another disease or disorder. In some embodiments, the impairment of neurological diseases or disorders such as alzheimer's disease and parkinson's disease includes neuropsychiatric symptoms such as apathy, depression, anxiety, cognitive impairment, psychosis, aggression, agitation, impulse control disorders, and/or sleep disorders.

The description herein sets forth details to provide an understanding of various embodiments of the disclosure, and is made with an understanding of the following facts: the disclosure provided is an example of the claimed subject matter and is not intended to limit the claims to the particular embodiments. Thus, particular embodiments disclosed herein may be combined with other particular embodiments disclosed herein, including particular embodiments under various headings provided for convenience and organization and should not be construed as limiting the claims in any way.

All published documents cited herein are incorporated by reference herein in their entirety.

Defining:

unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art.

As used herein, the singular forms "a", "an" and "the" are intended to include the plural forms as well, unless the context clearly indicates otherwise.

As used herein, unless otherwise specified, the term "about" is used in connection with a value or range of values provided to describe a particular solid form (e.g., a particular temperature or range of temperatures, such as to describe a melting, dehydrating, or glass transition; a change in mass, such as a change in mass as a function of temperature or humidity) (ii) a With respect to solvent or water content, for example, by mass or percentage; or peak position, e.g. by¹³C NMR, DSC, TGA, and XRPD), indicates that the values or ranges of values may deviate to the extent deemed reasonable by one of ordinary skill in the art while still describing the particular solid form. In particular, the term "about" when used in this context indicates that a value or range of values can vary by 5%, 4%, 3%, 2%, 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, or 0.1% of the recited value or range of values while still describing the particular solid form. In some embodiments, the values may vary by about 5%. The term "about" when used in reference to a value of 2 θ degrees refers to ± 0.3 degrees 2 θ or ± 0.2 degrees 2 θ. In some embodiments, "about" refers to a value of ± 0.2 degrees 2 theta in degrees 2 theta. In some embodiments, "about" refers to a temperature of ± 3 ℃.

As used herein, the phrase "alkali metal bicarbonate" used alone or in combination with other terms refers to a compound having the formula M (HCO)₃) Wherein M refers to an alkali metal (e.g., lithium, sodium, or potassium). Examples of alkali metal bicarbonate salts include, but are not limited to, lithium bicarbonate, sodium bicarbonate, and potassium bicarbonate.

As used herein, the phrase "alkali metal alkoxide" used alone or in combination with other terms refers to a base having the formula M (O-alkyl), wherein M refers to an alkali metal (e.g., lithium, sodium, or potassium). Examples of alkali metal alkoxides include, but are not limited to, lithium alkoxides, sodium alkoxides, and potassium alkoxides.

As used herein, the phrase "metal hydroxide base" used alone or in combination with other terms refers to a base having the formula MOH, wherein M refers to a metal, such as an alkali metal (e.g., lithium, sodium, or potassium). Examples of alkali metal hydroxide bases include, but are not limited to, lithium hydroxide, sodium hydroxide, and potassium hydroxide.

As used herein, the terms "comprises" and "comprising," or grammatical variants thereof, are to be taken as specifying the stated features, integers, steps, or components, but do not preclude the addition of one or more additional functions, integers, steps, components, or groups thereof. These terms encompass the term "consisting of … …".

The expressions "ambient temperature" and "room temperature" as used herein are understood in the art and generally refer to a temperature (e.g., reaction temperature) that is about the temperature of the room in which the reaction is conducted, e.g., from about 20 ℃ to about 30 ℃.

As used herein, the term "amorphous" or "amorphous form" is intended to mean that the substance, component, or product in question is not crystalline, as determined, for example, by XRPD; or wherein the substance, component or product in question is not birefringent when viewed under a microscope. For example, amorphous essentially means a random repeating arrangement of molecules or a lack of long range order of crystals, i.e., the amorphous form is amorphous. The amorphous form does not show a defined x-ray diffraction pattern with sharp maxima. In certain embodiments, a sample comprising an amorphous form of a substance may be substantially free of other amorphous forms and/or crystalline forms. For example, amorphous material can be identified by XRPD spectroscopy in the absence of readily distinguishable reflections.

As used herein, the term "chemical purity" or "purity" refers to a measure of the purity of a compound. In some embodiments, the compounds described herein can be isolated in at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99% purity. In some embodiments, the compounds described herein can be isolated in greater than about 90% enantiomeric purity. In some embodiments, the compounds described herein can be isolated in greater than about 95% enantiomeric purity. In some embodiments, the compounds described herein can be isolated in greater than about 99% enantiomeric purity. The measurement results can be determined by methods well known in the art, e.g., by elemental analysis, column chromatography, NMR spectroscopy, and the like.

As used herein, the term "crystalline" or "crystalline form" refers to a crystalline solid form of a compound, including but not limited to single or multicomponent crystalline forms, including, for example, solvates, hydrates, clathrates, and co-crystals. For example, crystalline means having a regular repeating and/or ordered arrangement of molecules, and having a distinguishable crystal lattice. The term "crystalline form" means a certain lattice configuration of a crystalline substance. Different crystalline forms of the same substance typically have different crystal lattices (e.g., unit cells), often have different physical properties due to their different crystal lattices, and in some cases have different water or solvent contents. The different crystal lattices may be identified by solid state characterization methods, such as by X-ray powder diffraction (XRPD). Other characterization methods such as Differential Scanning Calorimetry (DSC), thermogravimetric analysis (TGA), Dynamic Vapor Sorption (DVS), etc. further help identify the crystalline form and help determine stability and solvent/water content.

As used herein, the term "percent crystallinity" or "crystalline purity" means the percentage of crystalline form in a formulation or sample that may contain other forms, such as an amorphous form of the same compound or at least one other crystalline form of the compound or a mixture thereof. In some embodiments, the crystalline form may be isolated in a purity of at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99%. In some embodiments, the crystalline form may be isolated in greater than about 90% purity. In some embodiments, the crystalline form may be isolated in greater than about 95% purity. In some embodiments, the crystalline form may be isolated in greater than about 99% purity.

As used herein, "delaying the development of" a disorder refers to delaying, impeding, slowing, stabilizing, and/or delaying the development of the disorder. The delay may be of varying lengths of time depending on the history of the disease and/or the individual being treated.

As used herein, the term "disorder" or a specifically identified disorder disclosed herein (e.g., CNS disorder) refers to a disorder as defined in the Fifth Edition of the Diagnostic and Statistical Manual of Mental Disorders, the Fifth Edition, DSM-5.

As used herein, the term "enantiomeric purity" refers to a measure of the purity of a chiral compound. In some embodiments, the compounds described herein can be separated in an enantiomeric purity of at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99%. In some embodiments, the compounds described herein can be isolated in greater than about 99% enantiomeric purity. In some embodiments, the compounds described herein can be isolated in greater than about 90% enantiomeric purity. In some embodiments, the compounds described herein can be isolated in greater than about 95% enantiomeric purity. The measurement results can be determined by methods well known in the art, such as by specific rotation, chiral column chromatography, NMR spectroscopy, and the like.

The term "hydrate" as used herein refers to solid forms (e.g., crystalline forms) of compound 1 and salts thereof that include water. The water in the hydrate may be present in a stoichiometric amount with respect to the amount of salt in the solid, or may be present in different amounts as may be found in connection with channel hydrates.

The reactions of the methods described herein can be carried out in a suitable solvent that can be readily selected by one skilled in the art of organic synthesis. Suitable solvents can be substantially non-reactive with the starting materials (reactants), intermediates, or products at the temperatures at which the reaction is carried out (e.g., can be at temperatures in the range from the freezing point of the solvent to the boiling point of the solvent). A given reaction may be carried out in one solvent or a mixture of more than one solvent. Depending on the particular reaction step, a suitable solvent may be selected for the particular reaction step. In some embodiments, the reaction may be carried out in the absence of a solvent, such as when at least one of the reagents is a liquid or a gas. As used herein, the term "organic solvent" refers to a carbon-based solvent (i.e., they contain carbon in their structure) used to dissolve or disperse one or more compounds described herein.

Suitable solvents may include halogenated solvents such as carbon tetrachloride, bromodichloromethane, dibromochloromethane, bromoform, chloroform, bromochloromethane, dibromomethane, butyl chloride, dichloromethane (methylene chloride), tetrachloroethylene, trichloroethylene, 1,1, 1-trichloroethane, 1,1, 2-trichloroethane, 1, 1-dichloroethane, 2-chloropropane, 1,1, 1-trifluorotoluene, 1, 2-dichloroethane, 1, 2-dibromoethane, hexafluorobenzene, 1,2, 4-trichlorobenzene, 1, 2-dichlorobenzene, chlorobenzene, fluorobenzene, mixtures thereof, and the like.

Suitable solvents may include ether solvents including dimethoxymethane, tetrahydrofuran, 1, 3-dioxane, 1, 4-dioxane, furan, Tetrahydrofuran (THF), diethyl ether, ethylene glycol dimethyl ether, ethylene glycol diethyl ether, diethylene glycol dimethyl ether (diglyme), diethylene glycol diethyl ether, triethylene glycol dimethyl ether, anisole, t-butyl methyl ether, mixtures thereof, and the like.

Suitable solvents may include protic solvents (e.g., polar protic solvents), which may include, for example, but are not limited to, water, methanol, ethanol, 2-nitroethanol, 2-fluoroethanol, 2,2, 2-trifluoroethanol, ethylene glycol, 1-propanol, 2-methoxyethanol, 1-butanol, 2-butanol, isobutanol, tert-butanol, 2-ethoxyethanol, diethylene glycol, 1-pentanol, 2-pentanol or 3-pentanol, neopentyl alcohol, tert-pentanol, diethylene glycol monomethyl ether, diethylene glycol monoethyl ether, cyclohexanol, benzyl alcohol, phenol, or glycerol.

Suitable solvents may include aprotic solvents, which may include, for example, but are not limited to, N-Dimethylformamide (DMF), N-Dimethylacetamide (DMA), 1, 3-dimethyl-3, 4,5, 6-tetrahydro-2 (1H) -pyrimidinone (DMPU), 1, 3-dimethyl-2-imidazolidinone (DMI), N-methylpyrrolidone (NMP), formamide, N-methylacetamide, N-methylformamide, acetonitrile, dimethyl sulfoxide, propionitrile, ethyl formate, methyl acetate, hexachloroacetone, acetone, methyl ethyl ketone, ethyl acetate, sulfolane, N-dimethylpropionamide, tetramethylurea, nitromethane, nitrobenzene, or hexamethylphosphoramide.

Suitable solvents may include hydrocarbon solvents including benzene, cyclohexane, pentane, hexane, toluene, cycloheptane, methylcyclohexane, heptane, ethylbenzene, m-xylene, o-xylene or p-xylene, octane, indane, nonane or naphthalene.

As used herein, the term "peak" or "characteristic peak" refers to a reflection having a relative height/intensity of at least about 3% of the maximum peak height/intensity.

As used herein, "pharmaceutically acceptable" or "physiologically acceptable" refers to compounds (e.g., solid forms), compositions, dosage forms, and other materials that can be used to prepare pharmaceutical compositions suitable for veterinary or human pharmaceutical use.

The term "pharmaceutically acceptable excipient" refers to a non-toxic binder, filler, adjuvant, carrier, excipient, glidant, sweetener, diluent, preservative, dye/colorant, flavor enhancer, surfactant, wetting agent, dispersant, suspending agent, stabilizer, isotonic agent, solvent, emulsifier, anti-caking agent, flavoring agent, drying agent, plasticizer, vehicle, disintegrant, or lubricant that does not destroy the pharmacological activity of the compound with which it is formulated. Pharmaceutically acceptable excipients that may be used in the composition include ion exchangers, alumina, aluminum stearate, lecithin, serum proteins (such as human serum albumin), buffer substances (such as phosphates), glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes (such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts), silica sol, magnesium trisilicate, polyvinylpyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene block polymers, polyethylene glycol, and wool fat.

As used herein, "prevention" or "preventing" refers to a regimen that protects against the onset of a disorder such that the clinical symptoms of the disorder do not develop. Thus, "preventing" relates to administering a therapy to a subject prior to detectable signs of disease in the subject, including administering a compound disclosed herein (e.g., administering a compound disclosed herein to a subject in the absence of a detectable syndrome of the disorder). The subject may be at risk for developing the disorder. As used herein, a "at-risk" subject is a human at risk for developing a disorder to be treated. This may be indicated, for example, by one or more risk factors, which are measurable parameters associated with the development of the disorder and known in the art.

The preparation of the compounds may involve the protection and deprotection of various chemical groups. The need for protection and deprotection, and the choice of an appropriate Protecting Group (PG) can be readily determined by those skilled in the art. Chemical reactions of protecting Groups can be found, for example, in Wuts and Greene, Greene's Protective Groups in Organic Synthesis, 4 th edition, John Wiley & Sons: New York,2006, which is incorporated herein by reference in its entirety. The preparation of the compounds may also include a Leaving Group (LG), which is a molecular fragment that leaves upon cleavage of the bond. The leaving group may be an anion or a neutral fragment and is capable of stabilizing the additional electron density resulting from bond cleavage. Typical leaving groups are halides (e.g., Cl, Br, and I) and sulfonates (e.g., p-Toluenesulfonate (TSO), trifluoromethanesulfonate (TfO), methanesulfonate (MsO), etc.).

As used herein, the terms "reacting," "contacting," or "treating" are used as known in the art in describing a particular process, and generally refer to the co-introduction of chemical reagents in a manner that allows them to interact at the molecular level to achieve a chemical or physical transformation. In some embodiments, the reaction involves two reagents, wherein one or more equivalents of the second reagent are used with respect to the first reagent. The reaction steps of the methods described herein may be carried out for a time and under conditions suitable for the preparation of the identified product.

As used herein, the term "salt" refers to a substance resulting from the combination of a compound and an acid or base. For example, the free base compound 1 can be combined with the desired acid in a solvent or melt to produce a salt of compound 1. In some embodiments, an acid addition salt of compound 1 can be converted to a different acid addition salt by anion exchange. The salt prepared in the solvent system may be isolated by precipitation from the solvent. For example, precipitation and/or crystallization may be induced by evaporation, lowering the temperature, addition of an anti-solvent, or a combination thereof.

As used herein, the term "solid form" refers to a compound provided herein in an amorphous state or a crystalline state (e.g., a crystalline form), whereby a compound provided herein in a crystalline state may optionally comprise a solvent or water within the crystal lattice, e.g., to form a solvated or hydrated crystalline form. In some embodiments, a compound provided herein is in a crystalline state as described herein.

As used herein, a "solvate" is formed by the interaction of a solvent and a compound.

As used herein, the term "subject" to which administration is contemplated includes, but is not limited to, humans (i.e., male or female of any age group, such as pediatric subjects (e.g., infants, children, adolescents) or adult subjects (e.g., young, middle aged, or elderly) and/or other primates (e.g., cynomolgus monkeys, rhesus monkeys); mammals, including commercially relevant mammals, such as cows, pigs, horses, sheep, goats, cats, and/or dogs, and/or birds, including commercially relevant birds, such as chickens, ducks, geese, quail, and/or turkeys.) the "subject" may be independently diagnosed as having a disorder as defined herein, may currently experience symptoms associated with the disorder, or may have experienced symptoms in the past, may be at risk of developing the disorder, or may be reporting one or more symptoms of the disorder even though a diagnosis may not have been made yet, the subject is a human who may be independently diagnosed as having a disorder as defined herein, may be presently experiencing symptoms associated with the disorder, or may have experienced symptoms in the past, may be at risk of developing the disorder, or may be reporting one or more symptoms of the disorder even though a diagnosis may not have been made.

As used herein, the term "substantially", when referring to a characteristic pattern (e.g., XRPD pattern, DSC thermogram, TGA thermogram, etc.) of a crystalline form, means that the subject pattern may differ from the reference depicted herein, but that it falls within the scope of experimental error and, therefore, can be considered to be derived from the same crystalline form as the crystalline form disclosed herein, at the discretion of one of ordinary skill in the art. For example, the term "substantially" as used in the context of XRPD herein is intended to encompass variations disclosed herein (e.g., instrument variations, measurement variations, etc.).

As used herein, the term "substantially amorphous" means that a majority of the weight of a sample or formulation (e.g., a sample or formulation of a salt of compound 1) is amorphous, while the remainder of the sample is a crystalline form of the same compound. In some embodiments, a substantially amorphous sample has less than about 5% crystallinity (e.g., about 95% of the amorphous form of the same compound), preferably less than about 4% crystallinity (e.g., about 96% of the amorphous form of the same compound), more preferably less than about 3% crystallinity (e.g., about 97% of the amorphous form of the same compound), even more preferably less than about 2% crystallinity (e.g., about 98% of the amorphous form of the same compound), more preferably less than about 1% crystallinity (e.g., about 99% of the amorphous form of the same compound), and most preferably about 0% crystallinity (e.g., about 100% of the amorphous form of the same compound). In some embodiments, the term "completely amorphous" means less than about 99% or about 0% crystallinity.

As used herein, the term "substantially crystalline" means that a majority of the weight of a sample or formulation (e.g., a sample or formulation of a salt of compound 1) is crystalline, while the remainder of the sample is a non-crystalline form (e.g., an amorphous form) of the same compound. In some embodiments, a substantially crystalline sample has at least about 95% crystallinity (e.g., about 5% amorphous form of the same compound), preferably at least about 96% crystallinity (e.g., about 4% amorphous form of the same compound), more preferably at least about 97% crystallinity (e.g., about 3% amorphous form of the same compound), even more preferably at least about 98% crystallinity (e.g., about 2% amorphous form of the same compound), more preferably at least about 99% crystallinity (e.g., about 1% amorphous form of the same compound), and most preferably about 100% crystallinity (e.g., about 0% amorphous form of the same compound). In some embodiments, the term "fully crystalline" means at least about 99% or about 100% crystallinity.

The term "substantially isolated" means that the compound is at least partially or substantially separated from the environment in which it is formed or detected. Partial isolation may include, for example, enrichment of a composition with a compound, salt, hydrate, solvate, or solid form provided herein. Substantial isolation may include compositions containing at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97%, or at least about 99% by weight of the compounds, salts, hydrates, solvates, or solid forms provided herein.

As used herein, the term "therapeutically effective amount" or "effective amount" refers to an amount effective to elicit the desired biological or medical response, including an amount of a compound that, when administered to a subject to treat a disorder, is sufficient to effect such treatment of the disorder. The effective amount will vary depending on the compound, the disorder and its severity, and the age, weight, etc., of the subject to be treated. The effective amount may be one or more doses (e.g., a single dose or multiple doses may be required to achieve a desired therapeutic endpoint). An effective amount can be considered to be administered in an effective amount if the desired or beneficial result can be achieved or has been achieved in combination with one or more other agents. The appropriate dosage of any co-administered compound may optionally be reduced due to a combined, additive or synergistic effect of the compounds.

As used herein, the terms "treatment" and "treating" refer to a method of obtaining a beneficial or desired result, including but not limited to a therapeutic benefit. Therapeutic benefits include eradication and/or amelioration of the underlying disorder being treated; it also includes eradicating and/or ameliorating one or more symptoms associated with the underlying disorder such that an improvement is observed in the subject, but the subject may still be afflicted with the underlying disorder. In some embodiments, "treating" or "treating" includes one or more of: (a) inhibiting the disorder (e.g., reducing one or more symptoms caused by the disorder, and/or reducing the extent of the disorder); (b) slowing or arresting the development of one or more symptoms associated with the disorder (e.g., stabilizing the disorder and/or delaying the worsening or progression of the disorder); and/or (c) alleviating the disorder (e.g., causing regression of clinical symptoms, ameliorating the disorder, delaying progression of the disorder, and/or improving quality of life). In some embodiments, the treatment may be administered after one or more symptoms have developed. In other embodiments, the treatment may be administered without symptoms. For example, treatment can be administered to a susceptible individual prior to the onset of symptoms (e.g., based on a history of symptoms and/or based on genetic or other susceptibility factors). Treatment may also be continued after the symptoms have resolved, for example to prevent or delay their recurrence.

As used herein, the term "treatment-resistant depression" (also referred to as "treatment-resistant depression") refers to Major Depressive Disorder (MDD) in which the subject exhibits an inadequate response to treatment with at least two antidepressants (e.g., standard antidepressant drug treatments commercially available). An insufficient reaction may be a no reaction. An inadequate response may also be a condition when the subject does not show complete relief of symptoms or when the physician or clinician deems the subject's response to be inadequate. Symptoms of treatment-resistant depression can range from mild to severe. Factors that may lead to inadequate response include, but are not limited to, premature cessation of therapy, inadequate drug dosage, patient non-compliance, misdiagnosis, and concurrent mental disorders.

EtOAc (ethyl acetate); g (grams); h (hours); HCl (hydrochloric acid); m (mole); MeCN (acetonitrile); MeOH (methanol); mg (milligrams); min (minutes); mL (milliliters); mmol (millimole); NaHCO 2₃(sodium bicarbonate); NaOH (sodium hydroxide); nM (nanomolar); ph (phenyl); μ g (μ g); μ L (microliters); μ M (micromolar); wt% (weight percent).

Salts and crystalline forms thereof

Provided herein are salts of (R) -1- (8-fluoroisochroman-1-yl) -N-methyl methylamine (compound 1) and crystalline forms thereof. The compound (R) -1- (8-fluoroisochroman-1-yl) -N-methylmethanamine (compound 1) has the following structure:

Compound 1.

Compound 1 is described in U.S. patent application No. 15/663,688 (permissive), which is incorporated herein by reference in its entirety.

The compound 1(R) -1- (8-fluoroisochroman-1-yl) -N-methyl methylamine is named or identified using other commonly recognized nomenclature systems. For example, the compounds may be named or identified by a common name, a system name, or a non-system name. Commonly accepted nomenclature in the Chemical arts includes, but is not limited to, Chemical Abstracts Service (CAS) and the International Union of Pure and Applied Chemistry (IUPAC). The IUPAC name provided by ChemDraw Professional 15.0 has been used herein for compound 1.

Compound 1 can be prepared as a salt. In some embodiments, compound 1 can be prepared as a pharmaceutically acceptable salt. Non-limiting examples of pharmaceutically acceptable salts include malate, tartrate, citrate, phosphate, sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, monohydrogen phosphate, dihydrogen phosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, propionate, decanoate, octanoate, acrylate, formate, isobutyrate, hexanoate, heptanoate, propiolate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, butyne-1, 4-dioate, hexyne-1, 6-dioate, benzoate, chlorobenzoate, benzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phthalate, sulfonate, methylsulfonate, dimethylsulfonate, and dimethylsulfonate, and dimethylsulfonate, and dimethylsulfonate, and dimethylsulfonate, propanesulfonate, benzenesulfonate, p-toluenesulfonate, xylenesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, phenylacetate, phenylpropionate, phenylbutyrate, lactate, gamma-hydroxybutyrate, glycolate and mandelate. A list of other suitable pharmaceutically acceptable salts is found in Remington, The Science and Practice of Pharmacy, 21 st edition, Lippincott Williams and Wilkins, Philadelphia, Pa., 2006.

In some embodiments, the salt is the hydrochloride salt of compound 1. The hydrochloride salt form of compound 1 is referred to herein as "compound 1 hydrochloride. Alternative names for the salts are (R) -1- (8-fluoroisochroman-1-yl) -N-methylmethanamine hydrochloride (hydrochloride) or (R) -1- (8-fluoroisochroman-1-yl) -N-methylmethanamine hydrochloride (hydrochloride salt).

In some embodiments, the salt is a phosphate salt of compound 1. The phosphate form of compound 1 is referred to herein as "compound 1 phosphate". Alternative names for the salts are (R) -1- (8-fluoroisochroman-1-yl) -N-methyl methylamine phosphate (phosphate) or (R) -1- (8-fluoroisochroman-1-yl) -N-methyl methylamine phosphate (phosphoric acid salt).

In some embodiments, the salt is the l-tartrate salt of compound 1. The levotartrate form of compound 1 is referred to herein as "compound 1 levotartrate. Alternative names for the salts are (R) -1- (8-fluoroisochroman-1-yl) -N-methyl methylamine or (R) -1- (8-fluoroisochroman-1-yl) -N-methyl methylamine levo-tartrate.

In some embodiments, the salt is the dextro-tartrate salt of compound 1. The dextro-tartrate form of compound 1 is referred to herein as the "compound 1 dextro-tartrate" alternative names for the salts are (R) -1- (8-fluoroisochroman-1-yl) -N-methylmethanamine dextro-tartrate (D-tartrate) or (R) -1- (8-fluoroisochroman-1-yl) -N-methylmethanamine dextro-tartrate (D-tartaric acid salt).

In some embodiments, the salt is the fumarate salt of compound 1. The fumarate salt form of compound 1 is referred to herein as "compound 1 fumarate" alternative names for the salt are (R) -1- (8-fluoroisochroman-1-yl) -N-methylmethanemethane fumarate (fumarate) or (R) -1- (8-fluoroisochroman-1-yl) -N-methylmethanemethane fumarate (fumaric acid salt).

In some embodiments, the salt is the citrate salt of compound 1. The citrate salt form of compound 1 is referred to herein as "compound 1 citrate salt". Alternative names for the salts are (R) -1- (8-fluoroisochroman-1-yl) -N-methylmethanamine citrate (citrate) or (R) -1- (8-fluoroisochroman-1-yl) -N-methylmethanamine citrate (citric acid salt).

In some embodiments, the salt is the succinate salt of compound 1. The succinate salt form of compound 1 is referred to herein as "compound 1 succinate salt". Alternative names for the salts are (R) -1- (8-fluoroisochroman-1-yl) -N-methyl methylamine succinate (succinate) or (R) -1- (8-fluoroisochroman-1-yl) -N-methyl methylamine succinate (succinic acid salt).

In some embodiments, the salt is the glutarate salt of compound 1. The citrate salt form of compound 1 is referred to herein as "compound 1 glutarate salt". Alternative names for the salts are (R) -1- (8-fluoroisochroman-1-yl) -N-methyl methylamine glutarate (glutamate) or (R) -1- (8-fluoroisochroman-1-yl) -N-methyl methylamine glutarate (glutamic acid salt).

In some embodiments, the salt is the l-malate salt of compound 1. The levo-malate salt of compound 1 is referred to herein as the "compound 1 levo-malate salt". Alternative names for the salts are (R) -1- (8-fluoroisochroman-1-yl) -N-methylmethanamine levomalate (L-malate) or (R) -1- (8-fluoroisochroman-1-yl) -N-methylmethanamine levomalate (L-malic acid salt).

In some embodiments, the salt is a benzenesulfonate salt of compound 1. The benzenesulfonate salt form of compound 1 is referred to herein as "compound 1 benzenesulfonate salt". Alternative names for the salts are (R) -1- (8-fluoroisochroman-1-yl) -N-methylmethanamine benzene sulfonate (besylate) or (R) -1- (8-fluoroisochroman-1-yl) -N-methylmethanamine benzene sulfonate (benzylsulfonic acid salt).

In some embodiments, the salt is the p-toluenesulfonic acid salt of compound 1. The p-toluenesulfonate form of compound 1 is referred to herein as "compound 1 p-toluenesulfonate". Alternative names for the salts are (R) -1- (8-fluoroisochroman-1-yl) -N-methylmethylamine p-toluenesulfonate (tosilate) or (R) -1- (8-fluoroisochroman-1-yl) -N-methylmethylamine p-toluenesulfonate (p-toluenesulfonic acid salt).

The salts described herein can have about half, about 1, about 2, about 3 equivalents, etc. of acid relative to compound 1. In some embodiments, the salts described herein comprise about half the equivalent of acid relative to compound 1. In some embodiments, the salts described herein comprise about 1 equivalent of acid relative to compound 1. In some embodiments, the salts described herein comprise about 2 equivalents of acid relative to compound 1. In some embodiments, the salts described herein comprise about 3 equivalents of acid relative to compound 1. One skilled in the art will recognize that there is an equilibrium between the acid and compound 1, where protons may be present, depending on the conditions (e.g., solvent, temperature, etc.) and the strength of the acid. For example, under some conditions, the acid becomes the counter anion by losing one or more protons to compound 1, and compound 1 becomes the counter cation. In some cases, the proton of the acid may form a weak interaction with the basic site of compound 1, and thus the proton is shared between the acid and compound 1.

The salts described herein may have less than about 1, about 2, about 3, about 4, about 5, or greater than about 6 equivalents of solvent or hydrate relative to the salt. In some embodiments, the described salts have less than about 1 equivalent of solvent or hydrate relative to the salt. In some embodiments, the described salts have less than about 1 equivalent of hydrate relative to the salt. In some embodiments, the described salt has about 2 equivalents of solvent or hydrate relative to the salt. In some embodiments, the described salt has about 2 equivalents of hydrate relative to the salt. In some embodiments, the described salt has about 3 equivalents of solvent or hydrate relative to the salt. In some embodiments, the described salt has about 3 equivalents of hydrate relative to the salt.

In some embodiments, the salts described herein are anhydrous.

The salt of compound 1 may be isolated in one or more crystalline forms. Different crystalline forms of the same substance may have different bulk properties with respect to, for example, hygroscopicity, solubility, stability, and the like. The crystalline form having a high melting point may have good thermodynamic stability, which may be advantageous for extending the shelf life of pharmaceutical formulations containing the crystalline form. Crystalline forms with lower melting points may be thermodynamically less stable, but may favor increased water solubility, which translates into increased drug bioavailability. The crystalline form of weak hygroscopicity may be desirable for stability to heat or moisture, and may resist degradation during long term storage. The crystalline forms described herein have many advantages, for example, they have desirable characteristics. In addition, the crystalline forms disclosed herein can be used to improve performance characteristics of a drug product, such as dissolution profile, shelf life, and bioavailability.

Different crystalline forms of a particular substance (such as compound 1 described herein) may include an anhydrous form of the substance and a solvated/hydrated form of the substance, wherein each of the anhydrous form and the solvated/hydrated form are distinguished from each other by different XRPD patterns or other solid state characterization methods, thereby representing different crystal lattices. In some cases, a single crystalline form (e.g., identified by a unique XRPD pattern) may have variable water or solvent content, where the crystal lattice remains substantially unchanged despite compositional variations with respect to water and/or solvent.

XRPD reflectance patterns (peaks) are generally considered as fingerprints of particular crystalline forms. It is well known that the relative intensities of XRPD peaks can vary widely, depending on, among other things, the sample preparation technique, the crystal size distribution, the filter used, the sample installation procedure, and the particular instrument used. In some cases, depending on the machine type or setting (e.g., whether a Ni filter is used), it may be observed that new or existing peaks may disappear. In addition, instrument variations and other factors may affect the 2-theta (2 θ) value. Thus, peak assignments (such as those reported herein) can vary plus or minus (±) by about 0.2 ° (2 θ) or about 0.3 ° (2 θ).

In the same manner, temperature readings associated with DSC, TGA, or other thermal experiments may vary by about ± 3 ℃ depending on the instrument, particular setup, sample preparation, and the like. Thus, crystalline forms reported herein having a DSC thermogram "substantially" as shown in any of the figures are understood to accommodate such a change.

Crystalline forms of the substance may be obtained by a variety of methods known in the art. Such methods include, but are not limited to, melt recrystallization, melt cooling, solvent recrystallization, recrystallization in confined spaces, such as, for example, in nanopores or capillaries, recrystallization on surfaces or templates, such as, for example, on polymers, recrystallization in the presence of additives, such as, for example, eutectic counter molecules, desolvation, dehydration, rapid evaporation, rapid cooling, slow cooling, vapor diffusion, sublimation, exposure to moisture, grinding, and solvent drop grinding.

Compound 1 and its salts can be prepared in batches, referred to as batches, samples, or formulations. The batch, sample, or formulation can include compound 1 and salts thereof, and mixtures thereof, in any crystalline or non-crystalline form described herein, including hydrated and non-hydrated forms.

The compounds provided herein (e.g., salts of compound 1) can also include all isotopes of atoms occurring in the intermediate or final compounds. Isotopes include those atoms having the same number of atoms but different mass numbers. For example, isotopes of hydrogen include tritium and deuterium. One or more of the constituent atoms of the compounds provided herein may be replaced or substituted with an isotope of an atom in natural or unnatural abundance. In some embodiments, the compound comprises at least one deuterium atom. For example, one or more hydrogen atoms in a compound of the disclosure may be replaced or substituted with deuterium. In some embodiments, the compound comprises two or more deuterium atoms. In some embodiments, the compound comprises 1, 2, 3, 4, 5, 6, 7, or 8 deuterium atoms. Synthetic methods for including isotopes in organic compounds are known in the art. Examples of isotopes that can be incorporated into compounds disclosed herein include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine, chlorine, and iodine (e.g., ²H、³H、¹¹C、¹³C、¹⁴C、¹³N、¹⁵N、¹⁵O、¹⁸O、³¹P、³²P、³⁵S、¹⁸F、³⁶Cl、¹²³I and¹²⁵I)。

in some embodiments, compound 1 or salts thereof and crystalline forms thereof are substantially isolated.

Compound 1 can be observed and/or isolated as its various salt forms and polymorphs including, for example, hydrochloride (form HA and form HB), phosphate, levotartrate (form LA, form LB and form LC), dextrotartrate, fumarate (form FA and form FB), citrate, succinate, glutarate, levomalate, benzenesulfonate and p-toluenesulfonate.

Compound 1 hydrochloride

In some embodiments, there is provided (R) -1- (8-fluoroisochroman-1-yl) -N-methylmethanamine hydrochloride (compound 1 hydrochloride). In some embodiments, the compound 1 hydrochloride salt is crystalline.

Compound 1 hydrochloride can be prepared according to the procedure provided in U.S. patent No. 10,196,403. In some embodiments, compound 1 hydrochloride is provided that is prepared by isolating compound 1 hydrochloride form HA from a mixture of compound 1, HCl, and S1, wherein S1 is a solvent. In some embodiments, S1 is an organic solvent. In some embodiments, S1 is C_1-6An alkyl alcohol. In some embodiments, S1 is an ether. In some embodiments, S1 is C _1-6Alkyl acetate ester. In some embodiments, S1 is methanol. In some embodiments, S1 is THF. In some embodiments, S1 is ethyl acetate.

Compound 1 hydrochloride form HA

In some embodiments, there is provided (R) -1- (8-fluoroisochroman-1-yl) -N-methylmethanamine hydrochloride form HA (compound 1 hydrochloride form HA). In some embodiments, compound 1 hydrochloride form HA is crystalline.

In some embodiments, compound 1 hydrochloride form HA HAs a characteristic XRPD peak, expressed in 2 Θ, selected from 9.4 ° ± 0.2 °, 11.4 ± 0.2 ° and 15.1 ° ± 0.2 °. In some embodiments, compound 1 hydrochloride form HA HAs a characteristic XRPD peak, expressed in 2 Θ, at 9.4 ° ± 0.2 °. In some embodiments, compound 1 hydrochloride form HA HAs a characteristic XRPD peak, expressed in 2 Θ, at 11.4 ° ± 0.2 °. In some embodiments, compound 1 hydrochloride form HA HAs a characteristic XRPD peak, expressed in 2 Θ, at 15.1 ° ± 0.2 °.

In some embodiments, compound 1 hydrochloride form HA HAs a characteristic XRPD peak, expressed in 2 Θ, selected from 9.4 ° ± 0.2 °, 11.4 ± 0.2 °, 15.1 ° ± 0.2 °, 17.2 ° ± 0.2 ° and 17.6 ° ± 0.2 °. In some embodiments, compound 1 hydrochloride form HA HAs at least one characteristic XRPD peak, expressed in 2 Θ, selected from 9.4 ° ± 0.2 °, 11.4 ± 0.2 °, 15.1 ° ± 0.2 °, 17.2 ° ± 0.2 ° and 17.6 ° ± 0.2 °.

In some embodiments, compound 1 hydrochloride form HA HAs at least one characteristic XRPD peak, expressed in 2 Θ, selected from 9.4 ° ± 0.2 °, 11.4 ° ± 0.2 °, 14.2 ° ± 0.2 °, 15.1 ° ± 0.2 °, 17.2 ° ± 0.2 °, 17.6 ° ± 0.2 ° and 27.0 ° ± 0.2 °. In some embodiments, compound 1 hydrochloride form HA HAs at least one characteristic XRPD peak, expressed in 2 Θ, selected from 9.4 ° ± 0.2 °, 11.4 ° ± 0.2 °, 14.2 ° ± 0.2 °, 15.1 ° ± 0.2 °, 17.2 ° ± 0.2 °, 17.6 ° ± 0.2 °, 18.8 ° ± 0.2 °, 19.2 ° ± 0.2 °, 24.3 ° ± 0.2 ° and 27.0 ° ± 0.2 °.

In some embodiments, compound 1 hydrochloride form HA HAs at least two characteristic XRPD peaks expressed in 2 Θ selected from 9.4 ° ± 0.2 °, 11.4 ° ± 0.2 °, 14.2 ° ± 0.2 °, 15.1 ° ± 0.2 °, 17.2 ° ± 0.2 °, 17.6 ° ± 0.2 ° and 27.0 ° ± 0.2 °. In some embodiments, compound 1 hydrochloride form HA HAs at least two characteristic XRPD peaks expressed in 2 Θ selected from 9.4 ° ± 0.2 °, 11.4 ° ± 0.2 °, 14.2 ° ± 0.2 °, 15.1 ° ± 0.2 °, 17.2 ° ± 0.2 °, 17.6 ° ± 0.2 °, 18.8 ° ± 0.2 °, 19.2 ° ± 0.2 °, 24.3 ° ± 0.2 ° and 27.0 ° ± 0.2 °.

In some embodiments, compound 1 hydrochloride form HA HAs at least three characteristic XRPD peaks expressed in 2 Θ selected from 9.4 ° ± 0.2 °, 11.4 ° ± 0.2 °, 14.2 ° ± 0.2 °, 15.1 ° ± 0.2 °, 17.2 ° ± 0.2 °, 17.6 ° ± 0.2 ° and 27.0 ° ± 0.2 °. In some embodiments, compound 1 hydrochloride form HA HAs at least three characteristic XRPD peaks expressed in 2 Θ selected from 9.4 ° ± 0.2 °, 11.4 ° ± 0.2 °, 14.2 ° ± 0.2 °, 15.1 ° ± 0.2 °, 17.2 ° ± 0.2 °, 17.6 ° ± 0.2 °, 18.8 ° ± 0.2 °, 19.2 ° ± 0.2 °, 24.3 ° ± 0.2 ° and 27.0 ° ± 0.2 °.

In some embodiments, compound 1 hydrochloride form HA HAs an XRPD pattern with characteristic peaks substantially as shown in figure 1 (figure 1).

In some embodiments, compound 1 hydrochloride form HA HAs endothermic peaks at about 9 ℃ C and about 187 ℃ C. In some embodiments, compound 1 hydrochloride form HA HAs an endothermic peak at a temperature of about 99 ℃. In some embodiments, compound 1 hydrochloride form HA HAs an endothermic peak at a temperature of about 187 ℃. In some embodiments, compound 1 hydrochloride form HA HAs a DSC thermogram substantially as shown in figure 2 (figure 2). In some embodiments, compound 1 hydrochloride form HA HAs a TGA thermogram substantially as shown in figure 3 (figure 3). In some embodiments, compound 1 hydrochloride form HA HAs a DVS isotherm substantially as shown in figure 4 (figure 4).

In some embodiments, compound 1 hydrochloride form HA HAs a characteristic XRPD peak, expressed in 2 Θ, selected from 9.4 ° ± 0.2 °, 11.4 ± 0.2 ° and 15.1 ° ± 0.2 °; and has endothermic peaks at temperatures of about 99 ℃ and about 187 ℃. In some embodiments, compound 1 hydrochloride form HA HAs a characteristic XRPD peak, expressed in 2 Θ, selected from 9.4 ° ± 0.2 °, 11.4 ± 0.2 ° and 15.1 ° ± 0.2 °; and an endothermic peak at a temperature of about 99 ℃. In some embodiments, compound 1 hydrochloride form HA HAs a characteristic XRPD peak, expressed in 2 Θ, selected from 9.4 ° ± 0.2 °, 11.4 ± 0.2 ° and 15.1 ° ± 0.2 °; and an endothermic peak at a temperature of about 187 ℃. In some embodiments, compound 1 hydrochloride form HA HAs a characteristic XRPD peak, expressed in 2 Θ, selected from 9.4 ° ± 0.2 °, 11.4 ± 0.2 ° and 15.1 ° ± 0.2 °; and a DSC thermogram substantially as depicted in figure 2 (figure 2). In some embodiments, compound 1 hydrochloride form HA HAs a characteristic XRPD peak, expressed in 2 Θ, selected from 9.4 ° ± 0.2 °, 11.4 ± 0.2 ° and 15.1 ° ± 0.2 °; and a DVS isotherm substantially as depicted in fig. 4 (fig. 4).

In some embodiments, compound 1 hydrochloride salt form HA may be isolated in a crystalline purity of at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99%. In some embodiments, compound 1 hydrochloride salt form HA can be isolated in a crystalline purity of greater than about 99%. In some embodiments, compound 1 hydrochloride salt form HA can be isolated in a crystalline purity of greater than about 99.9%.

In some embodiments, compound 1 hydrochloride form HA is provided that is prepared by isolating compound 1 hydrochloride form HA from a mixture of compound 1, HCl, and S1, wherein S1 is a solvent.

In some embodiments, S1 is an organic solvent. In some casesIn embodiments, S1 is an ether. In some embodiments, S1 is C_1-6Alkyl acetate ester. In some embodiments, S1 is THF. In some embodiments, S1 is ethyl acetate.

Compound 1 hydrochloride form HB

In some embodiments, there is provided (R) -1- (8-fluoroisochroman-1-yl) -N-methylmethanamine hydrochloride form HB (compound 1 hydrochloride form HB). In some embodiments, compound 1 hydrochloride HB is crystalline.

In some embodiments, compound 1 hydrochloride form HB has a characteristic XRPD peak, expressed in 2 Θ, selected from 8.6 ° ± 0.2 °, 9.6 ° ± 0.2 ° and 10.3 ° ± 0.2 °. In some embodiments, compound 1 hydrochloride form HB has a characteristic XRPD peak, expressed in 2 Θ, at 8.6 ° ± 0.2 °. In some embodiments, compound 1 hydrochloride form HB has a characteristic XRPD peak, expressed in 2 Θ, at 9.6 ° ± 0.2 °. In some embodiments, compound 1 hydrochloride HB has a characteristic XRPD peak, expressed in 2 Θ, at 10.3 ° ± 0.2 °.

In some embodiments, compound 1 hydrochloride form HB has a characteristic XRPD peak, expressed in 2 θ, selected from 8.6 ° ± 0.2 °, 9.6 ° ± 0.2 °, 10.3 ° ± 0.2 ° and 17.3 ° ± 0.2 °. In some embodiments, compound 1 hydrochloride form HB has at least one characteristic XRPD peak, expressed in 2 Θ, selected from 8.6 ° ± 0.2 °, 9.6 ° ± 0.2 °, 10.3 ° ± 0.2 ° and 17.3 ° ± 0.2 °.

In some embodiments, compound 1 hydrochloride form HB has at least one characteristic XRPD peak, expressed in 2 Θ, selected from 8.6 ° ± 0.2 °, 9.6 ° ± 0.2 °, 10.3 ° ± 0.2 °, 12.6 ° ± 0.2 °, 14.7 ° ± 0.2 °, 17.3 ° ± 0.2 ° and 23.8 ° ± 0.2 °. In some embodiments, compound 1 hydrochloride form HB has at least one characteristic XRPD peak, expressed in 2 Θ, selected from 8.6 ° ± 0.2 °, 9.6 ° ± 0.2 °, 10.3 ° ± 0.2 °, 12.6 ° ± 0.2 °, 14.7 ° ± 0.2 °, 16.5 ° ± 0.2 °, 17.3 ° ± 0.2 °, 18.3 ° ± 0.2 °, 23.8 ° ± 0.2 °, 24.4 ° ± 0.2 °, 26.9 ° ± 0.2 °, and 27.1 ° ± 0.2 °.

In some embodiments, compound 1 hydrochloride form HB has at least two characteristic XRPD peaks, expressed in 2 Θ, selected from 8.6 ° ± 0.2 °, 9.6 ° ± 0.2 °, 10.3 ° ± 0.2 °, 12.6 ° ± 0.2 °, 14.7 ° ± 0.2 °, 17.3 ° ± 0.2 ° and 23.8 ° ± 0.2 °. In some embodiments, compound 1 hydrochloride form HB has at least two characteristic XRPD peaks, expressed in 2 Θ, selected from 8.6 ° ± 0.2 °, 9.6 ° ± 0.2 °, 10.3 ° ± 0.2 °, 12.6 ° ± 0.2 °, 14.7 ° ± 0.2 °, 16.5 ° ± 0.2 °, 17.3 ° ± 0.2 °, 18.3 ° ± 0.2 °, 23.8 ° ± 0.2 °, 24.4 ° ± 0.2 °, 26.9 ° ± 0.2 ° and 27.1 ° ± 0.2 °.

In some embodiments, compound 1 hydrochloride form HB has at least three characteristic XRPD peaks, expressed in 2 Θ, selected from 8.6 ° ± 0.2 °, 9.6 ° ± 0.2 °, 10.3 ° ± 0.2 °, 12.6 ° ± 0.2 °, 14.7 ° ± 0.2 °, 17.3 ° ± 0.2 ° and 23.8 ° ± 0.2 °. In some embodiments, compound 1 hydrochloride form HB has at least three characteristic XRPD peaks, expressed in 2 Θ, selected from 8.6 ° ± 0.2 °, 9.6 ° ± 0.2 °, 10.3 ° ± 0.2 °, 12.6 ° ± 0.2 °, 14.7 ° ± 0.2 °, 16.5 ° ± 0.2 °, 17.3 ° ± 0.2 °, 18.3 ° ± 0.2 °, 23.8 ° ± 0.2 °, 24.4 ° ± 0.2 °, 26.9 ° ± 0.2 °, and 27.1 ° ± 0.2 °.

In some embodiments, compound 1 hydrochloride form HB has an XRPD pattern having characteristic peaks substantially as shown in figure 5 (figure 5).

In some embodiments, compound 1 hydrochloride form HB can be isolated in a crystalline purity of at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99%. In some embodiments, compound 1 hydrochloride form HB can be isolated in a crystalline purity of greater than about 99%. In some embodiments, compound 1 hydrochloride form HB can be isolated in a crystalline purity of greater than about 99.9%.

In some embodiments, compound 1 hydrochloride form HB prepared by isolating compound 1 hydrochloride form HA from a mixture of compound 1, HCl and S1 is provided, wherein S1 is a solvent.

In some embodiments, S1 comprises water. In some embodiments, form HB is prepared by exposing form HA to high humidity. In some embodiments, form HB is prepared by exposing form HA to about 75% relative humidity.

Compound 1 phosphate

In some embodiments, (R) -1- (8-fluoroisochroman-1-yl) -N-methyl methylamine phosphate is provided. In some embodiments, compound 1 phosphate is crystalline.

In some embodiments, compound 1 phosphate has a characteristic XRPD peak, expressed in 2 Θ, selected from 4.6 ° ± 0.2 °, 9.1 ° ± 0.2 ° and 18.2 ° ± 0.2 °. In some embodiments, compound 1 phosphate has a characteristic XRPD peak, expressed in 2 Θ, at 4.6 ° ± 0.2 °. In some embodiments, compound 1 phosphate has a characteristic XRPD peak, expressed in 2 Θ, at 9.1 ° ± 0.2 °. In some embodiments, compound 1 phosphate has a characteristic XRPD peak, expressed in 2 Θ, at 18.2 ° ± 0.2 °.

In some embodiments, compound 1 phosphate has a characteristic XRPD peak, expressed in 2 Θ, selected from 4.6 ° ± 0.2 °, 9.1 ° ± 0.2 °, 18.2 ° ± 0.2 ° and 22.8 ° ± 0.2 °. In some embodiments, compound 1 phosphate has at least one characteristic XRPD peak, expressed in 2 Θ, selected from 4.6 ° ± 0.2 °, 9.1 ° ± 0.2 °, 18.2 ° ± 0.2 ° and 22.8 ° ± 0.2 °.

In some embodiments, compound 1 phosphate has at least one characteristic XRPD peak, expressed in 2 Θ, selected from 4.6 ° ± 0.2 °, 9.1 ° ± 0.2 °, 15.7 ° ± 0.2 °, 18.2 ° ± 0.2 °, 22.3 ° ± 0.2 °, 22.8 ° ± 0.2 °, and 24.8 ° ± 0.2 °. In some embodiments, compound 1 phosphate has at least one characteristic XRPD peak, expressed in 2 Θ, selected from 4.6 ° ± 0.2 °, 9.1 ° ± 0.2 °, 15.7 ° ± 0.2 °, 18.2 ° ± 0.2 °, 19.1 ° ± 0.2 °, 22.3 ° ± 0.2 °, 22.8 ° ± 0.2 °, 24.8 ° ± 0.2 °, 26.0 ° ± 0.2 °, 27.4 ° ± 0.2 ° and 30.1 ° ± 0.2 °.

In some embodiments, compound 1 phosphate has at least two characteristic XRPD peaks expressed in 2 Θ selected from 4.6 ° ± 0.2 °, 9.1 ° ± 0.2 °, 15.7 ° ± 0.2 °, 18.2 ° ± 0.2 °, 22.3 ° ± 0.2 °, 22.8 ° ± 0.2 ° and 24.8 ° ± 0.2 °. In some embodiments, compound 1 phosphate has at least two characteristic XRPD peaks expressed in 2 Θ selected from 4.6 ° ± 0.2 °, 9.1 ° ± 0.2 °, 15.7 ° ± 0.2 °, 18.2 ° ± 0.2 °, 19.1 ° ± 0.2 °, 22.3 ° ± 0.2 °, 22.8 ° ± 0.2 °, 24.8 ° ± 0.2 °, 26.0 ° ± 0.2 °, 27.4 ° ± 0.2 ° and 30.1 ° ± 0.2 °.

In some embodiments, compound 1 phosphate has at least three characteristic XRPD peaks, expressed in 2 Θ, selected from 4.6 ° ± 0.2 °, 9.1 ° ± 0.2 °, 15.7 ° ± 0.2 °, 18.2 ° ± 0.2 °, 22.3 ° ± 0.2 °, 22.8 ° ± 0.2 °, and 24.8 ° ± 0.2 °. In some embodiments, compound 1 phosphate has at least three characteristic XRPD peaks expressed in 2 Θ selected from 4.6 ° ± 0.2 °, 9.1 ° ± 0.2 °, 15.7 ° ± 0.2 °, 18.2 ° ± 0.2 °, 19.1 ° ± 0.2 °, 22.3 ° ± 0.2 °, 22.8 ° ± 0.2 °, 24.8 ° ± 0.2 °, 26.0 ° ± 0.2 °, 27.4 ° ± 0.2 ° and 30.1 ° ± 0.2 °.

In some embodiments, compound 1 phosphate has an XRPD pattern comprising characteristic peaks substantially as shown in figure 6 (figure 6).

In some embodiments, compound 1 phosphate has an endothermic peak at a temperature of about 213 ℃. In some embodiments, compound 1 phosphate has a DSC thermogram substantially as depicted in figure 7 (figure 7). In some embodiments, the compound 1 phosphate salt has a TGA thermogram substantially as depicted in figure 8 (figure 8). In some embodiments, compound 1 phosphate has a DVS isotherm substantially as depicted in figure 9 (figure 9).

In some embodiments, compound 1 phosphate has at least one characteristic XRPD peak, expressed in 2 Θ, selected from 4.6 ° ± 0.2 °, 9.1 ° ± 0.2 °, 18.2 ° ± 0.2 ° and 22.8 ° ± 0.2 °; and an endothermic peak at a temperature of about 213 ℃. In some embodiments, compound 1 phosphate has at least one characteristic XRPD peak, expressed in 2 Θ, selected from 4.6 ° ± 0.2 °, 9.1 ° ± 0.2 °, 18.2 ° ± 0.2 ° and 22.8 ° ± 0.2 °; and a DSC thermogram substantially as depicted in figure 7 (figure 7). In some embodiments, compound 1 phosphate has at least one characteristic XRPD peak, expressed in 2 Θ, selected from 4.6 ° ± 0.2 °, 9.1 ° ± 0.2 °, 18.2 ° ± 0.2 ° and 22.8 ° ± 0.2 °; and a DVS isotherm substantially as depicted in fig. 9 (fig. 9).

In some embodiments, compound 1 phosphate may be isolated in a crystalline purity of at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99%. In some embodiments, compound 1 phosphate may be isolated in a crystalline purity of greater than about 99%. In some embodiments, compound 1 phosphate may be isolated in a crystalline purity of greater than about 99.9%.

In some embodiments, provided is compound 1 phosphate prepared by separating compound 1 phosphate from a mixture of compound 1, phosphoric acid, and S1, wherein S1 is a solvent. In some embodiments, S1 is an organic solvent. In some embodiments, S1 is C_1-6An alkyl alcohol. In some embodiments, S1 is an ether. In some embodiments, S1 is C_1-6Alkyl acetate ester. In some embodiments, S1 is a mixture of organic solvents. In some embodiments, S1 is C_1-6Alkyl alcohol and C_1-6A mixture of alkyl acetates. In some embodiments, S1 is THF. In some embodiments, S1 is ethyl acetate. In some embodiments, S1 is a mixture of methanol and acetone. In some embodiments, S1 is a mixture of methanol and ethyl acetate.

Compound 1L-tartrate

In some embodiments, there is provided (R) -1- (8-fluoroisochroman-1-yl) -N-methylmethanamine l-tartrate (compound 1 l-tartrate). In some embodiments, compound 1 l-tartrate is crystalline.

In some embodiments, compound 1 l-tartrate is provided prepared by isolating compound 1 l-tartrate from a mixture of compound 1, tartaric acid, and S1, wherein S1 is a solvent. In some embodiments, S1 is an organic solvent. In some embodiments, S1 is C_1-6An alkyl alcohol. In some embodiments, S1 is an ether. In some embodiments, S1 is C_1-6Alkyl acetate ester. In some embodiments, S1 is C_1-6An alkyl ketone. In some embodiments, S1 is C_1-6Alkyl alcohol and C_1-6Mixtures of alkyl ketones. In some embodiments, S1 is C_1-6Alkyl alcohol and C_1-6A mixture of alkyl acetates. In some embodiments, S1 is methanol. In some embodiments, S1 is THF. In some embodiments, S1 is ethyl acetate. In some embodiments of the present invention, the substrate is,s1 is a mixture of methanol and acetone. In some embodiments, S1 is a mixture of methanol and ethyl acetate.

Compound 1L-tartrate form LA

In some embodiments, there is provided (R) -1- (8-fluoroisochroman-1-yl) -N-methylmethanamine l-tartrate form LA (compound 1 l-tartrate form LA). In some embodiments, compound 1 l-tartrate form LA is crystalline.

In some embodiments, compound 1 levotartrate form LA has a characteristic XRPD peak, expressed in 2 Θ, selected from 12.1 ° ± 0.2 °, 18.1 ° ± 0.2 ° and 24.2 ° ± 0.2 °. In some embodiments, compound 1 levotartrate form LA has a characteristic XRPD peak, expressed in 2 Θ, at 12.1 ° ± 0.2 °. In some embodiments, compound 1 levotartrate form LA has a characteristic XRPD peak, expressed in 2 Θ, at 18.1 ° ± 0.2 °. In some embodiments, compound 1 levotartrate form LA has a characteristic XRPD peak, expressed in 2 Θ, at 24.2 ° ± 0.2 °.

In some embodiments, compound 1 levo-tartrate form LA has at least one characteristic XRPD peak, expressed in 2 Θ, selected from 12.1 ° ± 0.2 °, 15.0 ° ± 0.2 °, 16.4 ° ± 0.2 °, 16.9 ° ± 0.2 °, 17.1 ° ± 0.2 °, 18.1 ° ± 0.2 °, 23.9 ° ± 0.2 ° and 24.2 ° ± 0.2 °. In some embodiments, compound 1 levo-tartrate form LA has at least one characteristic XRPD peak, expressed in 2 Θ, selected from 12.1 ° ± 0.2 °, 15.0 ° ± 0.2 °, 16.4 ° ± 0.2 °, 16.9 ° ± 0.2 °, 17.1 ° ± 0.2 °, 18.1 ° ± 0.2 °, 19.3 ° ± 0.2 °, 23.9 ° ± 0.2 °, 24.2 ° ± 0.2 °, 24.8 ° ± 0.2 ° and 27.2 ° ± 0.2 °.

In some embodiments, compound 1 levo-tartrate form LA has at least two characteristic XRPD peaks, expressed in 2 Θ, selected from 12.1 ° ± 0.2 °, 15.0 ° ± 0.2 °, 16.4 ° ± 0.2 °, 16.9 ° ± 0.2 °, 17.1 ° ± 0.2 °, 18.1 ° ± 0.2 °, 23.9 ° ± 0.2 ° and 24.2 ° ± 0.2 °. In some embodiments, compound 1 levo-tartrate form LA has at least two characteristic XRPD peaks expressed in 2 Θ selected from 12.1 ° ± 0.2 °, 15.0 ° ± 0.2 °, 16.4 ° ± 0.2 °, 16.9 ° ± 0.2 °, 17.1 ° ± 0.2 °, 18.1 ° ± 0.2 °, 19.3 ° ± 0.2 °, 23.9 ° ± 0.2 °, 24.2 ° ± 0.2 °, 24.8 ° ± 0.2 ° and 27.2 ° ± 0.2 °.

In some embodiments, compound 1 levo-tartrate form LA has at least three characteristic XRPD peaks, expressed in 2 Θ, selected from 12.1 ° ± 0.2 °, 15.0 ° ± 0.2 °, 16.4 ° ± 0.2 °, 16.9 ° ± 0.2 °, 17.1 ° ± 0.2 °, 18.1 ° ± 0.2 °, 23.9 ° ± 0.2 ° and 24.2 ° ± 0.2 °. In some embodiments, compound 1 levo-tartrate form LA has at least three characteristic XRPD peaks expressed in 2 Θ selected from 12.1 ° ± 0.2 °, 15.0 ° ± 0.2 °, 16.4 ° ± 0.2 °, 16.9 ° ± 0.2 °, 17.1 ° ± 0.2 °, 18.1 ° ± 0.2 °, 19.3 ° ± 0.2 °, 23.9 ° ± 0.2 °, 24.2 ° ± 0.2 °, 24.8 ° ± 0.2 ° and 27.2 ° ± 0.2 °.

In some embodiments, compound 1 l-tartrate form LA has an XRPD pattern comprising characteristic peaks substantially as shown in figure 10 (figure 10).

In some embodiments, compound 1 levotartrate form LA has endothermic peaks at temperatures of about 89 ℃ and about 138 ℃. In some embodiments, compound 1 levotartrate form LA has an endothermic peak at a temperature of about 89 ℃. In some embodiments, compound 1 levotartrate form LA has an endothermic peak at a temperature of about 138 ℃. In some embodiments, compound 1 levotartrate form LA has a DSC thermogram substantially as depicted in figure 11 (figure 11). In some embodiments, compound 1 levotartrate form LA has a TGA thermogram substantially as depicted in figure 12 (figure 12). In some embodiments, compound 1 l-tartrate form LA has a DVS isotherm substantially as depicted in figure 13 (figure 13).

In some embodiments, compound 1 levotartrate form LA has at least one characteristic XRPD peak, expressed in 2 Θ, selected from 12.1 ° ± 0.2 °, 18.1 ° ± 0.2 ° and 24.2 ° ± 0.2 °; and has endothermic peaks at temperatures of about 89 ℃ and about 138 ℃. In some embodiments, compound 1 levotartrate form LA has at least one characteristic XRPD peak, expressed in 2 Θ, selected from 12.1 ° ± 0.2 °, 18.1 ° ± 0.2 ° and 24.2 ° ± 0.2 °; and an endothermic peak at a temperature of about 89 ℃. In some embodiments, compound 1 levotartrate form LA has at least one characteristic XRPD peak, expressed in 2 Θ, selected from 12.1 ° ± 0.2 °, 18.1 ° ± 0.2 ° and 24.2 ° ± 0.2 °; and an endothermic peak at a temperature of about 138 ℃. In some embodiments, compound 1 levotartrate form LA has at least one characteristic XRPD peak, expressed in 2 Θ, selected from 12.1 ° ± 0.2 °, 18.1 ° ± 0.2 ° and 24.2 ° ± 0.2 °; and a DSC thermogram substantially as depicted in figure 11 (figure 11). In some embodiments, compound 1 levotartrate form LA has at least one characteristic XRPD peak, expressed in 2 Θ, selected from 12.1 ° ± 0.2 °, 18.1 ° ± 0.2 ° and 24.2 ° ± 0.2 °; and a DVS isotherm substantially as depicted in fig. 13 (fig. 13).

In some embodiments, compound 1 l-tartrate form LA may be isolated in a crystalline purity of at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99%. In some embodiments, compound 1 l-tartrate form LA may be isolated in a crystalline purity of greater than about 99%. In some embodiments, compound 1 l-tartrate form LA may be isolated in a crystalline purity of greater than about 99.9%.

In some embodiments, compound 1 l-tartrate form LA prepared by isolating compound 1 l-tartrate form LA from a mixture of compound 1, l-tartaric acid, and S1, wherein S1 is a solvent, is provided. In some embodiments, S1 is an organic solvent. In some embodiments, S1 is an ether. In some embodiments, S1 is C_1-6Alkyl acetate ester. In some embodiments, S1 is THF. In some embodiments, S1 is ethyl acetate.

Compound 1L-tartrate form LB

In some embodiments, provided is (R) -1- (8-fluoroisochroman-1-yl) -N-methylmethanamine levotartrate form LB (compound 1 levotartrate form LB). In some embodiments, compound 1 levotartrate form LB is crystalline.

In some embodiments, compound 1 levo-tartrate form LB has a characteristic XRPD peak, expressed in 2 Θ, selected from 18.7 ° ± 0.2 °, 25.0 ° ± 0.2 ° and 31.4 ° ± 0.2 °. In some embodiments, compound 1 levotartrate form LB has a characteristic XRPD peak, expressed in 2 Θ, at 18.7 ° ± 0.2 °. In some embodiments, compound 1 levotartrate form LB has a characteristic XRPD peak, expressed in 2 Θ, at 25.0 ° ± 0.2 °. In some embodiments, compound 1 levotartrate form LB has a characteristic XRPD peak, expressed in 2 Θ, at 31.4 ° ± 0.2 °.

In some embodiments, compound 1 levo-tartrate form LB has at least one characteristic XRPD peak, expressed in 2 Θ, selected from 6.3 ° ± 0.2 °, 12.5 ° ± 0.2 °, 18.1 ° ± 0.2 °, 18.7 ° ± 0.2 °, 23.9 ° ± 0.2 °, 25.0 ° ± 0.2 ° and 31.4 ° ± 0.2 °. In some embodiments, compound 1 levo-tartrate form LB has at least one characteristic XRPD peak, expressed in 2 Θ, selected from 6.3 ° ± 0.2 °, 12.5 ° ± 0.2 °, 18.1 ° ± 0.2 °, 18.7 ° ± 0.2 °, 20.0 ° ± 0.2 °, 23.9 ° ± 0.2 °, 24.2 ° ± 0.2 °, 25.0 ° ± 0.2 ° and 31.4 ° ± 0.2 °.

In some embodiments, compound 1 levo-tartrate form LB has at least two characteristic XRPD peaks expressed in 2 Θ selected from 6.3 ° ± 0.2 °, 12.5 ° ± 0.2 °, 18.1 ° ± 0.2 °, 18.7 ° ± 0.2 °, 23.9 ° ± 0.2 °, 25.0 ° ± 0.2 ° and 31.4 ° ± 0.2 °. In some embodiments, compound 1 levo-tartrate form LB has at least two characteristic XRPD peaks expressed in 2 Θ selected from 6.3 ° ± 0.2 °, 12.5 ° ± 0.2 °, 18.1 ° ± 0.2 °, 18.7 ° ± 0.2 °, 20.0 ° ± 0.2 °, 23.9 ° ± 0.2 °, 24.2 ° ± 0.2 °, 25.0 ° ± 0.2 ° and 31.4 ° ± 0.2 °.

In some embodiments, compound 1 levo-tartrate form LB has at least three characteristic XRPD peaks, expressed in 2 Θ, selected from 6.3 ° ± 0.2 °, 12.5 ° ± 0.2 °, 18.1 ° ± 0.2 °, 18.7 ° ± 0.2 °, 23.9 ° ± 0.2 °, 25.0 ° ± 0.2 ° and 31.4 ° ± 0.2 °. In some embodiments, compound 1 levo-tartrate form LB has at least three characteristic XRPD peaks expressed in 2 Θ selected from 6.3 ° ± 0.2 °, 12.5 ° ± 0.2 °, 18.1 ° ± 0.2 °, 18.7 ° ± 0.2 °, 20.0 ° ± 0.2 °, 23.9 ° ± 0.2 °, 24.2 ° ± 0.2 °, 25.0 ° ± 0.2 ° and 31.4 ° ± 0.2 °.

In some embodiments, compound 1 levotartrate form LB has an XRPD pattern comprising characteristic peaks substantially as shown in figure 14 (figure 14). In some embodiments, the compound levotartrate form LB has a DVS isotherm substantially as shown in figure 15 (figure 15).

In some embodiments, compound 1 l-tartrate form LB may be isolated in a crystalline purity of at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99%. In some embodiments, compound 1, l-tartrate form LB may be isolated in greater than about 99% crystalline purity. In some embodiments, compound 1, l-tartrate form LB may be isolated in a crystalline purity of greater than about 99.9%.

In some embodiments, compound 1 l-tartrate form LB prepared by isolating compound 1 l-tartrate form LB from a mixture of compound 1, l-tartaric acid, and S1, wherein S1 is a solvent, is provided. In some embodiments, S1 is an organic solvent. In some embodiments, S1 is C_1-6An alkyl alcohol. In some embodiments, S1 is C_1-6An alkyl ketone. In some embodiments, S1 is a mixture of organic solvents. In some embodiments, S1 is C_1-6Alkyl alcohol and C_1-6Mixtures of alkyl ketones. In some embodiments, S1 is a mixture of methanol and acetone.

Compound 1L-tartrate form LC

In some embodiments, provided is (R) -1- (8-fluoroisochroman-1-yl) -N-methylmethanamine l-tartrate form LC (compound 1 l-tartrate form LC). In some embodiments, compound 1 l-tartrate form LC is crystalline.

In some embodiments, compound 1 levo-tartrate form LC has a characteristic XRPD peak, expressed in 2 Θ, selected from 12.2 ° ± 0.2 °, 16.5 ° ± 0.2 ° and 24.8 ° ± 0.2 °. In some embodiments, compound 1 levotartrate form LC has a characteristic XRPD peak, expressed in 2 Θ, at 12.2 ° ± 0.2 °. In some embodiments, compound 1 levotartrate form LC has a characteristic XRPD peak, expressed in 2 Θ, at 16.5 ° ± 0.2 °. In some embodiments, compound 1 levotartrate form LC has a characteristic XRPD peak, expressed in 2 Θ, at 24.8 ° ± 0.2 °.

In some embodiments, compound 1 levo-tartrate form LC has at least one characteristic XRPD peak, expressed in 2 Θ, selected from 12.2 ° ± 0.2 °, 15.4 ° ± 0.2 °, 16.5 ° ± 0.2 °, 18.7 ° ± 0.2 °, 19.8 ° ± 0.2 °, 22.6 ° ± 0.2 °, 24.8 ° ± 0.2 ° and 25.5 ° ± 0.2 °. In some embodiments, compound 1 levo-tartrate form LC has at least one characteristic XRPD peak, expressed in 2 Θ, selected from 12.2 ° ± 0.2 °, 12.8 ° ± 0.2 °, 15.4 ° ± 0.2 °, 16.5 ° ± 0.2 °, 18.7 ° ± 0.2 °, 19.8 ° ± 0.2 °, 20.0 ° ± 0.2 °, 22.4 ° ± 0.2 °, 22.6 ° ± 0.2 °, 24.8 ° ± 0.2 °, 25.0 ° ± 0.2 °, 25.5 ° ± 0.2 ° and 27.1 ° ± 0.2 °.

In some embodiments, compound 1 levo-tartrate form LC has at least two characteristic XRPD peaks expressed in 2 Θ selected from 12.2 ° ± 0.2 °, 15.4 ° ± 0.2 °, 16.5 ° ± 0.2 °, 18.7 ° ± 0.2 °, 19.8 ° ± 0.2 °, 22.6 ° ± 0.2 °, 24.8 ° ± 0.2 ° and 25.5 ° ± 0.2 °. In some embodiments, compound 1 levo-tartrate form LC has at least two characteristic XRPD peaks expressed in 2 Θ selected from 12.2 ° ± 0.2 °, 12.8 ° ± 0.2 °, 15.4 ° ± 0.2 °, 16.5 ° ± 0.2 °, 18.7 ° ± 0.2 °, 19.8 ° ± 0.2 °, 20.0 ° ± 0.2 °, 22.4 ° ± 0.2 °, 22.6 ° ± 0.2 °, 24.8 ° ± 0.2 °, 25.0 ° ± 0.2 °, 25.5 ° ± 0.2 ° and 27.1 ° ± 0.2 °.

In some embodiments, compound 1 levo-tartrate form LC has at least three characteristic XRPD peaks, expressed in 2 Θ, selected from 12.2 ° ± 0.2 °, 15.4 ° ± 0.2 °, 16.5 ° ± 0.2 °, 18.7 ° ± 0.2 °, 19.8 ° ± 0.2 °, 22.6 ° ± 0.2 °, 24.8 ° ± 0.2 ° and 25.5 ° ± 0.2 °. In some embodiments, compound 1 levo-tartrate form LC has at least three characteristic XRPD peaks, expressed in 2 Θ, selected from 12.2 ° ± 0.2 °, 12.8 ° ± 0.2 °, 15.4 ° ± 0.2 °, 16.5 ° ± 0.2 °, 18.7 ° ± 0.2 °, 19.8 ° ± 0.2 °, 20.0 ° ± 0.2 °, 22.4 ° ± 0.2 °, 22.6 ° ± 0.2 °, 24.8 ° ± 0.2 °, 25.0 ° ± 0.2 °, 25.5 ° ± 0.2 ° and 27.1 ° ± 0.2 °.

In some embodiments, compound 1 levotartrate form LC has an XRPD pattern comprising characteristic peaks substantially as shown in figure 16 (figure 16).

In some embodiments, compound 1 levotartrate form LC has an endothermic peak at a temperature of about 137 ℃. In some embodiments, compound 1 levotartrate form LC has a DSC thermogram substantially as depicted in figure 17 (figure 17). In some embodiments, compound 1 levotartrate form LC has a TGA thermogram substantially as depicted in figure 18 (figure 18). In some embodiments, compound 1 l-tartrate form LC has a DVS isotherm substantially as depicted in figure 19 (figure 19).

In some embodiments, compound 1 levo-tartrate form LC has at least one characteristic XRPD peak, expressed in 2 Θ, selected from 12.2 ° ± 0.2 °, 16.5 ° ± 0.2 ° and 24.8 ° ± 0.2 °; and an endothermic peak at a temperature of about 137 ℃. In some embodiments, compound 1 levo-tartrate form LC has at least one characteristic XRPD peak, expressed in 2 Θ, selected from 12.2 ° ± 0.2 °, 16.5 ° ± 0.2 ° and 24.8 ° ± 0.2 °; and a DSC thermogram substantially as depicted in figure 17 (figure 17). In some embodiments, compound 1 levo-tartrate form LC has at least one characteristic XRPD peak, expressed in 2 Θ, selected from 12.2 ° ± 0.2 °, 16.5 ° ± 0.2 ° and 24.8 ° ± 0.2 °; and a DVS isotherm substantially as depicted in fig. 19 (fig. 19).

In some embodiments, compound 1 l-tartrate form LC may be isolated in a crystalline purity of at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99%. In some embodiments, compound 1 l-tartrate form LC may be isolated in greater than about 99% crystalline purity. In some embodiments, compound 1 l-tartrate form LC may be isolated in a crystalline purity of greater than about 99.9%.

In some embodiments, compound 1 l-tartrate form LB prepared by isolating compound 1 l-tartrate form LB from a mixture of compound 1, l-tartaric acid, and S1, wherein S1 is a solvent, is provided. In some embodiments, S1 is an organic solvent. In some embodiments, S1 is C_1-6An alkyl alcohol.In some embodiments, S1 is C_1-6Alkyl acetate ester. In some embodiments, S1 is a mixture of organic solvents. In some embodiments, S1 is C_1-6Alkyl alcohol and C_1-6A mixture of alkyl acetates. In some embodiments, S1 is a mixture of methanol and ethyl acetate.

Compound 1D-tartrate

In some embodiments, there is provided (R) -1- (8-fluoroisochroman-1-yl) -N-methylmethanamine d-tartrate (compound 1 d-tartrate). In some embodiments, compound 1 d-tartrate is crystalline.

In some embodiments, compound 1 d-tartrate has a characteristic XRPD peak, expressed in 2 Θ, selected from 11.9 ° ± 0.2 °, 16.9 ° ± 0.2 ° and 17.9 ° ± 0.2 °. In some embodiments, compound 1 dextrotartrate has a characteristic XRPD peak, expressed in 2 Θ, at 11.9 ° ± 0.2 °. In some embodiments, compound 1 dextrotartrate has a characteristic XRPD peak, expressed in 2 Θ, at 16.9 ° ± 0.2 °. In some embodiments, compound 1 dextrotartrate has a characteristic XRPD peak, expressed in 2 Θ, at 17.9 ° ± 0.2 °.

In some embodiments, compound 1 d-tartrate has characteristic XRPD peaks expressed in 2 Θ selected from 11.9 ° ± 0.2 °, 16.9 ° ± 0.2 °, 17.9 ° ± 0.2 ° and 23.9 ° ± 0.2 °. In some embodiments, compound 1 d-tartrate has at least one characteristic XRPD peak, expressed in 2 Θ, selected from 11.9 ° ± 0.2 °, 16.9 ° ± 0.2 °, 17.9 ° ± 0.2 ° and 23.9 ° ± 0.2 °.

In some embodiments, compound 1 d-tartrate has at least one characteristic XRPD peak, expressed in 2 Θ, selected from 11.9 ° ± 0.2 °, 12.3 ° ± 0.2 °, 16.1 ° ± 0.2 °, 16.9 ° ± 0.2 °, 17.9 ° ± 0.2 °, 19.1 ° ± 0.2 °, and 23.9 ° ± 0.2 °. In some embodiments, compound 1 dextrotartrate has at least one characteristic XRPD peak, expressed in 2 Θ, selected from 6.0 ° ± 0.2 °, 11.9 ° ± 0.2 °, 12.3 ° ± 0.2 °, 13.4 ° ± 0.2 °, 14.9 ° ± 0.2 °, 16.1 ° ± 0.2 °, 16.9 ° ± 0.2 °, 17.9 ° ± 0.2 °, 19.1 ° ± 0.2 °, 21.6 ° ± 0.2 °, 23.9 ° ± 0.2 °, and 24.6 ° ± 0.2 °.

In some embodiments, compound 1 d-tartrate has at least two characteristic XRPD peaks, expressed in 2 Θ, selected from 11.9 ° ± 0.2 °, 12.3 ° ± 0.2 °, 16.1 ° ± 0.2 °, 16.9 ° ± 0.2 °, 17.9 ° ± 0.2 °, 19.1 ° ± 0.2 ° and 23.9 ° ± 0.2 °. In some embodiments, compound 1 dextrotartrate has at least two characteristic XRPD peaks, expressed in 2 Θ, selected from 6.0 ° ± 0.2 °, 11.9 ° ± 0.2 °, 12.3 ° ± 0.2 °, 13.4 ° ± 0.2 °, 14.9 ° ± 0.2 °, 16.1 ° ± 0.2 °, 16.9 ° ± 0.2 °, 17.9 ° ± 0.2 °, 19.1 ° ± 0.2 °, 21.6 ° ± 0.2 °, 23.9 ° ± 0.2 °, and 24.6 ° ± 0.2 °.

In some embodiments, compound 1 d-tartrate has at least three characteristic XRPD peaks, expressed in 2 Θ, selected from 11.9 ° ± 0.2 °, 12.3 ° ± 0.2 °, 16.1 ° ± 0.2 °, 16.9 ° ± 0.2 °, 17.9 ° ± 0.2 °, 19.1 ° ± 0.2 ° and 23.9 ° ± 0.2 °. In some embodiments, compound 1 dextrotartrate has at least three characteristic XRPD peaks, expressed in 2 Θ, selected from 6.0 ° ± 0.2 °, 11.9 ° ± 0.2 °, 12.3 ° ± 0.2 °, 13.4 ° ± 0.2 °, 14.9 ° ± 0.2 °, 16.1 ° ± 0.2 °, 16.9 ° ± 0.2 °, 17.9 ° ± 0.2 °, 19.1 ° ± 0.2 °, 21.6 ° ± 0.2 °, 23.9 ° ± 0.2 °, and 24.6 ° ± 0.2 °.

In some embodiments, compound 1 dextrotartrate has an XRPD pattern comprising characteristic peaks substantially as shown in figure 20 (figure 20).

In some embodiments, compound 1 dextrotartrate has endothermic peaks at temperatures of about 76 ℃ and about 153 ℃. In some embodiments, compound 1 dextrotartrate has an endothermic peak at a temperature of about 76 ℃. In some embodiments, compound 1 dextrotartrate has an endothermic peak at a temperature of about 153 ℃. In some embodiments, compound 1 d-tartrate has a DVS isotherm substantially as depicted in figure 21 (figure 21).

In some embodiments, compound 1 d-tartrate has at least one characteristic XRPD peak, expressed in 2 Θ, selected from 11.9 ° ± 0.2 °, 16.9 ° ± 0.2 °, 17.9 ° ± 0.2 ° and 23.9 ° ± 0.2 °; and has endothermic peaks at temperatures of about 76 ℃ and about 153 ℃. In some embodiments, compound 1 d-tartrate has at least one characteristic XRPD peak, expressed in 2 Θ, selected from 11.9 ° ± 0.2 °, 16.9 ° ± 0.2 °, 17.9 ° ± 0.2 ° and 23.9 ° ± 0.2 °; and an endothermic peak at a temperature of about 76 ℃. In some embodiments, compound 1 d-tartrate has at least one characteristic XRPD peak, expressed in 2 Θ, selected from 11.9 ° ± 0.2 °, 16.9 ° ± 0.2 °, 17.9 ° ± 0.2 ° and 23.9 ° ± 0.2 °; and an endothermic peak at a temperature of about 153 ℃. In some embodiments, compound 1 d-tartrate has at least one characteristic XRPD peak, expressed in 2 Θ, selected from 11.9 ° ± 0.2 °, 16.9 ° ± 0.2 °, 17.9 ° ± 0.2 ° and 23.9 ° ± 0.2 °; and a DVS isotherm substantially as depicted in fig. 21 (fig. 21).

In some embodiments, compound 1 dextrotartrate can be isolated in a crystalline purity of at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99%. In some embodiments, compound 1 dextrotartrate can be isolated in a crystalline purity of greater than about 99%. In some embodiments, the compound dextrotartrate salt may be isolated in a crystalline purity of greater than about 99.9%.

In some embodiments, compound 1 d-tartrate salt prepared by isolating compound 1 d-tartrate salt from a mixture of compound 1, d-tartaric acid and S1, wherein S1 is a solvent, is provided. In some embodiments, S1 is an organic solvent. In some embodiments, S1 is an ether. In some embodiments, S1 is C_1-6Alkyl acetate ester. In some embodiments, S1 is THF.

In some embodiments, S1 is ethyl acetate.

Compound 1 fumarate salt

In some embodiments, (R) -1- (8-fluoroisochroman-1-yl) -N-methylmethanemethanemeumarate (compound 1 fumarate) is provided. In some embodiments, compound 1 fumarate salt is crystalline.

In some embodiments, provided is compound 1 fumarate made by isolating compound 1 fumarate from a mixture of compound 1, fumaric acid, and S1, wherein S1 is a solvent. In some embodiments, S1 is an organic solvent. In thatIn some embodiments, S1 is C_1-6An alkyl alcohol. In some embodiments, S1 is an ether. In some embodiments, S1 is C_1-6Alkyl acetate ester. In some embodiments, S1 is C_1-6An alkyl ketone. In some embodiments, S1 is a mixture of organic solvents. In some embodiments, S1 is C _1-6Alkyl alcohol and C_1-6Mixtures of alkyl ketones. In some embodiments, S1 is methanol. In some embodiments, S1 is THF. In some embodiments, S1 is ethyl acetate. In some embodiments, S1 is a mixture of methanol and acetone.

Compound 1 fumarate salt form FA

In some embodiments, there is provided (R) -1- (8-fluoroisochroman-1-yl) -N-methylmethanemethanemeumarate form FA (compound 1 fumarate form FA). In some embodiments, compound 1 fumarate salt form FA is crystalline.

In some embodiments, compound 1 fumarate form FA has a characteristic XRPD peak, expressed in 2 Θ, selected from 7.7 ° ± 0.2 °, 14.2 ° ± 0.2 ° and 15.2 ° ± 0.2 °. In some embodiments, compound 1 fumarate form FA has a characteristic XRPD peak, expressed in 2 Θ, at 7.7 ° ± 0.2 °. In some embodiments, compound 1 fumarate salt form FA has a characteristic XRPD peak, expressed in 2 Θ, at 14.2 ° ± 0.2 °. In some embodiments, compound 1 fumarate salt form FA has a characteristic XRPD peak, expressed in 2 Θ, at 15.2 ° ± 0.2 °.

In some embodiments, compound 1 fumarate form FA has a characteristic XRPD peak, expressed in 2 Θ, selected from 7.7 ° ± 0.2 °, 15.2 ° ± 0.2 °, 22.9 ° ± 0.2 ° and 30.7 ° ± 0.2 °. In some embodiments, compound 1 fumarate form FA has at least one characteristic XRPD peak, expressed in 2 Θ, selected from 7.7 ° ± 0.2 °, 15.2 ° ± 0.2 °, 22.9 ° ± 0.2 ° and 30.7 ° ± 0.2 °.

In some embodiments, compound 1 fumarate form FA has at least one characteristic XRPD peak, expressed in 2 Θ, selected from 7.7 ° ± 0.2 °, 13.0 ° ± 0.2 °, 14.2 ° ± 0.2 °, 15.2 ° ± 0.2 °, 22.9 ° ± 0.2 °, 24.6 ° ± 0.2 °, 26.0 ° ± 0.2 ° and 30.7 ° ± 0.2 °. In some embodiments, compound 1 fumarate form FA has at least one characteristic XRPD peak, expressed in 2 Θ, selected from 7.7 ° ± 0.2 °, 12.1 ° ± 0.2 °, 13.0 ° ± 0.2 °, 14.2 ° ± 0.2 °, 14.6 ° ± 0.2 °, 15.2 ° ± 0.2 °, 18.1 ° ± 0.2 °, 18.8 ° ± 0.2 °, 22.9 ° ± 0.2 °, 24.6 ° ± 0.2 °, 26.0 ° ± 0.2 °, and 30.7 ° ± 0.2 °.

In some embodiments, compound 1 fumarate form FA has at least two characteristic XRPD peaks expressed in 2 Θ selected from 7.7 ° ± 0.2 °, 13.0 ° ± 0.2 °, 14.2 ° ± 0.2 °, 15.2 ° ± 0.2 °, 22.9 ° ± 0.2 °, 24.6 ° ± 0.2 °, 26.0 ° ± 0.2 ° and 30.7 ° ± 0.2 °. In some embodiments, compound 1 fumarate form FA has at least two characteristic XRPD peaks expressed in 2 Θ selected from 7.7 ° ± 0.2 °, 12.1 ° ± 0.2 °, 13.0 ° ± 0.2 °, 14.2 ° ± 0.2 °, 14.6 ° ± 0.2 °, 15.2 ° ± 0.2 °, 18.1 ° ± 0.2 °, 18.8 ° ± 0.2 °, 22.9 ° ± 0.2 °, 24.6 ° ± 0.2 °, 26.0 ° ± 0.2 ° and 30.7 ° ± 0.2 °.

In some embodiments, compound 1 fumarate form FA has at least three characteristic XRPD peaks expressed in 2 Θ selected from 7.7 ° ± 0.2 °, 13.0 ° ± 0.2 °, 14.2 ° ± 0.2 °, 15.2 ° ± 0.2 °, 22.9 ° ± 0.2 °, 24.6 ° ± 0.2 °, 26.0 ° ± 0.2 ° and 30.7 ° ± 0.2 °. In some embodiments, compound 1 fumarate form FA has at least three characteristic XRPD peaks, expressed in 2 Θ, selected from 7.7 ° ± 0.2 °, 12.1 ° ± 0.2 °, 13.0 ° ± 0.2 °, 14.2 ° ± 0.2 °, 14.6 ° ± 0.2 °, 15.2 ° ± 0.2 °, 18.1 ° ± 0.2 °, 18.8 ° ± 0.2 °, 22.9 ° ± 0.2 °, 24.6 ° ± 0.2 °, 26.0 ° ± 0.2 °, and 30.7 ° ± 0.2 °.

In some embodiments, compound 1 fumarate form FA has an XRPD pattern comprising characteristic peaks substantially as shown in figure 22 (figure 22).

In some embodiments, compound 1 fumarate form FA has an endothermic peak at a temperature of about 138 ℃. In some embodiments, compound 1 fumarate form FA has a DSC thermogram substantially as depicted in figure 23 (figure 23). In some embodiments, compound 1 levofumarate form FA has a TGA thermogram substantially as depicted in figure 24 (figure 24). In some embodiments, compound 1 fumarate form FA has a DVS isotherm substantially as depicted in figure 25 (figure 25).

In some embodiments, compound 1 fumarate form FA has a characteristic XRPD peak, expressed in 2 Θ, selected from 7.7 ° ± 0.2 °, 14.2 ° ± 0.2 ° and 15.2 ° ± 0.2 °; and an endothermic peak at a temperature of about 147 ℃. In some embodiments, compound 1 fumarate form FA has a characteristic XRPD peak, expressed in 2 Θ, selected from 7.7 ° ± 0.2 °, 14.2 ° ± 0.2 ° and 15.2 ° ± 0.2 °; and a DSC heatmap substantially as depicted in figure 23 (figure 23). In some embodiments, compound 1 fumarate form FA has a characteristic XRPD peak, expressed in 2 Θ, selected from 7.7 ° ± 0.2 °, 14.2 ° ± 0.2 ° and 15.2 ° ± 0.2 °; and a DVS isotherm substantially as depicted in fig. 25 (fig. 25).

In some embodiments, compound 1 fumarate salt form FA can be isolated in a crystalline purity of at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99%. In some embodiments, compound 1, as the fumarate salt of FA can be isolated in a crystalline purity of greater than about 99%. In some embodiments, compound 1, as the fumarate salt of FA can be isolated in a crystalline purity of greater than about 99.9%.

In some embodiments, provided is compound 1 fumarate form FA prepared by isolating compound 1 fumarate form FA from a mixture of compound 1, fumaric acid, and S1, wherein S1 is a solvent. In some embodiments, S1 is an organic solvent. In some embodiments, S1 is C _1-6An alkyl alcohol. In some embodiments, S1 is an ether. In some embodiments, S1 is C_1-6An alkyl ketone. In some embodiments, S1 is a mixture of organic solvents. In some embodiments, S1 is C_1-6Alkyl alcohol and C_1-6Mixtures of alkyl ketones. In some embodiments, S1 is methanol. In some embodiments, S1 is THF. In some embodiments, S1 is a mixture of methanol and acetone.

Compound 1 fumarate salt FB

In some embodiments, there is provided (R) -1- (8-fluoroisochroman-1-yl) -N-methylmethanemethanemeumarate form FB (compound 1 fumarate form FB). In some embodiments, compound 1 fumarate salt form FB is crystalline.

In some embodiments, compound 1 fumarate salt form FB has characteristic XRPD peaks expressed in 2 Θ selected from 6.7 ° ± 0.2 °, 13.8 ° ± 0.2 ° and 20.2 ° ± 0.2 °. In some embodiments, compound 1 fumarate salt form FB has a characteristic XRPD peak, expressed in 2 Θ, at 6.7 ° ± 0.2 °. In some embodiments, compound 1 fumarate salt form FB has a characteristic XRPD peak, expressed in 2 Θ, at 13.8 ° ± 0.2 °. In some embodiments, compound 1 fumarate salt form FB has a characteristic XRPD peak, expressed in 2 Θ, at 20.2 ° ± 0.2 °. In some embodiments, compound 1 fumarate salt form FB has a characteristic XRPD peak, expressed in 2 Θ, at 27.0 ° ± 0.2 °.

In some embodiments, compound 1 fumarate salt form FB has at least one characteristic XRPD peak, expressed in 2 Θ, selected from 6.7 ° ± 0.2 °, 13.4 ° ± 0.2 °, 13.8 ° ± 0.2 °, 20.2 ° ± 0.2 °, 23.5 ° ± 0.2 °, 25.1 ° ± 0.2 °, 27.0 ° ± 0.2 ° and 29.6 ° ± 0.2 °. In some embodiments, compound 1 fumarate salt form FB has at least one characteristic XRPD peak, expressed in 2 Θ, selected from 6.7 ° ± 0.2 °, 13.4 ° ± 0.2 °, 13.8 ° ± 0.2 °, 20.2 ° ± 0.2 °, 23.1 ° ± 0.2 °, 23.5 ° ± 0.2 °, 24.2 ° ± 0.2 °, 25.1 ° ± 0.2 °, 27.0 ° ± 0.2 ° and 29.6 ° ± 0.2 °.

In some embodiments, compound 1 fumarate salt form FB has at least two characteristic XRPD peaks expressed in 2 Θ selected from 6.7 ° ± 0.2 °, 13.4 ° ± 0.2 °, 13.8 ° ± 0.2 °, 20.2 ° ± 0.2 °, 23.5 ° ± 0.2 °, 25.1 ° ± 0.2 °, 27.0 ° ± 0.2 ° and 29.6 ° ± 0.2 °. In some embodiments, compound 1 fumarate salt form FB has at least two characteristic XRPD peaks expressed in 2 Θ selected from 6.7 ° ± 0.2 °, 13.4 ° ± 0.2 °, 13.8 ° ± 0.2 °, 20.2 ° ± 0.2 °, 23.1 ° ± 0.2 °, 23.5 ° ± 0.2 °, 24.2 ° ± 0.2 °, 25.1 ° ± 0.2 °, 27.0 ° ± 0.2 ° and 29.6 ° ± 0.2 °.

In some embodiments, compound 1 fumarate salt form FB has at least three characteristic XRPD peaks expressed in 2 Θ selected from 6.7 ° ± 0.2 °, 13.4 ° ± 0.2 °, 13.8 ° ± 0.2 °, 20.2 ° ± 0.2 °, 23.5 ° ± 0.2 °, 25.1 ° ± 0.2 °, 27.0 ° ± 0.2 ° and 29.6 ° ± 0.2 °. In some embodiments, compound 1 fumarate salt form FB has at least three characteristic XRPD peaks expressed in 2 Θ selected from 6.7 ° ± 0.2 °, 13.4 ° ± 0.2 °, 13.8 ° ± 0.2 °, 20.2 ° ± 0.2 °, 23.1 ° ± 0.2 °, 23.5 ° ± 0.2 °, 24.2 ° ± 0.2 °, 25.1 ° ± 0.2 °, 27.0 ° ± 0.2 ° and 29.6 ° ± 0.2 °.

In some embodiments, compound 1 fumarate salt form FB has an XRPD pattern comprising characteristic peaks substantially as shown in figure 26 (figure 26).

In some embodiments, compound 1 fumarate salt form FB has endothermic peaks at about 96 ℃, about 139 ℃, and about 146 ℃. In some embodiments, compound 1 fumarate salt form FB has an endothermic peak at a temperature of about 96 ℃. In some embodiments, compound 1 fumarate salt form FB has an endothermic peak at a temperature of about 139 ℃. In some embodiments, compound 1 fumarate salt form FB has an endothermic peak at a temperature of about 146 ℃ C. In some embodiments, compound 1 fumarate salt form FB has a DSC thermogram substantially as depicted in figure 27 (figure 27). In some embodiments, compound 1 fumarate salt form FB has a TGA thermogram substantially as depicted in figure 28 (figure 28). In some embodiments, compound 1 fumarate salt form FB has a DVS isotherm substantially as depicted in figure 29 (figure 29).

In some embodiments, compound 1 fumarate salt form FB has at least one characteristic XRPD peak, expressed in 2 Θ, selected from 6.7 ° ± 0.2 °, 13.8 ° ± 0.2 ° and 20.2 ° ± 0.2 °; and endothermic peaks at temperatures of about 96 ℃, about 139 ℃ and about 146 ℃. In some embodiments, compound 1 fumarate salt form FB has at least one characteristic XRPD peak, expressed in 2 Θ, selected from 6.7 ° ± 0.2 °, 13.8 ° ± 0.2 ° and 20.2 ° ± 0.2 °; and an endothermic peak at about 95 ℃. In some embodiments, compound 1 fumarate salt form FB has at least one characteristic XRPD peak, expressed in 2 Θ, selected from 6.7 ° ± 0.2 °, 13.8 ° ± 0.2 ° and 20.2 ° ± 0.2 °; and an endothermic peak at a temperature of about 139 ℃. In some embodiments, compound 1 fumarate salt form FB has at least one characteristic XRPD peak, expressed in 2 Θ, selected from 6.7 ° ± 0.2 °, 13.8 ° ± 0.2 ° and 20.2 ° ± 0.2 °; and an endothermic peak at a temperature of about 146 ℃. In some embodiments, compound 1 fumarate salt form FB has at least one characteristic XRPD peak, expressed in 2 Θ, selected from 6.7 ° ± 0.2 °, 13.8 ° ± 0.2 ° and 20.2 ° ± 0.2 °; and a DSC heatmap substantially as depicted in figure 27 (figure 27). In some embodiments, compound 1 fumarate salt form FB has at least one characteristic XRPD peak, expressed in 2 Θ, selected from 6.7 ° ± 0.2 °, 13.8 ° ± 0.2 ° and 20.2 ° ± 0.2 °; and a DVS isotherm substantially as depicted in fig. 29 (fig. 29).

In some embodiments, compound 1 fumarate salt form FB can be isolated in a crystalline purity of at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99%. In some embodiments, compound 1 fumarate salt form FB can be isolated in a crystalline purity of greater than about 99%. In some embodiments, compound 1 fumarate salt form FB can be isolated in a crystalline purity of greater than about 99.9%.

In some embodiments, compound 1 fumarate form FB is provided prepared by isolating compound 1 fumarate form FB from a mixture of compound 1, fumaric acid, and S1, wherein S1 is a solvent. In some embodiments, S1 is an organic solvent. In some embodiments, S1 is C_1-6Alkyl acetate ester. In some embodiments, S1 is ethyl acetate.

Compound 1 citrate salt

In some embodiments, there is provided (R) -1- (8-fluoroisochroman-1-yl) -N-methylmethanamine citrate. In some embodiments, compound 1 citrate salt is crystalline. In some embodiments, compound 1 citrate has a characteristic XRPD peak, expressed in 2 Θ, selected from 6.5 ° ± 0.2 °, 15.5 ° ± 0.2 ° and 20.4 ° ± 0.2 °. In some embodiments, compound 1 citrate has a characteristic XRPD peak, expressed in 2 Θ, at 6.5 ° ± 0.2 °. In some embodiments, compound 1 citrate has a characteristic XRPD peak, expressed in 2 Θ, at 15.5 ° ± 0.2 °. In some embodiments, compound 1 citrate has a characteristic XRPD peak, expressed in 2 Θ, at 20.4 ° ± 0.2 °.

In some embodiments, compound 1 citrate has at least one characteristic XRPD peak, expressed in 2 Θ, selected from 6.5 ° ± 0.2 °, 10.2 ° ± 0.2 °, 13.0 ° ± 0.2 °, 14.5 ° ± 0.2 °, 15.5 ° ± 0.2 °, 17.8 ° ± 0.2 °, 19.4 ° ± 0.2 °, and 20.4 ° ± 0.2 °. In some embodiments, compound 1 citrate has at least one characteristic XRPD peak, expressed in 2 Θ, selected from 6.5 ° ± 0.2 °, 10.2 ° ± 0.2 °, 13.0 ° ± 0.2 °, 14.5 ° ± 0.2 °, 15.5 ° ± 0.2 °, 16.5 ° ± 0.2 °, 17.3 ° ± 0.2 °, 17.8 ° ± 0.2 °, 19.4 ° ± 0.2 °, 20.4 ° ± 0.2 °, 20.8 ° ± 0.2 °, 21.2 ° ± 0.2 °, 21.5 ° ± 0.2 °, 22.0 ° ± 0.2 °, 23.1 ° ± 0.2 ° and 26.0 ° ± 0.2 °.

In some embodiments, compound 1 citrate has at least two characteristic XRPD peaks expressed in 2 Θ selected from 6.5 ° ± 0.2 °, 10.2 ° ± 0.2 °, 13.0 ° ± 0.2 °, 14.5 ° ± 0.2 °, 15.5 ° ± 0.2 °, 17.8 ° ± 0.2 °, 19.4 ° ± 0.2 ° and 20.4 ° ± 0.2 °. In some embodiments, compound 1 citrate has at least two characteristic XRPD peaks expressed in 2 Θ selected from 6.5 ° ± 0.2 °, 10.2 ° ± 0.2 °, 13.0 ° ± 0.2 °, 14.5 ° ± 0.2 °, 15.5 ° ± 0.2 °, 16.5 ° ± 0.2 °, 17.3 ° ± 0.2 °, 17.8 ° ± 0.2 °, 19.4 ° ± 0.2 °, 20.4 ° ± 0.2 °, 20.8 ° ± 0.2 °, 21.2 ° ± 0.2 °, 21.5 ° ± 0.2 °, 22.0 ° ± 0.2 °, 23.1 ° ± 0.2 ° and 26.0 ° ± 0.2 °.

In some embodiments, compound 1 citrate has at least three characteristic XRPD peaks expressed in 2 Θ selected from 6.5 ° ± 0.2 °, 10.2 ° ± 0.2 °, 13.0 ° ± 0.2 °, 14.5 ° ± 0.2 °, 15.5 ° ± 0.2 °, 17.8 ° ± 0.2 °, 19.4 ° ± 0.2 ° and 20.4 ° ± 0.2 °. In some embodiments, compound 1 citrate has at least three characteristic XRPD peaks expressed in 2 Θ selected from 6.5 ° ± 0.2 °, 10.2 ° ± 0.2 °, 13.0 ° ± 0.2 °, 14.5 ° ± 0.2 °, 15.5 ° ± 0.2 °, 16.5 ° ± 0.2 °, 17.3 ° ± 0.2 °, 17.8 ° ± 0.2 °, 19.4 ° ± 0.2 °, 20.4 ° ± 0.2 °, 20.8 ° ± 0.2 °, 21.2 ° ± 0.2 °, 21.5 ° ± 0.2 °, 22.0 ° ± 0.2 °, 23.1 ° ± 0.2 ° and 26.0 ° ± 0.2 °.

In some embodiments, compound 1 citrate has an XRPD pattern containing characteristic peaks substantially as shown in figure 30 (figure 30).

In some embodiments, compound 1 citrate has an endothermic peak at a temperature of about 142 ℃. In some embodiments, compound 1 citrate has a DSC thermogram substantially as depicted in figure 31 (figure 31). In some embodiments, compound 1 citrate has a TGA thermogram substantially as depicted in figure 32 (figure 32). In some embodiments, compound 1 citrate has a DVS isotherm substantially as depicted in figure 33 (figure 33).

In some embodiments, compound 1 citrate has at least one characteristic XRPD peak, expressed in 2 Θ, selected from 6.5 ° ± 0.2 °, 15.5 ° ± 0.2 °, and 20.4 ° ± 0.2 °; and an endothermic peak at a temperature of about 142 ℃. In some embodiments, compound 1 citrate has at least one characteristic XRPD peak, expressed in 2 Θ, selected from 6.5 ° ± 0.2 °, 15.5 ° ± 0.2 °, and 20.4 ° ± 0.2 °; and a DSC heatmap substantially as depicted in figure 31 (figure 31). In some embodiments, compound 1 citrate has at least one characteristic XRPD peak, expressed in 2 Θ, selected from 6.5 ° ± 0.2 °, 15.5 ° ± 0.2 °, and 20.4 ° ± 0.2 °; and a DVS isotherm substantially as depicted in fig. 33 (fig. 33).

In some embodiments, compound 1 citrate salt may be isolated in a crystalline purity of at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99%. In some embodiments, compound 1 citrate salt may be isolated in a crystalline purity of greater than about 99%.

In some embodiments, compound 1 citrate salt may be isolated in a crystalline purity of greater than about 99.9%.

In some embodiments, provided is compound 1 citrate salt prepared by isolating compound 1 citrate salt from a mixture of compound 1, citric acid, and S1, wherein S1 is a solvent. In some embodiments, S1 is an organic solvent. In some embodiments, S1 is C _1-6An alkyl alcohol. In some embodiments, S1 is an ether. In some embodiments, S1 is C_1-6Alkyl acetate ester. In some embodiments, S1 is C_1-6An alkyl ketone. In some embodiments, S1 is a mixture of organic solvents. In some embodiments, S1 is C_1-6Alkyl alcohol and C_1-6Mixtures of alkyl ketones. In some embodiments, S1 is C_1-6Alkyl alcohol and C_1-6A mixture of alkyl acetates. In some embodiments, S1 is ethyl acetate. In some embodiments, S1 is a mixture of methanol and acetone. In some embodiments, S1 is THF. In some embodiments, S1 is a mixture of methanol and ethyl acetate.

Compound 1 succinate salt

In some embodiments, there is provided (R) -1- (8-fluoroisochroman-1-yl) -N-methyl methylamine succinate. In some embodiments, compound 1 succinate salt is crystalline.

In some embodiments, compound 1 succinate salt has a characteristic XRPD peak, expressed in 2 Θ, selected from 6.6 ° ± 0.2 °, 12.8 ° ± 0.2 ° and 13.9 ° ± 0.2 °. In some embodiments, compound 1 succinate salt has a characteristic XRPD peak, expressed in 2 Θ, at 6.6 ° ± 0.2 °. In some embodiments, compound 1 succinate salt has a characteristic XRPD peak, expressed in 2 Θ, at 12.8 ° ± 0.2 °. In some embodiments, compound 1 succinate salt has a characteristic XRPD peak, expressed in 2 Θ, at 13.9 ° ± 0.2 °.

In some embodiments, compound 1 succinate salt has a characteristic XRPD peak, expressed in 2 Θ, selected from 12.8 ° ± 0.2 °, 13.9 ° ± 0.2 °, 19.8 ° ± 0.2 ° and 26.5 ° ± 0.2 °. In some embodiments, compound 1 succinate salt has at least one characteristic XRPD peak, expressed in 2 Θ, selected from 12.8 ° ± 0.2 °, 13.9 ° ± 0.2 °, 19.8 ° ± 0.2 ° and 26.5 ° ± 0.2 °.

In some embodiments, compound 1 succinate salt has at least one characteristic XRPD peak, expressed in 2 Θ, selected from 12.8 ° ± 0.2 °, 13.9 ° ± 0.2 °, 16.0 ° ± 0.2 °, 19.2 ° ± 0.2 °, 19.8 ° ± 0.2 °, 21.1 ° ± 0.2 °, 22.9 ° ± 0.2 °, 23.3 ° ± 0.2 °, 25.4 ° ± 0.2 ° and 26.5 ° ± 0.2 °. In some embodiments, compound 1 succinate has at least one characteristic XRPD peak, expressed in 2 Θ, selected from 6.6 ° ± 0.2 °, 9.0 ° ± 0.2 °, 11.5 ° ± 0.2 °, 12.8 ° ± 0.2 °, 13.9 ° ± 0.2 °, 16.0 ° ± 0.2 °, 19.2 ° ± 0.2 °, 19.8 ° ± 0.2 °, 21.1 ° ± 0.2 °, 22.9 ° ± 0.2 °, 23.3 ° ± 0.2 °, 25.2 ° ± 0.2 °, 25.4 ° ± 0.2 ° and 26.5 ° ± 0.2 °.

In some embodiments, compound 1 succinate salt has at least two characteristic XRPD peaks expressed in 2 Θ selected from 12.8 ° ± 0.2 °, 13.9 ° ± 0.2 °, 16.0 ° ± 0.2 °, 19.2 ° ± 0.2 °, 19.8 ° ± 0.2 °, 21.1 ° ± 0.2 °, 22.9 ° ± 0.2 °, 23.3 ° ± 0.2 °, 25.4 ° ± 0.2 ° and 26.5 ° ± 0.2 °. In some embodiments, compound 1 succinate has at least two characteristic XRPD peaks expressed in 2 Θ selected from 6.6 ° ± 0.2 °, 9.0 ° ± 0.2 °, 11.5 ° ± 0.2 °, 12.8 ° ± 0.2 °, 13.9 ° ± 0.2 °, 16.0 ° ± 0.2 °, 19.2 ° ± 0.2 °, 19.8 ° ± 0.2 °, 21.1 ° ± 0.2 °, 22.9 ° ± 0.2 °, 23.3 ° ± 0.2 °, 25.2 ° ± 0.2 °, 25.4 ° ± 0.2 ° and 26.5 ° ± 0.2 °.

In some embodiments, compound 1 succinate salt has at least three characteristic XRPD peaks expressed in 2 Θ selected from 12.8 ° ± 0.2 °, 13.9 ° ± 0.2 °, 16.0 ° ± 0.2 °, 19.2 ° ± 0.2 °, 19.8 ° ± 0.2 °, 21.1 ° ± 0.2 °, 22.9 ° ± 0.2 °, 23.3 ° ± 0.2 °, 25.4 ° ± 0.2 ° and 26.5 ° ± 0.2 °. In some embodiments, compound 1 succinate has at least three characteristic XRPD peaks expressed in 2 Θ selected from 6.6 ° ± 0.2 °, 9.0 ° ± 0.2 °, 11.5 ° ± 0.2 °, 12.8 ° ± 0.2 °, 13.9 ° ± 0.2 °, 16.0 ° ± 0.2 °, 19.2 ° ± 0.2 °, 19.8 ° ± 0.2 °, 21.1 ° ± 0.2 °, 22.9 ° ± 0.2 °, 23.3 ° ± 0.2 °, 25.2 ° ± 0.2 °, 25.4 ° ± 0.2 ° and 26.5 ° ± 0.2 °.

In some embodiments, compound 1 succinate salt has an XRPD pattern comprising characteristic peaks substantially as shown in figure 34 (figure 34).

In some embodiments, compound 1 succinate salt has an endothermic peak at a temperature of about 153 ℃. In some embodiments, compound 1 succinate salt has a DSC thermogram substantially as depicted in figure 35 (figure 35). In some embodiments, compound 1 succinate salt has a TGA thermogram substantially as depicted in figure 36 (figure 36). In some embodiments, compound 1 succinate salt has a DVS isotherm substantially as depicted in figure 37 (figure 37).

In some embodiments, compound 1 succinate salt has at least one characteristic XRPD peak, expressed in 2 Θ, selected from 12.8 ° ± 0.2 °, 13.9 ° ± 0.2 °, 19.8 ° ± 0.2 ° and 26.5 ° ± 0.2 °; and an endothermic peak at a temperature of about 153 ℃. In some embodiments, compound 1 succinate salt has at least one characteristic XRPD peak, expressed in 2 Θ, selected from 12.8 ° ± 0.2 °, 13.9 ° ± 0.2 °, 19.8 ° ± 0.2 ° and 26.5 ° ± 0.2 °; and a DSC thermogram substantially as depicted in figure 35 (figure 35). In some embodiments, compound 1 succinate salt has at least one characteristic XRPD peak, expressed in 2 Θ, selected from 12.8 ° ± 0.2 °, 13.9 ℃ 0.2 °, 19.8 ° ± 0.2 °, and 26.5 ° ± 0.2 °; and a DVS isotherm substantially as depicted in fig. 37 (fig. 37).

In some embodiments, compound 1 succinate salt can be isolated in a crystalline purity of at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99%. In some embodiments, compound 1 succinate salt can be isolated in greater than about 99% crystalline purity.

In some embodiments, compound 1 succinate salt can be isolated in a crystalline purity of greater than about 99.9%.

In some embodiments, provided is compound 1 succinate salt prepared by isolating compound 1 succinate salt from a mixture of compound 1, succinic acid and S1, wherein S1 is a solvent. In some embodiments, S1 is an organic solvent. In some embodiments, S1 is an ether. In some embodiments, S1 is C_1-6Alkyl acetate ester. In some embodiments, S1 is THF. In some embodiments, S1 is ethyl acetate.

Compound 1 glutarate

In some embodiments, (R) -1- (8-fluoroisochroman-1-yl) -N-methylmethanemethylamine glutarate is provided. In some embodiments, compound 1 glutarate salt is crystalline.

In some embodiments, compound 1 glutarate salt has a characteristic XRPD peak expressed in 2 θ selected from 9.1 ° ± 0.2 °, 10.6 ° ± 0.2 ° and 18.2 ° ± 0.2 °. In some embodiments, compound 1 glutarate salt has a characteristic XRPD peak, expressed in 2 θ, at 9.1 ° ± 0.2 °. In some embodiments, compound 1 glutarate salt has a characteristic XRPD peak, expressed in 2 θ, at 10.6 ° ± 0.2 °. In some embodiments, compound 1 glutarate salt has a characteristic XRPD peak, expressed in 2 θ, at 18.2 ° ± 0.2 °.

In some embodiments, compound 1 glutarate salt has a characteristic XRPD peak, expressed in 2 θ, selected from 9.1 ° ± 0.2 °, 10.6 ° ± 0.2 °, 18.2 ° ± 0.2 ° and 19.0 ° ± 0.2 °. In some embodiments, compound 1 glutarate salt has at least one characteristic XRPD peak, expressed in 2 Θ, selected from 9.1 ° ± 0.2 °, 10.6 ° ± 0.2 °, 18.2 ° ± 0.2 ° and 19.0 ° ± 0.2 °.

In some embodiments, compound 1 glutarate salt has at least one characteristic XRPD peak, expressed in 2 Θ, selected from 9.1 ° ± 0.2 °, 10.6 ° ± 0.2 °, 18.2 ° ± 0.2 °, 19.0 ° ± 0.2 °, 22.5 ° ± 0.2 °, 27.4 ° ± 0.2 ° and 28.0 ° ± 0.2 °. In some embodiments, compound 1 glutarate salt has at least one characteristic XRPD peak, expressed in 2 Θ, selected from 9.1 ° ± 0.2 °, 10.6 ° ± 0.2 °, 18.2 ° ± 0.2 °, 19.0 ° ± 0.2 °, 21.8 ° ± 0.2 °, 21.9 ° ± 0.2 °, 22.5 ° ± 0.2 °, 25.8 ° ± 0.2 °, 27.4 ° ± 0.2 ° and 28.0 ° ± 0.2 °.

In some embodiments, compound 1 glutarate salt has at least two characteristic XRPD peaks expressed in 2 Θ selected from 9.1 ° ± 0.2 °, 10.6 ° ± 0.2 °, 18.2 ° ± 0.2 °, 19.0 ° ± 0.2 °, 22.5 ° ± 0.2 °, 27.4 ° ± 0.2 ° and 28.0 ° ± 0.2 °. In some embodiments, compound 1 glutarate salt has at least two characteristic XRPD peaks expressed in 2 Θ selected from 9.1 ° ± 0.2 °, 10.6 ° ± 0.2 °, 18.2 ° ± 0.2 °, 19.0 ° ± 0.2 °, 21.8 ° ± 0.2 °, 21.9 ° ± 0.2 °, 22.5 ° ± 0.2 °, 25.8 ° ± 0.2 °, 27.4 ° ± 0.2 ° and 28.0 ° ± 0.2 °.

In some embodiments, compound 1 glutarate salt has at least three characteristic XRPD peaks expressed in 2 Θ selected from 9.1 ° ± 0.2 °, 10.6 ° ± 0.2 °, 18.2 ° ± 0.2 °, 19.0 ° ± 0.2 °, 22.5 ° ± 0.2 °, 27.4 ° ± 0.2 ° and 28.0 ° ± 0.2 °. In some embodiments, compound 1 glutarate salt has at least three characteristic XRPD peaks expressed in 2 Θ selected from 9.1 ° ± 0.2 °, 10.6 ° ± 0.2 °, 18.2 ° ± 0.2 °, 19.0 ° ± 0.2 °, 21.8 ° ± 0.2 °, 21.9 ° ± 0.2 °, 22.5 ° ± 0.2 °, 25.8 ° ± 0.2 °, 27.4 ° ± 0.2 ° and 28.0 ° ± 0.2 °.

In some embodiments, compound 1 glutarate salt has an XRPD pattern containing characteristic peaks substantially as shown in figure 38 (figure 38). In some embodiments, compound 1 glutarate salt has a DVS isotherm substantially as shown in figure 39 (figure 39).

In some embodiments, compound 1 glutarate salt may be isolated in a crystalline purity of at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99%. In some embodiments, compound 1 glutarate salt may be isolated with a crystalline purity of greater than about 99%.

In some embodiments, compound 1 glutarate salt may be isolated with a crystalline purity of greater than about 99.9%.

In some embodiments, compound 1 glutarate salt prepared by isolating compound 1 glutarate salt from a mixture of compound 1, glutaric acid, and S1 is provided, wherein S1 is a solvent. In some embodiments, S1 is an organic solvent. In some embodiments, S1 is C_1-6An alkyl alcohol. In some embodiments, S1 is C_1-6Alkyl acetate ester. In some embodiments, S1 is C_1-6An alkyl ketone. In some embodiments, S1 is a mixture of organic solvents. In some embodiments, S1 is C_1-6Alkyl alcohol and C_1-6Mixtures of alkyl ketones. In some embodiments, S1 is a mixture of methanol and acetone. In some embodiments, S1 is THF. In some embodiments, S1 is ethyl acetate.

Compound 1L-malate

In some embodiments, there is provided (R) -1- (8-fluoroisochroman-1-yl) -N-methylmethanamine levomalate. In some embodiments, compound 1 l-malate salt is crystalline.

In some embodiments, compound 1 levomalate has a characteristic XRPD peak, expressed in 2 Θ, selected from 13.5 ° ± 0.2 °, 18.8 ° ± 0.2 °, and 25.2 ° ± 0.2 °. In some embodiments, compound 1 levomalate salt has a characteristic XRPD peak, expressed in 2 Θ, at 13.5 ° ± 0.2 °. In some embodiments, compound 1 levomalate salt has a characteristic XRPD peak, expressed in 2 Θ, at 18.8 ° ± 0.2 °. In some embodiments, compound 1 levomalate salt has a characteristic XRPD peak, expressed in 2 Θ, at 25.2 ° ± 0.2 °.

In some embodiments, compound 1 levorotatory malate salt has at least one characteristic XRPD peak, expressed in 2 Θ, selected from 13.5 ° ± 0.2 °, 14.4 ° ± 0.2 °, 15.2 ° ± 0.2 °, 18.8 ° ± 0.2 °, 23.8 ° ± 0.2 °, 24.8 ° ± 0.2 °, and 25.2 ° ± 0.2 °. In some embodiments, compound 1 levorotatory malate salt has at least one characteristic XRPD peak, expressed in 2 Θ, selected from 13.5 ° ± 0.2 °, 14.4 ° ± 0.2 °, 15.2 ° ± 0.2 °, 17.7 ° ± 0.2 °, 18.8 ° ± 0.2 °, 22.4 ° ± 0.2 °, 23.8 ° ± 0.2 °, 24.6 ° ± 0.2 °, 24.8 ° ± 0.2 °, and 25.2 ° ± 0.2 °.

In some embodiments, compound 1 levorotatory malate salt has at least two characteristic XRPD peaks expressed in 2 Θ selected from 13.5 ° ± 0.2 °, 14.4 ° ± 0.2 °, 15.2 ° ± 0.2 °, 18.8 ° ± 0.2 °, 23.8 ° ± 0.2 °, 24.8 ° ± 0.2 °, and 25.2 ° ± 0.2 °. In some embodiments, compound 1 levorotatory malate salt has at least two characteristic XRPD peaks expressed in 2 Θ selected from 13.5 ° ± 0.2 °, 14.4 ° ± 0.2 °, 15.2 ° ± 0.2 °, 17.7 ° ± 0.2 °, 18.8 ° ± 0.2 °, 22.4 ° ± 0.2 °, 23.8 ° ± 0.2 °, 24.6 ° ± 0.2 °, 24.8 ° ± 0.2 ° and 25.2 ° ± 0.2 °.

In some embodiments, compound 1 levorotatory malate salt has at least three characteristic XRPD peaks expressed in 2 Θ selected from 13.5 ° ± 0.2 °, 14.4 ° ± 0.2 °, 15.2 ° ± 0.2 °, 18.8 ° ± 0.2 °, 23.8 ° ± 0.2 °, 24.8 ° ± 0.2 °, and 25.2 ° ± 0.2 °. In some embodiments, compound 1 levorotatory malate salt has at least three characteristic XRPD peaks expressed in 2 Θ selected from 13.5 ° ± 0.2 °, 14.4 ° ± 0.2 °, 15.2 ° ± 0.2 °, 17.7 ° ± 0.2 °, 18.8 ° ± 0.2 °, 22.4 ° ± 0.2 °, 23.8 ° ± 0.2 °, 24.6 ° ± 0.2 °, 24.8 ° ± 0.2 ° and 25.2 ° ± 0.2 °.

In some embodiments, compound 1 l-malate has an XRPD pattern comprising characteristic peaks substantially as shown in figure 40 (figure 40).

In some embodiments, compound 1 l-malate has an endothermic peak at a temperature of about 82 ℃. In some embodiments, compound 1 l-malate has a DSC thermogram substantially as depicted in figure 41 (figure 41). In some embodiments, compound 1 levomalate salt has a TGA thermogram substantially as depicted in figure 42 (figure 42). In some embodiments, compound 1 l-malate has a DVS isotherm substantially as depicted in figure 43 (figure 43).

In some embodiments, compound 1 levorotatory malate salt has at least one characteristic XRPD peak, expressed in 2 Θ, selected from 13.5 ° ± 0.2 °, 18.8 ° ± 0.2 ° and 25.2 ° ± 0.2 °; and an endothermic peak at a temperature of about 82 ℃. In some embodiments, compound 1 levorotatory malate salt has at least one characteristic XRPD peak, expressed in 2 Θ, selected from 13.5 ° ± 0.2 °, 18.8 ° ± 0.2 ° and 25.2 ° ± 0.2 °; and a DSC heatmap substantially as depicted in figure 41 (figure 41). In some embodiments, compound 1 levorotatory malate salt has at least one characteristic XRPD peak, expressed in 2 Θ, selected from 13.5 ° ± 0.2 °, 18.8 ° ± 0.2 ° and 25.2 ° ± 0.2 °; and a DVS isotherm substantially as depicted in fig. 43 (fig. 43).

In some embodiments, compound 1 l-malate salt can be isolated in a crystalline purity of at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99%. In some embodiments, compound 1 l-malate salt can be isolated in a crystalline purity of greater than about 99%. In some embodiments, compound 1 l-malate salt can be isolated in a crystalline purity of greater than about 99.9%.

In some embodiments, provided is compound 1 l-malate salt prepared by isolating compound 1 l-malate salt from a mixture of compound 1, l-malic acid, and S1, wherein S1 is a solvent. In some embodiments, S1 is an organic solvent. In some embodiments, S1 is C_1-6An alkyl alcohol. In some embodiments, S1 is an ether. In some embodiments, S1 is C_1-6Alkyl acetate ester. In some embodiments, S1 is methanol. In some embodiments, S1 is THF. In some embodiments, S1 is ethyl acetate.

Compound 1 benzenesulfonate

In some embodiments, there is provided (R) -1- (8-fluoroisochroman-1-yl) -N-methylmethanemethanesulfonate. In some embodiments, compound 1 benzenesulfonate is crystalline. In some embodiments, compound 1 benzenesulfonate has characteristic XRPD peaks expressed in 2 θ selected from 6.0 ° ± 0.2 °, 12.0 ° ± 0.2 ° and 24.1 ° ± 0.2 °. In some embodiments, compound 1 benzenesulfonate has a characteristic XRPD peak, expressed in 2 θ, at 6.0 ° ± 0.2 °. In some embodiments, compound 1 benzenesulfonate has a characteristic XRPD peak, expressed in 2 θ, at 12.0 ° ± 0.2 °. In some embodiments, compound 1 benzenesulfonate has a characteristic XRPD peak, expressed in 2 θ, at 24.1 ° ± 0.2 °.

In some embodiments, the compound 1 benzenesulfonate salt has at least one characteristic XRPD peak, expressed in 2 Θ, selected from 6.0 ° ± 0.2 °, 12.0 ° ± 0.2 °, 16.6 ° ± 0.2 °, 24.1 ° ± 0.2 °, 26.8 ° ± 0.2 °, and 30.3 ° ± 0.2 °. In some embodiments, the compound 1 benzenesulfonate salt has at least one characteristic XRPD peak, expressed in 2 Θ, selected from 6.0 ° ± 0.2 °, 12.0 ° ± 0.2 °, 16.4 ° ± 0.2 °, 16.6 ° ± 0.2 °, 19.0 ° ± 0.2 °, 21.2 ° ± 0.2 °, 22.2 ° ± 0.2 °, 23.2 ° ± 0.2 °, 24.1 ° ± 0.2 °, 26.8 ° ± 0.2 ° and 30.3 ° ± 0.2 °.

In some embodiments, the compound 1 benzenesulfonate salt has at least two characteristic XRPD peaks, expressed in 2 Θ, selected from 6.0 ° ± 0.2 °, 12.0 ° ± 0.2 °, 16.6 ° ± 0.2 °, 24.1 ° ± 0.2 °, 26.8 ° ± 0.2 °, and 30.3 ° ± 0.2 °. In some embodiments, the compound 1 benzenesulfonate salt has at least two characteristic XRPD peaks, expressed in 2 Θ, selected from 6.0 ° ± 0.2 °, 12.0 ° ± 0.2 °, 16.4 ° ± 0.2 °, 16.6 ° ± 0.2 °, 19.0 ° ± 0.2 °, 21.2 ° ± 0.2 °, 22.2 ° ± 0.2 °, 23.2 ° ± 0.2 °, 24.1 ° ± 0.2 °, 26.8 ° ± 0.2 ° and 30.3 ° ± 0.2 °.

In some embodiments, the compound 1 benzenesulfonate salt has at least three characteristic XRPD peaks, expressed in 2 Θ, selected from 6.0 ° ± 0.2 °, 12.0 ° ± 0.2 °, 16.6 ° ± 0.2 °, 24.1 ° ± 0.2 °, 26.8 ° ± 0.2 °, and 30.3 ° ± 0.2 °. In some embodiments, the compound 1 benzenesulfonate salt has at least three characteristic XRPD peaks, expressed in 2 Θ, selected from 6.0 ° ± 0.2 °, 12.0 ° ± 0.2 °, 16.4 ° ± 0.2 °, 16.6 ° ± 0.2 °, 19.0 ° ± 0.2 °, 21.2 ° ± 0.2 °, 22.2 ° ± 0.2 °, 23.2 ° ± 0.2 °, 24.1 ° ± 0.2 °, 26.8 ° ± 0.2 ° and 30.3 ° ± 0.2 °.

In some embodiments, the benzenesulfonate salt of compound 1 has an XRPD pattern containing characteristic peaks substantially as shown in figure 44 (figure 44).

In some embodiments, compound 1 benzenesulfonate has an endothermic peak at a temperature of about 136 ℃. In some embodiments, compound 1 benzenesulfonate has a DSC thermogram substantially as depicted in figure 45 (figure 45). In some embodiments, the compound 1 benzenesulfonate has a TGA thermogram substantially as depicted in figure 46 (figure 46). In some embodiments, the compound 1 benzenesulfonate has a DVS isotherm substantially as depicted in figure 47 (figure 47).

In some embodiments, compound 1 benzenesulfonate has at least one characteristic XRPD peak, expressed in 2 Θ, selected from 6.0 ° ± 0.2 °, 12.0 ° ± 0.2 °, and 24.1 ° ± 0.2 °; and an endothermic peak at a temperature of about 136 ℃. In some embodiments, compound 1 benzenesulfonate has at least one characteristic XRPD peak, expressed in 2 Θ, selected from 6.0 ° ± 0.2 °, 12.0 ° ± 0.2 °, and 24.1 ° ± 0.2 °; and a DSC heatmap substantially as depicted in figure 45 (figure 45). In some embodiments, compound 1 benzenesulfonate has at least one characteristic XRPD peak, expressed in 2 Θ, selected from 6.0 ° ± 0.2 °, 12.0 ° ± 0.2 °, and 24.1 ° ± 0.2 °; and a DVS isotherm substantially as depicted in fig. 47 (fig. 47).

In some embodiments, the compound 1 benzenesulfonate salt may be isolated in at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99% crystalline purity. In some embodiments, the compound 1 benzenesulfonate salt may be isolated in a crystalline purity of greater than about 99%.

In some embodiments, the compound 1 benzenesulfonate salt may be isolated in a crystalline purity of greater than about 99.9%.

In some embodiments, there is provided a compound 1 benzenesulfonate salt prepared by separating compound 1 benzenesulfonate salt from a mixture of compound 1, benzenesulfonic acid and S1,wherein S1 is a solvent. In some embodiments, S1 is an organic solvent. In some embodiments, S1 is C_1-6An alkyl alcohol. In some embodiments, S1 is an ether. In some embodiments, S1 is C_1-6Alkyl acetate ester. In some embodiments, S1 is C_1-6An alkyl ketone. In some embodiments, S1 is a mixture of organic solvents. In some embodiments, S1 is C_1-6Alkyl alcohol and C_1-6Mixtures of alkyl ketones. In some embodiments, S1 is ethyl acetate. In some embodiments, S1 is THF. In some embodiments, S1 is a mixture of methanol and acetone.

Compound 1 tosylate

In some embodiments, there is provided (R) -1- (8-fluoroisochroman-1-yl) -N-methylmethanamine p-toluenesulfonate (compound 1 p-toluenesulfonate).

In some embodiments, compound 1 p-toluenesulfonate, prepared by separating compound 1 p-toluenesulfonate from a mixture of compound 1, p-toluenesulfonic acid and S1, is provided, wherein S1 is a solvent. In some embodiments, S1 is an organic solvent. In some embodiments, S1 is C_1-6An alkyl alcohol. In some embodiments, S1 is an ether. In some embodiments, S1 is C_1-6Alkyl acetate ester. In some embodiments, S1 is C_1-6An alkyl ketone. In some embodiments, S1 is a mixture of organic solvents. In some embodiments, S1 is C_1-6Alkyl alcohol and C_1-6Mixtures of alkyl ketones. In some embodiments, S1 is methanol. In some embodiments, S1 is THF. In some embodiments, S1 is ethyl acetate. In some embodiments, S1 is a mixture of methanol and acetone. Process for preparing compound 1 and compound 1 phosphate

Also provided herein are methods for preparing compound 1 or a salt thereof. A method for preparing compound 1 is described in U.S. patent No. 10,196,403, which is incorporated herein by reference in its entirety. The methods provided herein for preparing compound 1 or a salt thereof have certain advantages over methods currently disclosed in the art. For example, the methods described herein exhibit good scalability, yield, and stereochemical selectivity. The process described herein involves chiral resolution by crystallization, which avoids chiral separation by HPLC and is therefore more suitable for manufacture on a kilogram scale.

The present invention provides a process for the preparation of (R) -1- (8-fluoroisochroman-1-yl) -N-methyl methylamine phosphate (compound 1 phosphate) having the following structure:

compound 1 phosphate

Wherein the method comprises:

(a) reacting a compound of formula III having the structure:

or a salt thereof, wherein X is halogen, with N-methylaminoacetaldehyde dimethylacetal (compound 4) having the structure:

compound 4

In the presence of a1, wherein a1 is an acid, to provide a compound of formula II having the structure:

or a salt thereof, wherein X is halogen;

(b) hydrogenating a compound of formula II or a salt thereof in the presence of a metal catalyst to provide 1- (8-fluoroisochroman-1-yl) -N-methyl methylamine (racemic compound 1) having the structure:

racemic compound 1;

(c) reacting racemic compound 1 with dibenzoyl-levotartaric acid in the presence of S3, wherein S3 is the solvent, to provide (R) -1- (8-fluoroisochroman-1-yl) -N-methylmethanemethyldibenzoyl-levotartaric acid salt (compound 1 dibenzoyl-levotartaric acid salt) having the following structure:

compound 1 dibenzoyl-l-tartrate;

(d) reacting compound 1 dibenzoyl-levotartrate with B1, wherein B1 is a base, to provide compound 1 having the structure:

Compound 1; and

(e) compound 1 is reacted with phosphoric acid to provide compound 1 phosphate.

Provided herein is a method of preparing compound 1 having the structure:

the compound 1 is a compound of formula (I),

wherein the method comprises:

(a) reacting a compound of formula III having the structure:

or a salt thereof, wherein X is halogen, with N-methylaminoacetaldehyde dimethylacetal (compound 4) having the structure:

compound 4

In the presence of a1, wherein a1 is an acid, to provide a compound of formula II having the structure:

or a salt thereof, wherein X is halogen;

(b) hydrogenating a compound of formula II or a salt thereof in the presence of a metal catalyst to provide 1- (8-fluoroisochroman-1-yl) -N-methyl methylamine (racemic compound 1) having the structure:

racemic compound 1;

(c) reacting racemic compound 1 with dibenzoyl-levotartaric acid in the presence of S3, wherein S3 is the solvent, to provide (R) -1- (8-fluoroisochroman-1-yl) -N-methylmethanemethyldibenzoyl-levotartaric acid salt (compound 1 dibenzoyl-levotartaric acid salt) having the following structure:

compound 1 dibenzoyl-l-tartrate; and

(d) reacting compound 1 dibenzoyl-levotartrate with B1, wherein B1 is a base, to provide compound 1.

In some embodiments, there is provided a method of preparing compound 1, wherein the method comprises:

(a) hydrogenating a compound of formula II or a salt thereof in the presence of a metal catalyst to provide racemic compound 1;

(b) reacting racemic compound 1 with dibenzoyl-levotartaric acid in the presence of S3, wherein S3 is a solvent, to provide compound 1 dibenzoyl-levotartaric acid salt; and

(c) reacting compound 1 dibenzoyl-levotartrate with B1, wherein B1 is a base, to provide compound 1.

In some embodiments, there is provided a method of preparing compound 1, wherein the method comprises:

(a) reacting racemic compound 1 with dibenzoyl-levotartaric acid in the presence of S3, wherein S3 is a solvent, to provide compound 1 dibenzoyl-levotartaric acid salt; and

(c) reacting compound 1 dibenzoyl-levotartrate with B1, wherein B1 is a base, to provide compound 1.

The present invention provides a process for the preparation of (R) -1- (8-fluoroisochroman-1-yl) -N-methyl methylamine phosphate (compound 1 phosphate) having the following structure:

compound 1 phosphate the method comprises reacting (R) -1- (8-fluoroisochroman-1-yl) -N-methylmethanamine (compound 1) having the structure:

Compound 1

With phosphoric acid. In some embodiments, compound 1 phosphate is crystalline.

In some embodiments, the phosphoric acid is an aqueous solution of phosphoric acid. In some embodiments, the aqueous solution of phosphoric acid is about 80% to about 95% by weight aqueous phosphoric acid solution. In some embodiments, the aqueous solution of phosphoric acid is about 87% by weight aqueous phosphoric acid.

In some embodiments, the reaction of compound 1 with phosphoric acid is carried out in the presence of S1a, wherein S1a is a solvent. In some embodiments, S1a is a polar aprotic solvent, water, or a mixture thereof. In some embodiments, the polar aprotic solvent of S1 is acetonitrile. In some embodiments, S1a is a mixture of acetonitrile and water.

In some embodiments, the reaction of compound 1 with phosphoric acid is carried out at a temperature between about 15 ℃ and about 25 ℃. In some embodiments, the reaction of compound 1 with phosphoric acid is performed at about 20 ℃. In some embodiments, between about 1 and about 5 molar equivalents of phosphoric acid are used per molar equivalent of compound 1. In some embodiments, about 1 molar equivalent of phosphoric acid is used per molar equivalent of compound 1.

Compound 1 can be prepared by a process comprising reacting (R) -1- (8-fluoroisochroman-1-yl) -N-methylmethanamine dibenzoyl-levotartrate (compound 1 dibenzoyl-levotartrate) having the structure:

compound 1 dibenzoyl-l-tartrate is reacted with B1, wherein B1 is a base.

In some embodiments, B1 is an alkali metal hydroxide base. In some embodiments, B1 is potassium hydroxide. In some embodiments, B1 is an aqueous solution of potassium hydroxide. In some embodiments, the aqueous solution of potassium hydroxide is from about 10% to about 20% by weight aqueous potassium hydroxide solution. In some embodiments, the aqueous solution of potassium hydroxide is about 14% by weight aqueous potassium hydroxide solution.

In some embodiments, the reaction of compound 1 dibenzoyl-l-tartrate with the base is carried out in the presence of S2, wherein S2 is a solvent. In some embodiments, S2 is a polar aprotic solvent. In some embodiments, the polar aprotic solvent is an ether. In some embodiments, S2 is tert-butyl methyl ether.

In some embodiments, the reaction of compound 1 dibenzoyl-l-tartrate with B1 is carried out at a temperature between about 20 ℃ and about 30 ℃. In some embodiments, the reaction of compound 1 dibenzoyl-l-tartrate with a base is carried out at a temperature of about 23 ℃. In some embodiments, between about 0.5 and about 5 molar equivalents of B1 are used per molar equivalent of compound 1 dibenzoyl-l-tartrate. In some embodiments, between about 1 and about 3 molar equivalents of B1 are used per molar equivalent of compound 1 dibenzoyl-l-tartrate. In some embodiments, between about 1 and about 2 molar equivalents of B1 are used per molar equivalent of compound 1 dibenzoyl-l-tartrate. In some embodiments, about 1 molar equivalent of B1 is used per molar equivalent of compound 1 dibenzoyl-l-tartrate.

In some embodiments, the reaction of compound 1 dibenzoyl-l-tartrate with B1 is also carried out in the presence of sodium chloride. In some embodiments, about 1 to about 10 molar equivalents of sodium chloride is used per molar equivalent of the compound 1 dibenzoyl-l-tartrate. In some embodiments, about 5 molar equivalents of sodium chloride is used per molar equivalent of compound 1 dibenzoyl-l-tartrate.

(R) -1- (8-fluoroisochroman-1-yl) -N-methylmethanamine dibenzoyl-levotartrate (compound 1 dibenzoyl-levotartrate) can be prepared by a process comprising reacting 1- (8-fluoroisochroman-1-yl) -N-methylmethanamine (racemic compound 1) having the following structure:

with dibenzoyl-levotartaric acid in the presence of S3, wherein S3 is a solvent.

In some embodiments, S3 is a polar protic solvent. In some embodiments, S3 is C_1-6alkyl-OH. In some embodiments, S3 is methanol. In some embodiments, S3 is a mixture of methanol and water. In some embodiments, the reaction is carried out at a temperature of from about 20 ℃ to about 70 ℃. In some embodiments, the precipitation is performed at a temperature of about 20 ℃. In some embodiments, about 1 to about 5 molar equivalents of dibenzoyl-levotartaric acid are used per molar equivalent of racemic compound 1. In some embodiments, about 1 molar equivalent of dibenzoyl-levotartaric acid is used per molar equivalent of racemic compound 1.

The method of preparing compound 1 dibenzoyl-l-tartrate may further comprise precipitating compound 1 dibenzoyl-l-tartrate from a mixture comprising racemic compound 1, dibenzoyl-l-tartrate and S3. In some embodiments, S3 is methanol. In some embodiments, S3 is a mixture of methanol and water.

The method of preparing the compound 1 dibenzoyl-l-tartrate may further comprise isolating the compound 1 dibenzoyl-l-tartrate from S3a, wherein S3a is a solvent. In some embodiments, S3a is a polar protic solvent. In some embodiments, S3a is C_1-6alkyl-OH. In some embodiments, S3a is methanol. In some embodiments, the isolation of compound 1 dibenzoyl-l-tartrate is carried out at a temperature of from about 10 ℃ to about 65 ℃.

1- (8-fluoroisochroman-1-yl) -N-methyl methylamine (racemic compound 1) can be prepared by a process comprising reacting a compound of formula II having the structure:

or a salt thereof, wherein X is halogen, in the presence of a metal catalyst.

In some embodiments, the compound of formula II is compound 2, i.e., 1- (5-bromo-8-fluoroisochroman-1-yl) -N-methylmethanamine triflate (compound 2) having the structure:

In some embodiments, the metal catalyst is palladium on activated carbon. In some embodiments, the hydrogenation of the compound of formula II is carried out at a hydrogen pressure of about 2 to about 10 bar. In some embodiments, the hydrogenation of the compound of formula II is carried out at a hydrogen pressure of about 5 bar.

In some embodiments, the hydrogenation of the compound of formula II is carried out at a temperature between about 20 ℃ and about 30 ℃. In some embodiments, the hydrogenation of the compound of formula II is carried out at a temperature of about 25 ℃.

In some embodiments, the hydrogenation of the compound of formula II is carried out in the presence of S4, wherein S4 is a solvent.In some embodiments, S4 is a polar protic solvent. In some embodiments, S4 is C_1-6alkyl-OH. In some embodiments, S4 is methanol.

In some embodiments, the hydrogenation of the compound of formula II is carried out in the presence of B2, wherein B2 is a base. In some embodiments, B2 is a carbonate base. In some embodiments, B2 is potassium carbonate. In some embodiments, B2 is an aqueous solution of potassium carbonate. In some embodiments, the aqueous solution of potassium carbonate is about 5% by weight potassium carbonate.

The compounds of formula II can be prepared by: reacting a compound of formula III having the structure:

or a salt thereof, wherein X is halogen,

with N-methylaminoacetaldehyde dimethylacetal (Compound 4) having the structure:

compound 4

In the presence of a1, wherein a1 is an acid.

In some embodiments, the compound of formula III is 2- (2-bromo-5-fluorophenyl) ethan-1-ol (compound 3) having the structure:

compound 3.

In some embodiments, a1 is trifluoromethanesulfonic acid. In some embodiments, the reaction of the compound of formula III with compound 4 is carried out in the presence of S5, wherein S5 is a solvent. In some embodiments, S5 is a halogenated solvent. In some embodiments, S5 is dichloromethane.

In some embodiments, the reaction of the compound of formula III with compound 4 is carried out at a temperature between about 0 ℃ and about 35 ℃. In some embodiments, the reaction of the compound of formula III with compound 4 is carried out at a temperature of about 30 ℃. In some embodiments, about 1.2 molar equivalents of compound 4 are used per molar equivalent of the compound of formula III. In some embodiments, about 4 molar equivalents of a1 are used per molar equivalent of the compound of formula III.

It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment (and the embodiments are intended to be combined as if written in multiple dependent manners). Conversely, various features of the invention which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination.

The reaction of the process described herein may be carried out in air or under an inert atmosphere. In general, reactions containing reagents or products that substantially react with air can be carried out using air-sensitive synthesis techniques well known to those skilled in the art.

The methods described herein may be monitored according to any suitable method known in the art. For example, the light can be detected by spectroscopic means (such as nuclear magnetic resonance spectroscopy (e.g.,¹h or¹³C) Infrared spectroscopy, spectrophotometry (e.g., UV visible light) or mass spectrometry) or by chromatography (e.g., High Performance Liquid Chromatography (HPLC) or thin layer chromatography). The compound obtained by the reaction may be purified by any suitable method known in the art. For example, chromatography (medium pressure), HPLC or preparative thin layer chromatography on a suitable adsorbent (e.g. silica gel, alumina, etc.); distilling; subliming, grinding or recrystallizing. The purity of a compound is usually determined by physical methods such as measuring the melting point (if a solid), obtaining an NMR spectrum or performing an HPLC separation. If the melting point is lowered, if the unwanted signal in the NMR spectrum is reduced, or if extraneous peaks in the HPLC trace are removed, the compound can be said to have been purified. In some embodiments, the compound is substantially purified.

Application method

In some embodiments, the present disclosure provides a method for treating a neurological or psychiatric disease or disorder in a subject, comprising administering to the subject an effective amount of a compound of the present disclosure (or a pharmaceutically acceptable salt thereof) or a composition comprising a compound of the present disclosure (or a pharmaceutically acceptable salt thereof). Neurological and/or psychiatric diseases and disorders may exhibit a variety of psychiatric and behavioral symptoms including apathy, depression, anxiety, cognitive impairment, psychosis, aggression, agitation, poor impulse control, and sleep disruption.

In one embodiment, the neurological or psychiatric disease or disorder is bipolar disorder, anxiety, depression, alzheimer's disease with agitation, alzheimer's disease with aggression, or alzheimer's disease with aggression.

In one embodiment, the neurological or psychiatric disease or disorder is bipolar disorder, anxiety, depression, dementia, alzheimer's disease with agitation or with agitation attack, neurocognitive disorder with behavioral and psychological symptoms.

In one embodiment, the neurological or psychiatric disease or disorder is a behavioral and psychological symptom of neurocognitive disorders (including dementia and alzheimer's disease). The behavioral and psychological symptoms include disorders of sensation, thought, mood or behavior, including delusions (distressing beliefs), hallucinations, psychosis, agitation (easy restlessness, repetitive problems, struggle or complaints, hoarding, pacing, inappropriate screaming, crying, disruptive sounds, nursing refusing to leave home), aggression (physical or verbal), depression or agitation, anxiety (worry, shadow), indifference or indifference, disinhibition (social inappropriate behavior, sexual inappropriate behavior, irritability or instability, dyskinesia (repetitive purposeless movement, wandering, hunting, night's behavior (waking and getting up at night), impulsion, attention deficit, executive dysfunction.

Assays are used herein to identify representative candidate treatments. Examples of candidate therapies include, but are not limited to, treatment of alzheimer's disease with a surge, alzheimer's disease surge and alzheimer's disease with a surge of challenge. Aggression and agitation are common symptoms of neurological and psychiatric diseases and disorders. Aggression and agitation are associated with hyperactivity in the subcortical brain region, which can be modeled in animals using psychostimulants (e.g., PCP, amphetamine). For example, psychostimulants induce excessive spontaneous activity (HLA) in animals. Antipsychotics (e.g., haloperidol, clozapine, and risperidone) have been shown to reduce psychostimulant-induced HLA and are more effective against the challenge in alzheimer's disease. Other drugs used off-label or currently being studied in clinical trials for the surge in alzheimer's disease are mood stabilisers such as lithium (which also reduces amphetamine-induced HLA) and antidepressants (e.g. citalopram). Antidepressants exhibit activity in assays such as forced swim and tail suspension tests. Thus, the above assays help identify candidate treatments for the stroke in alzheimer's disease and the stroke/challenge in other neurological and psychiatric diseases and disorders.

In one embodiment, there is provided a method of treating bipolar disorder in a subject in need thereof, the method comprising the step of administering to the subject an effective amount of a compound according to formula I, or a pharmaceutically acceptable salt thereof.

In one embodiment, there is provided a method of treating anxiety in a subject in need thereof, the method comprising the step of administering to the subject an effective amount of a compound according to formula I, or a pharmaceutically acceptable salt thereof.

In some embodiments, the neurological or psychiatric disease or disorder is selected from psychoses, including schizophrenia (paranoid, disorganized, catatonic, or undifferentiated), schizophreniform disorders, schizoaffective disorders, delusional disorders, brief psychotic disorders, shared psychotic disorders, substance-induced or drug-induced (e.g., phencyclidine, ketamine and other dissociative anesthetics, amphetamines and other psychostimulants and cocaine) psychoses resulting from general medical conditions, psychotic disorders, psychosis associated with affective disorders, brief reactive psychosis, schizoaffective psychosis, schizophrenia, "schizophrenic spectrum" disorders (such as schizophrenia or schizopersonality disorder), or psychosis-associated diseases (such as major depression, manic depressive (bipolar) disorder, alzheimer's disease, and post-traumatic stress syndrome), including positive, negative and cognitive symptoms of schizophrenia and other psychoses; cognitive disorders including dementia (semantic dementia, frontotemporal dementia, dementia with depressive features, persistence, subcortical dementia, dementia with lewy bodies, parkinson-ALS dementia complex and dementia associated with alzheimer's disease, ischemia, multi-infarct dementia, trauma, vascular problems, stroke, HIV disease, parkinson's disease, huntington's disease, down syndrome, pick's disease, creutzfeldt-jakob disease, perinatal hypoxia or substance abuse), delirium, amnestic disorders or age-related cognitive decline; anxiety disorders including acute stress disorder, agoraphobia, generalized anxiety disorder, obsessive-compulsive disorder, panic attacks, panic disorder, post-traumatic stress disorder, separation anxiety disorder, social phobia, specific phobias, substance-induced anxiety disorder, and anxiety caused by general medical conditions; substance-related disorders and addictive behaviors (including substance-induced delirium, persisting dementia, persisting amnestic disorder, psychotic disorder or anxiety disorder; resistance, dependence or withdrawal from substances including alcohol, amphetamine, cannabis, cocaine, hallucinogens, inhalants, nicotine, opioids, phencyclidine, sedatives, hypnotics or anxiolytics); eating disorders such as obesity, bulimia nervosa, pica and compulsive eating disorders; bipolar disorders (including bipolar I disorder, bipolar II disorder, circulatory disorder, substance/drug-induced bipolar and related disorders, bipolar and related disorders resulting from another medical condition, bipolar and related disorders specified otherwise, and bipolar and related disorders not specified), depressive disorders (including unipolar depression, seasonal depression and postpartum depression, atypical depression, dysthymia, senile depression, endogenous depression, melancholic depression, perinatal depression, mood depression, chronic depression, premenstrual syndrome (PMS), and Premenstrual Dysphoric Disorder (PDD)), mood disorders resulting from general medical conditions, and substance-induced mood disorders; attention, learning, and developmental disorders, such as pervasive developmental disorders including autistic disorder, attention and conduct disorders including Attention Deficit Hyperactivity Disorder (ADHD), disorders (such as autism and autism spectrum disorders including asperger's syndrome, pervasive developmental disorder, rett syndrome, and fragile X syndrome), depression, benign amnesia, childhood learning disorders, specific learning disorders, intellectual development disorders, and closed brain injury; movement disorders and symptoms including tremors, movement disorders, dystonia, tics, dysarthria, ataxia, myoclonus, essential tremors, tardive dyskinesia, restless leg syndrome, tourette's syndrome, multiple system atrophy, multiple sclerosis, huntington's disease, parkinson's disease and atypical parkinson's disease; epilepsy; urinary incontinence; neuronal damage including eye damage, retinopathy or macular degeneration of the eye, tinnitus, hearing loss and loss, and brain edema; vomiting; and sleep disorders including insomnia, disturbed sleep, jet lag, somnolence, cataplexy, sleep apnea, obstructive sleep apnea, REM sleep behavior disorder, restless leg syndrome, periodic limb movement disorder, circadian rhythm sleep disorder, sleep phase shift disorder, sleepwalking, nighttime fear, bedwetting, rapid eye movement sleep behavior disorder, shift work sleep disorder, excessive daytime sleepiness, non-24 hour wake cycle disorder, sleep paralysis and narcolepsy.

In some embodiments, the neurological or psychiatric disease or disorder is alzheimer's disease, parkinson's disease, depression, cognitive impairment, stroke, schizophrenia, down syndrome, or fetal alcohol syndrome. In some embodiments, the neurological or psychiatric disorder is alzheimer's disease. In some embodiments, the neurological or psychiatric disorder is parkinson's disease. In some embodiments, the neurological or psychiatric disorder is depression. In some embodiments, the neurological or psychiatric disorder is cognitive impairment. In some embodiments, the cognitive impairment is cognitive dysfunction associated with depression (e.g., major depressive disorder). In some embodiments, the neurological or psychiatric disorder is stroke. In some embodiments, the neurological or psychiatric disorder is schizophrenia. In some embodiments, the neurological or psychiatric disorder is down syndrome. In some embodiments, the neurological or psychiatric disorder is fetal alcohol syndrome.

In some embodiments, the neurological or psychiatric disease or disorder is bipolar disorder. Bipolar disorder (including bipolar I and bipolar II) is a serious psychiatric disorder with an prevalence of about 2% of the population and with an impact on both sexes. It is a relapsing-remitting condition characterized by cycling between mood elevations (i.e., mania) and depression, which distinguishes it from other disorders such as major depressive disorder and schizophrenia. Although most individuals experience significant depression, type I biphasic is defined by the appearance of a full manic episode. Symptoms of mania include an elevated or irritable mood, hyperactivity, exaggeration, decreased sleep need, competitive thoughts, and, in some cases, psychosis. Depressive episodes are characterized by anhedonia, sad mood, despair, poor self-esteem, attentiveness and somnolence. Type II biphasic is defined as the occurrence of major depressive episodes and hypomanic (less severe mania) episodes, but the subject is much more time in the depressed state. Other related conditions include circulatory disorders.

In some embodiments, the neurological or psychiatric disease or disorder is schizophrenia. Schizophrenia is a disorder of unknown origin that usually first appears in early adulthood and is characterized by psychotic symptoms, staged progression and development, and/or deterioration of social behavior and professional ability, among other features. Typical psychotic symptoms are thought disorder (e.g., diverse, fragmentary, incoherent, incredible or simple delusional content or thoughts of distress) and psychosomatic disorder (e.g., loss of association, over imagination, disorganized until unintelligible) as well as perceptual disorder (e.g., hallucinations), affective disorder (e.g., superficial or inappropriate emotion), self-perception disorder, intention disorder, impulse disorder and/or interpersonal disorder, and psychomotor disorder (e.g., stress). Other symptoms are also associated with this disorder. Schizophrenia is divided into several subgroups: paranoid type, characterized by delusions and hallucinations, and without thought disorder, disorganized behavior, and affective flattening; disorganized, also known as "adolescent schizophrenia", in which thought disorders and affective flattening co-exist; catatonic, where prominent disturbances in mental movement are evident, and symptoms may include catatonic stupor and waxy flexing; and non-typing, wherein psychotic symptoms are present but not meeting the criteria of paranoid, disorganized or catatonic type. The symptoms of schizophrenia usually appear in three major groups: positive, negative and cognitive symptoms. Positive symptoms are those that represent "excess" experienced normally, such as hallucinations and delusions. Negative symptoms refer to those symptoms for which the subject suffers from a lack of normal experience, such as anhedonia and lack of social interaction. Cognitive symptoms involve cognitive impairment in schizophrenic patients, such as persistent attention deficit and decision deficits.

In some embodiments, the neurological or psychiatric disease or disorder is an anxiety disorder. Anxiety disorders are characterized by fear, worry, and uneasiness, often generalized and broadly referred to as excessive reaction to a situation. Anxiety disorders differ by the context or object type and related cognitive concepts that induce fear, anxiety or avoidance behavior. Anxiety differs from fear in that anxiety is an emotional response to perceived future threats, whereas fear is related to perceived or actual direct threats. They also differ in the content of the associated ideas or beliefs. Examples of anxiety disorders include dissociative anxiety disorder, selective mutism, specific phobias, social anxiety disorder (social phobia), panic disorder, panic attack indicator, agoraphobia, generalized anxiety disorder, substance/drug-induced anxiety disorder, anxiety disorder resulting from another medical condition, illness anxiety disorder, social (practical) communication disorder, other specified anxiety disorder, and unspecified anxiety disorder; stressor-related disorders including reactive attachment disorder, disinhibiting social engagement disorder, post-traumatic stress disorder (PTSD), acute stress disorder, and adaptation disorder.

Cognitive impairment includes a decline in cognitive function or cognitive domains (e.g., working memory, attention and vigilance, verbal learning and memory, visual learning and memory, reasoning and solving problems (e.g., executive function, processing speed, and/or social cognition)). In particular, cognitive impairment may indicate attention deficit, thought disorder, thought retardation, difficulty in understanding, inattention, impaired ability to solve problems, poor memory, difficulty in expressing thoughts, and/or difficulty in integrating thoughts, emotions and behaviors, or difficulty in eliminating unrelated thoughts.

In some embodiments, the neurological or psychiatric disease or disorder involves cognitive deficits (cognitive areas are complex attention, executive function, learning and memory, language, perceptual motor, social cognition, as defined by DSM-5). In some embodiments, the neurological or psychiatric disorder is associated with a deficiency in dopamine signaling. In some embodiments, the neurological or psychiatric disorder is associated with basal ganglia dysfunction. In some embodiments, the neurological or psychiatric disorder is associated with dysregulated spontaneous activity. In some embodiments, the neurological or psychiatric disorder is associated with impaired prefrontal cortex function.

In some embodiments, the present disclosure provides a method of treating one or more symptoms of a neurological and/or psychiatric disease or disorder provided herein. Such diseases or disorders include mood disorders including bipolar I disorder, bipolar II disorder, mania, circulatory disorder, substance/drug-induced bipolar and related disorders, bipolar and related disorders caused by another medical condition, other specified bipolar and related disorders, and unspecified bipolar and related disorders; psychotic disorders, including schizophrenia, schizophrenic spectrum Disorder, acute schizophrenia, chronic schizophrenia, NOS schizophrenia, schizophreniform Personality Disorder, schizophrenic Personality Disorder, delusional Disorder, psychosis, psychotic Disorder, brief psychotic Disorder, shared psychotic Disorder, psychotic Disorder resulting from a general medical condition, drug-induced psychosis (e.g., cocaine, alcohol, amphetamine), schizoaffective Disorder, agitation, aggression, delirium, catatonic fainting, tension, dissociative identity Disorder, paranoid Personality Disorder, psychotic depression, schizotypal Personality Disorder (schizotypal personalitic Disorder), childhood disintegrative Disorder (Heller's Syndrome)), disintegrating psychosis, dissociative memory Disorder, somatomotic symptom Disorder, parkinson's disease, excitatory psychosis (acute psychosis), Tourette's syndrome and organic or NOS psychosis; depressive disorders including destructive mood disorder, Major Depressive Disorder (MDD) (including major depressive episode), dysthymia, persistent depressive disorder (dysthymia), treatment resistant depression, premenstrual dysphoric disorder, substance/drug-induced depressive disorder, depressive disorder resulting from another medical condition, other specified depressive disorders, and unspecified depressive disorder; anxiety disorders; and other disorders including substance abuse or dependence (e.g., nicotine, alcohol, cocaine), addiction, cyber-game disorders, eating disorders, behavioral disorders, convulsions, vertigo, epilepsy, agitation, aggression, neurodegenerative disorders, Alzheimer's disease, Parkinson's disease, dyskinesia, Huntington's disease, dementia, premenstrual dysphoria, Attention Deficit Disorder (ADD) and Attention Deficit Hyperactivity Disorder (ADHD)), multiple-kinetic syndrome, autism spectrum disorders, obsessive-compulsive disorders, pain, fibromyalgia, migraine, cognitive impairment, dyskinesia, Restless Leg Syndrome (RLS), multiple sclerosis, primary progressive multiple sclerosis, Parkinson's disease, Huntington's disease, dyskinesia, multiple sclerosis, sleep disorders, sleep apnea, narcolepsy, excessive daytime sleepiness, jet lag, and/or jet lag, Hypnotic side effects of drugs, insomnia, sexual dysfunction, hypertension, emesis, lesch-niehan disease (Lesche-Nyhane disease), Wilson's disease, Rett syndrome and Huntington's chorea. In some embodiments, the neurological and/or psychiatric disorders include aggression and aggression.

In some embodiments, the aggression and aggression are associated with alzheimer's disease, parkinson's disease, and/or autism.

In some embodiments, the agitation is associated with psychiatric disorders such as depression and schizophrenia.

In some embodiments, the neurological and/or psychiatric disease or disorder is obsessive-compulsive disorder and related disorders (e.g., body deformation disorders, hoarding disorders, trichotillomania, peeling disorders).

In some embodiments, the neurological and/or psychiatric disease or disorder is destructive impulse control and conduct disorder, including oppositional defiant disorder, intermittent explosive disorder, conduct disorder, antisocial personality disorder, pyromania, kleptomania, other specific destructive impulse control and conduct disorder, non-specific destructive impulse control and conduct disorder.

Depressive disorders include major depressive disorder and dysthymia, and are associated with depressed mood (sadness), inattention, insomnia, fatigue, appetite disorders, excessive guilt, and suicidal thoughts.

In some embodiments, the present disclosure provides a method of treating one or more symptoms, including depression (e.g., major depressive disorder or dysthymia); bipolar disorder, seasonal affective disorder; cognitive deficits; sleep-related disorders (e.g., sleep apnea, insomnia, narcolepsy, cataplexy), including those resulting from psychiatric disorders; chronic fatigue syndrome; anxiety (e.g., generalized anxiety disorder, social anxiety disorder, panic disorder); obsessive-compulsive disorder; post-menopausal vasomotor symptoms (e.g., hot flashes, night sweats); neurodegenerative diseases (e.g., Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, primary lateral sclerosis, progressive muscle atrophy, progressive bulbar (atrophy) paralysis, pseudobulbar paralysis spinal muscular atrophy diseases (e.g., SMA type I (also known as Werdnig-Hoff mann disease), SMA type II, SMA type III (also known as Kugerberg-Welander disease) and Kennedy's disease (also known as progressive spinal bulbar atrophy)), Harlervoren-Schwartz's disease (Hallervorden-Spatz disease), Seeberg's disease (Seitelberger Disease) (infantile axonal dystrophy), adrenoleukodystrophy, Alexandria, Autosomal Dominant Cerebellar Ataxia (ADCA), simple autonomic failure (Bradbury-Eggerston Syndrome), CADASIL Syndrome, and neuronal ceroid lipofuscinosis such as Batten Disease (Batten Disease) ) (ii) a Mania disorder; dysthymic disorder; and obesity.

In some embodiments, the depressive disorder is associated with acute suicidal ideation or suicidal ideation. The United States Food and Drug Administration (The United States Food and Drug Administration) employs a "black box" marker warning indicating that antidepressants may increase The risk of suicidal thoughts and behaviors in some children, adolescents and young adults (under 24 years of age) with depressive disorders such as MDD. In some embodiments, provided compounds do not increase the risk of suicidal thoughts and/or behaviors in children, adolescents, and/or young adults with depressive disorders (e.g., with MDD). In some embodiments, the present disclosure provides a method of treating one or more symptoms of a depressive disorder (e.g., MDD) in a child, adolescent, and/or young adult without increasing the risk of suicidal thoughts and/or behaviors.

In some embodiments, the present disclosure provides a method of treating one or more symptoms including senile dementia, early-onset alzheimer's Disease, dementia of the alzheimer's type, cognition, memory loss, amnesia/amnesia Syndrome, disturbance of consciousness, coma, attention deficit, language disorders, agnostic disorders, aphasia, apraxia, Mild Cognitive Impairment (MCI), benign amnesia, mild neurocognitive impairment, severe neurocognitive impairment, neurocognitive disorders resulting from Disease (e.g., huntington's Disease, parkinson's Disease, prion Disease, traumatic brain injury, HIV or AIDS), binge's Disease (subcortical leukosis), and capcrara Syndrome (capcrapras Syndrome).

In some embodiments, the disclosure provides a method of treating one or more symptoms of pain (e.g., neuropathic pain, sensitization associated with neuropathic pain, or inflammatory pain).

In some embodiments, the pain is neuropathic pain, including post-herpetic (or post-herpetic) neuralgia, reflex sympathetic dystrophy/causalgia or nerve trauma, phantom limb pain, carpal tunnel syndrome, and peripheral neuropathy (such as diabetic neuropathy or neuropathy caused by chronic alcohol use).

In some embodiments, the pain is acute pain, nociceptive pain, arthritic pain, rheumatoid arthritis, osteoarthritis, joint pain, musculoskeletal pain, back pain (back pain), back pain (dorsalgia), herniated disc, hip pain, visceral pain, headache, tension headache, acute tension headache, chronic cluster headache, general migraine, typical migraine, cluster headache, mixed headache, post-traumatic headache, eye fatigue headache, transient unilateral neuralgia (SUNCT) headache, SUNCT syndrome, herpes zoster (herpes zoster), acute herpes zoster, herpes zoster (shingles), post-herpetic neuralgia (shingles), causalgia, central pain syndrome, chronic back pain, neuralgia, neuropathic pain syndrome, joint pain, muscular and joint pain, Neuropathy, diabetic-related neuropathic pain, fibrositis, peripheral neuropathy caused by chemotherapy, peripheral neuropathy, neuropathic pain, nerve trauma, sensitization accompanying neuropathic pain, complex regional pain Syndrome, compressive neuropathy, craniofacial pain, chronic joint pain, chronic knee pain, chronic pain Syndrome, cancer pain, trigeminal neuralgia (trigeminus), trigeminal neuralgia (tic doloreaux), reflex sympathetic burning pain, painful peripheral neuropathy, spinal nerve injury, arachnoiditis, spinal pain, Bernhardt-Ross Syndrome (Bernhardt-Roth Syndrome), carpal tunnel Syndrome, cerebrospinal fluid Syndrome, peroneal muscular atrophy (Charcot-Marie-tooth disease), Hereditary motor and sensory neuropathy, peroneal atrophy, cluster tic syndrome, coccygodynia syndrome, fascio-ventricular syndrome, degenerative disc disease, failed back surgery syndrome, genital-pelvic pain/penetration disorder, gout, inflammatory pain, lumbar radiculopathy, neuroma (painful scar), pain associated with multiple sclerosis, pelvic floor disorder, phantom limb pain, piriformis syndrome, psychogenic pain, radiculodynia syndrome, Raeder's syndrome, referred pain, reflex sympathetic dystrophy syndrome, sciatica, sciatic pain, scoliosis, herniated disc, somatalgia, spinal stenosis, stiff person syndrome (ff-persuson syndrome/stiff-man syndrome), acrodynia, sympathogenic persistent pain (sympathogenic pain), Toloxa-Hunter syndrome (tolosa-hunter syndrome), whiplash pain, or pain associated with Lyme disease.

In some embodiments, the present disclosure provides a method of treating one or more symptoms, including obesity; migraine or migraine-type headache; and male or female sexual dysfunction including, but not limited to, sexual dysfunction due to psychological and/or physiological factors, erectile dysfunction, premature ejaculation, vaginal dryness, lack of sexual arousal, inability to obtain orgasm; and psychiatric sexual dysfunction including, but not limited to, suppression of libido, suppression of excitement, suppression of female orgasm, suppression of male orgasm, functional dyspareunia, functional vaginismus, and atypical psychiatric sexual dysfunction.

In some embodiments, the present disclosure provides a method of inhibiting Rapid Eye Movement (REM) during sleep and equivalent daytime.

In some embodiments, the present disclosure provides a method of inhibiting or eliminating pathological or excessive REM during the night or equivalent day.

In some embodiments, the present disclosure provides a method of treating one or more symptoms, including cataplexy (sudden involuntary transient muscle weakness onset or paralysis while awake); nocturnal sleep disorders/fragmentation of sleep associated with narcolepsy or other disorders; sleep paralysis associated with narcolepsy or other disorders; pre-sleep and pre-wake hallucinations associated with narcolepsy or other conditions; and excessive daytime sleepiness associated with narcolepsy, sleep apnea or shift work disorders, and other medical conditions such as cancer, chronic fatigue syndrome, and fibromyalgia.

In some embodiments, the present disclosure provides a method of treating one or more symptoms of a movement disease or disorder (including akinesia, akinetic rigidity syndrome, dyskinesia, and dystonia). Examples of akinesia and akinesia-tonic syndrome include Parkinson's disease, drug-induced parkinsonism, postencephalitic parkinsonism, secondary parkinsonism, atypical parkinsonism, idiopathic parkinsonism, progressive supranuclear palsy, multiple system atrophy, corticobasal degeneration, parkinsonism-ALS dementia complex and basal ganglia calcification, drug-induced parkinsonism (such as neuroleptic-induced parkinsonism, neuroleptic malignant syndrome, neuroleptic-induced acute dystonia, neuroleptic-induced acute akathisia, neuroleptic-induced tardive dyskinesia and drug-induced postural tremor), Gilles de la Tourette's syndrome, epilepsy, muscle spasms and disorders associated with muscle spasms or weakness (including tremor). Examples of dyskinesias include drug-induced (e.g., levodopa (L-DOPA)) dyskinetic tremors (e.g., resting tremors, postural tremors, intention tremors), chorea (e.g., sydenham's chorea, huntington's disease, benign hereditary chorea, acanthocytosis, symptomatic chorea, drug-induced chorea, and hemiballism), myoclonus (including both systemic and focal myoclonus), tics (including simple, complex, and symptomatic ones). Examples of dystonia include systemic dystonia, idiopathic dystonia, drug-induced dystonia, symptomatic dystonia, paroxysmal dystonia, focal dystonia, blepharospasm, oromandibular dystonia, spasmodic dysphonia, spastic torticollis, axial dystonia, dystonic writer's spasm, and hemiplegic dystonia. Other examples of movement diseases or disorders include stereotypic movement disorders, persistent (chronic) movement disorders, drug-induced movement disorders, psychogenic movement disorders, substance/drug-induced movement disorders, extrapyramidal movement disorders, hyperkinetic movement disorders, hypokinetic movement disorders, alternating hemiplegia, Angel syndrome (Angelman syndrome), Harlervorden-Spatz Disease, Ataxia, dentate cerebellar Ataxia, Ataxia telangiectasia (Louis-Barsyndrome), Friedreich's Ataxia, hereditary spinal cord Ataxia, Marchardo-Joseph Disease, spinocerebellar Ataxia, progressive myoclonus Ataxia, hand-foot dyskinesia, substance/drug-induced movement disorders, extrapyramidal movement disorders, hyperkinetic movement disorders, hypokinetic movement disorders, alternating hemiplegia, Atheroic syndrome, Friedreich's syndrome, hereditary spinal cord sclerosis, Marchardo-Joseph Disease, Marcharcot-Joseph's Ataxia, progressive myoclonic Ataxia, limb Ataxia, athetosis, hyperkinetic disorders, and other disorders of the like, Tosses, blepharospasm (twitching eyes), cerebral palsy, tardive dystonia, tardive dyskinesia, idiopathic torsion dystonia, focal dystonia, idiopathic familial dystonia, idiopathic non-familial dystonia, cervical dystonia (spastic torticollis), primary dystonia, orofacial dystonia, developmental coordination disorder, bulbar muscular atrophy (Kennedy's Disease), schei-de ger Syndrome (she-Drager Syndrome), and Stiff Person Syndrome (Stiff-Person (Stiff-Man) Syndrome).

In some embodiments, the disclosure provides a method of treating one or more symptoms of epilepsy and/or convulsions, including abdominal epilepsy, absence seizures, acquired epilepsy, acquired epileptiform aphasia, eccardi syndrome (Aicardi syndrome), Alpers 'disease, Alpers-Huttenlocher syndrome (Alpers-Huttenlocher syndrome), angelers' syndrome, benign focal epilepsy in children, benign intracranial hypertension, benign lateral schizoepilepsy (BRE), CDKL5 disorder, childhood absence epilepsy, dentate cerebellar ataxia, dutch syndrome (dosee syndrome), delavir syndrome (Dravet syndrome), cognitive disorder focal convulsions, epilepsy with convulsive grand, epilepsy with myoclonic loss, hemiparalysis, convulsions, epilepsy with convulsive hemiparalysis, convulsive syndrome, Focal convulsions, frontal epilepsy, generalized tonic convulsions, hereditary epilepsy, Glutl deficiency syndrome, hypothalamic hamartoma, idiopathic epilepsy, idiopathic systemic epilepsy, idiopathic locally related epilepsy, idiopathic local epilepsy, idiopathic convulsion, juvenile absence epilepsy, juvenile myoclonic epilepsy, Laforda disease, Ladiforma progressive myoclonic epilepsy, Landao-Klefner syndrome, Ladouur-Klefner syndrome, Lassuur-Graham-Littley syndrome, Lennox syndrome, Lingosyndrome (Lennox-Gastrout syndrome), medically refractory epilepsy, medial temporal lobe sclerosis, myoclonic epilepsy, neonatal epilepsy, lobar epilepsy, Tagetian syndrome, Tansmophor syndrome, Panthon syndrome (Panthon-Bartonel syndrome), Panthon syndrome (Panthon-Barton syndrome), Panthol syndrome, Panthol-Jolt syndrome, etc Epilobelia, PCDH19 epilepsy, photosensitive epilepsy, progressive myoclonic epilepsy, lasimason encephalitis (Rasmussen's encephalitis), lasimason syndrome (Rasmussen's syndrome), refractory epilepsy, convulsive disorders, status epilepticus, stedgkin-Weber syndrome (Sturge-Weber syndrome), symptomatic systemic epilepsy, symptomatic regional epilepsy, TBCK-related ID syndrome, temporal lobe epilepsy, temporal lobe seizure, tonic convulsion, wester syndrome, tremor, cerebellar tremor outflow, intention tremor, essential tremor, benign essential tremor, parkinson's tremor, and drug-induced postural tremor.

Pharmaceutical composition

According to one embodiment, the present disclosure provides a composition comprising compound 1 or a salt thereof (or a crystalline form, hydrate, or solvate thereof) and a pharmaceutically acceptable carrier, adjuvant, or vehicle. In some embodiments, the amount of compound 1 in the compositions of the present disclosure is an amount effective to treat, prevent, and/or manage a variety of neurological and/or psychiatric diseases, disorders, and/or symptoms in a subject. In some embodiments, the compositions of the present disclosure are formulated for administration to a subject in need of such a composition. In some embodiments, the compositions of the present disclosure are formulated for oral administration to a subject.

As used herein, the term "subject" to which administration is contemplated includes, but is not limited to, humans (i.e., male or female of any age group, such as pediatric subjects (e.g., infants, children, adolescents) or adult subjects (e.g., young, middle aged, or elderly) and/or other primates (e.g., cynomolgus monkeys, rhesus monkeys), mammals, including commercially relevant mammals, such as cattle, pigs, horses, sheep, goats, cats, and/or dogs, and/or birds, including commercially relevant birds, such as chickens, ducks, geese, quail, and/or turkeys.

In certain embodiments, provided herein is a composition (e.g., a pharmaceutical composition) comprising compound 1 or a salt thereof (or a crystalline form, hydrate, or solvate thereof) and a pharmaceutically acceptable excipient or carrier. In some embodiments, provided herein is a method of treating neurological or psychiatric diseases and disorders in a subject in need thereof, comprising administering an effective amount of compound 1 or a salt thereof (or a crystalline form, hydrate or solvate thereof) or a pharmaceutical composition described herein. Examples of carriers and excipients are well known to those skilled in the art and are described in, for example, Ansel, Howard C et al, Ansel's Pharmaceutical Delivery Forms and Drug Delivery systems, Philadelphia, Lippincott, Williams & Wilkins, 2004; gennaro, Alfonso R. et al, Remington, The Science and Practice of pharmacy Philadelphia, Lippincott, Williams & Wilkins, 2000; and Rowe, Raymond C.handbook of Pharmaceutical excipients Chicago, Pharmaceutical Press, 2005. The formulations may also contain one or more buffers, stabilizers, surfactants, wetting agents, lubricants, emulsifiers, suspending agents, preservatives, antioxidants, opacifiers, glidants, processing aids, colorants, sweeteners, fragrances, flavoring agents, diluents, and other known additives to provide an elegant presentation of the drug (i.e., a compound of the present disclosure or pharmaceutical composition thereof) or to aid in the manufacture of the pharmaceutical product (i.e., a drug).

The compositions of the present disclosure may be administered orally, parenterally, by inhalation, topically, rectally, nasally, buccally, sublingually, vaginally, or via an implantable reservoir. The term "parenteral" as used herein includes subcutaneous, intravenous, intramuscular, intraarticular, intrasynovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques. Preferably, the composition is administered orally, intraperitoneally, or intravenously. Sterile injectable forms of the compositions of the present disclosure can be aqueous or oleaginous suspensions. These suspensions may be formulated according to the techniques known in the art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1, 3-butanediol. Acceptable vehicles and solvents that may be used include water, ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. The pharmaceutically acceptable compositions of the present disclosure may be administered orally in any orally acceptable dosage form, including capsules, tablets, aqueous suspensions or solutions.

The amount of compound 1 or a salt thereof (or a crystalline form, hydrate, or solvate thereof) that can be combined with a carrier material to produce a composition in a single dosage form will vary depending upon a variety of factors, including the host treated and the particular mode of administration. It will also be understood that the specific dose and treatment regimen for any particular subject will depend upon a variety of factors including the activity of the specific form of compound 1 employed, the age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, the judgment of the treating physician, and the severity of the particular disease being treated.

Combination therapy

In some embodiments, the present disclosure provides a method of treating a neurological and/or psychiatric disease or disorder described herein comprising administering a compound of the present disclosure in combination with one or more agents. Suitable agents that may be used in combination with compound 1 or a salt (or crystalline form, hydrate or solvate thereof) thereof include anti-parkinson agents, anti-alzheimer agents, antidepressants, antipsychotics, antihypertensives, CNS inhibitors, anticholinergics, nootropic agents, epilepsy agents, attention (e.g., ADD/ADHD) agents, sleep-promoting agents, wake-promoting agents and pain-relieving agents. In some embodiments, a suitable agent is an anxiolytic.

Suitable anti-parkinson drugs include dopamine replacement therapy (e.g. levodopa, carbidopa, COMT inhibitors such as entacapone or tolcapone), dopamine agonists (e.g. D1 agonist, D2 agonist, mixed D1/D2 agonist, bromocriptine, pergolide, cabergoline, ropinirole, pramipexole, piribedil or apomorphine in combination with domperidone), histamine H2 antagonists, monoamine oxidase inhibitors (e.g. selegiline, rasagiline, safinamide and tranylcypromine), certain atypical antipsychotics such as pimavanserin (a non-dopaminergic antipsychotic and inverse agonist of the serotonin 5-HT2A receptor) and amantadine.

In some embodiments, compound 1 or a salt thereof (or a crystalline form, hydrate, or solvate thereof) may be used in combination with levodopa (with or without a selective extracerebral decarboxylase inhibitor such as carbidopa or benserazide), anticholinergics such as biperiden (optionally as its hydrochloride or lactate) and trihexyphenidyl (benzhexyl) hydrochloride, COMT inhibitors such as entacapone or tolcapone, MAO a/B inhibitors, antioxidants, A2a adenosine receptor antagonists, cholinergic agonists, MDA receptor antagonists, serotonin receptor antagonists, and dopamine receptor agonists such as alendronol, bromocriptine, fenoldopam, lisuride, nagolide, pergolide, and pramipexole. It will be appreciated that the dopamine agonist may be in the form of a pharmaceutically acceptable salt, for example, alendronate hydrobromide, bromocriptine mesylate, fenoldopam mesylate, naxagolide hydrochloride and pergolide mesylate. Lisuride and pramipexole are commonly used in non-salt form.

Suitable anti-alzheimer's disease agents include beta-secretase inhibitors, gamma-secretase inhibitors, cholinesterase inhibitors such as donepezil, galantamine or rivastigmine, HMG-CoA reductase inhibitors, NSAIDs including ibuprofen, vitamin E and anti-amyloid antibodies. In some embodiments, the anti-alzheimer's disease drug is memantine.

Suitable antidepressants and anxiolytics include norepinephrine reuptake inhibitors (including tertiary amine tricyclic and secondary amine tricyclic), Selective Serotonin Reuptake Inhibitors (SSRI), monoamine oxidase inhibitors (MAOI), monoamine oxidase Reversible Inhibitor (RIMA), Serotonin and Norepinephrine Reuptake Inhibitors (SNRI), Corticotropin Releasing Factor (CRF) antagonists, alpha-adrenergic receptor antagonists, neurokinin-1 receptor antagonists, atypical antidepressants, benzodiazepines, 5-HTl A agonists or antagonists (especially 5-HTl A partial agonists), and Corticotropin Releasing Factor (CRF) antagonists.

Particularly suitable antidepressants and anxiolytics include amitriptyline, clomipramine, doxepin, imipramine and trimipramine; amoxapine, desipramine, citalopram, escitalopram, maprotiline, nortriptyline and protriptyline; fluoxetine, fluvoxamine, paroxetine, and sertraline; isocarboxazid, phenelzine, tranylcypromine, and selegiline; moclobemide; venlafaxine; desvenlafaxine, duloxetine; aprepitant; bupropion, vilazodone, mirtazapine, lithium, nefazodone, trazodone, and viloxazine; alprazolam, chlordiazepoxide, clonazepam, chlordiazepoxide (chlorzepate), diazepam, halazepam, lorazepam, oxazepam and pramepam; buspirone, fluoroxingcron, gepirone (gepirone) and ixabepilone, reboxetine, vortioxetine, loratadine (clorazepate) and ketamine and their pharmaceutically acceptable salts. In some embodiments, suitable antidepressants and anxiolytics are tianeptine or a pharmaceutically acceptable salt thereof.

Suitable antipsychotic and mood stabilizer agents include D2 antagonists, 5HT2A antagonists, atypical antipsychotics, lithium and anticonvulsants.

Particularly suitable antipsychotics and mood stabilizers include chlorpromazine, fluphenazine, haloperidol, amisulpride, perphenazine, thioridazine, trifluoperazine, aripiprazole, asenapine, clozapine, olanzapine, paliperidone, ipiprazole, paliperidone, cariprazine, pimavanserin, ilotone (illopiridone), lumapine (lumaperone), MIN-101, quetiapine, risperidone, ziprasidone, lurasidone, flupentixol, levomepromazine, piperazines, perphenazine, pimozide, prochlorperazine, zulopendrol, olanzapine and fluoxetine, lithium, carbamazepine, lamotrigine, valproic acid, iloperidone, thiothixene, gabapentin, tiagabine and pharmaceutically acceptable salts thereof.

Suitable epilepsy agents include levetiracetam, oxcarbazepine, clobazamine, retigabine, zonisamide, felbamate, eslicarbazepine acetate, lacosamide, carbamazepine, tiagabine, mesufamid, propubic acid, lamotrigine, bravaracetam, rufinamide, topiramate and perampanel (perampanel).

Suitable attention medications include methylphenidate, atomoxetine, guanfacine, dexamphetamine, lisdexamphetamine (lisdexamphetamine), methamphetamine, and clonidine.

Suitable sleep-promoting agents include ramelteon, triazolam, zopiclone, eszopiclone, zolpidem, temazepam, and trazodone.

Suitable wakefulness-promoting drugs include modafinil, dextroamphetamine, caffeine, and armodafinil.

Suitable analgesic drugs include dextromethorphan, tapentadol, buprenorphine, codeine, fentanyl, hydrocodone, hydromorphone, morphine, naloxonol ether, oxycodone, tramadol, gabapentin (gabapentin), difluprednate, pregabalin, acetylsalicylic acid, bromfenac, diclofenac, diflunisal, indomethacin, ketorolac, meloxicam, and naproxen.

In some embodiments, the compounds and compositions of the present disclosure may be used in combination with other therapies. Suitable therapies include psychotherapy, cognitive behavioral therapy, electroconvulsive therapy, transcranial magnetic stimulation, vagus nerve stimulation, and deep brain stimulation.

The exact amount required will vary from subject to subject depending on the species, age and general condition of the subject, the severity of the condition, the particular agent, its mode of administration and the like. The compounds and compositions of the present disclosure are preferably formulated in dosage unit form to facilitate administration and uniformity of dosage. The expression "dosage unit form" as used herein refers to physically discrete units of a medicament suitable for use in a subject to be treated. It will be understood, however, that the total daily amount of the compounds and compositions of the present disclosure will be decided by the attending physician within the scope of sound medical judgment.

Depending on the severity of the infection being treated, the pharmaceutically acceptable compositions of the present disclosure may be administered to humans and other animals orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (e.g., by powders, ointments, or drops), buccally, sublingually, as an oral or nasal spray, and the like. In some embodiments, compound 1 or a salt thereof (or a crystalline form, hydrate, or solvate thereof) may be administered orally or parenterally at a dosage level of about 0.01mg/kg to about 50mg/kg, preferably about 1mg/kg to about 25mg/kg, of the subject's body weight once or more daily to achieve the desired therapeutic effect.

In some embodiments, a combination of two or more therapeutic agents may be administered with compound 1 or a salt thereof (or a crystalline form, hydrate, or solvate thereof). In some embodiments, a combination of three or more therapeutic agents may be administered with compound 1 or a salt thereof (or a crystalline form, hydrate, or solvate thereof).

Other examples of agents that may also be combined with the compounds and compositions of the present disclosure include: vitamin harmonizing nutrientA supplement, an antiemetic (e.g., a 5-HT3 receptor antagonist, a dopamine antagonist, a K1 receptor antagonist, a histamine receptor antagonist, a cannabinoid, a benzodiazepine drug, or an anticholinergic); agents for treating Multiple Sclerosis (MS), such as interferon-beta (e.g., Anddaltephridine (dalfampridine), alemtuzumab),And mitoxantrone; for the treatment of huntington's disease, such as tetrabenazine; for treatment of asthma, e.g. albuterol andanti-inflammatory agents, such as corticosteroids, T F blockers, IL-1RA, azathioprine, and sulfasalazine; immunomodulatory and immunosuppressive agents, such as cyclosporine, tacrolimus, rapamycin, mycophenolate mofetil, interferon, corticosteroids, cyclophosphamide, azathioprine, and sulfasalazine; neurotrophic factors such as acetylcholinesterase inhibitors, MAO inhibitors, interferons, anticonvulsants, ion channel blockers, riluzole; agents for the treatment of cardiovascular diseases, such as beta blockers, ACE inhibitors, diuretics, nitrates, calcium channel blockers and statins, fibrates, cholesterol absorption inhibitors, bile acid sequestrants and nicotinic acid; agents for the treatment of liver diseases, such as corticosteroids, cholestyramine, interferons and antiviral agents; agents for treating blood disorders, such as corticosteroids, anti-leukemia agents, and growth factors; agents for treating immunodeficiency disorders, such as gamma globulin; and antidiabetic agents, such as biguanides (metformin, phenformin, buformin), thiazolidinediones (rosiglitazone, pioglitazone, troglitazone), sulfonylureas (tolbutamide, acetylbenzenesulfonylcyclohexamide, azomethine Urea (tolazamide), chlorpropamide, glipizide, glyburide, glimepiride, gliclazide), meglitinides (repaglinide, nateglinide), alpha-glucosidase inhibitors (miglitol, acarbose), incretin mimetics (exenatide, liraglutide, taslutamide), gastric inhibitory peptide analogs, DPP-4 inhibitors (vildagliptin, sitagliptin, saxagliptin, linagliptin, alogliptin), amylin analogs (pramlintide), and insulin analogs.

In some embodiments, compound 1 or a salt thereof (or a crystalline form, hydrate, or solvate thereof) is administered in combination with an antisense agent, a monoclonal or polyclonal antibody, or an siRNA therapeutic agent.

Those additional agents may be administered separately from the compositions containing the compounds of the present invention as part of a multiple dose regimen. Alternatively, those agents may be part of a single dosage form, mixed together with the compounds of the present disclosure in a single composition. If administered as part of a multi-dose regimen, the two active agents may be taken simultaneously, sequentially or within a period of time (typically within five hours) of each other.

As used herein, the terms "combination," "combined," and related terms refer to the simultaneous or sequential administration of therapeutic agents according to the present disclosure. For example, compound 1 or a salt thereof (or a crystalline form, hydrate, or solvate thereof) and an additional therapeutic agent may be administered simultaneously or sequentially in separate unit dosage forms or together in a single unit dosage form. Accordingly, the present disclosure provides a single unit dosage form comprising compound 1 or a salt thereof (or a crystalline form, hydrate, or solvate thereof), an additional therapeutic agent, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

The amount of both the compound of the invention and the additional therapeutic agent (in those compositions comprising the additional therapeutic agent as described above) that can be combined with the carrier material to produce a single dosage form will vary depending on the host treated and the particular mode of administration. Preferably, the compositions of the present disclosure should be formulated such that a dosage of between 0.01-100mg/kg body weight/day of the present invention can be administered.

In those compositions comprising an additional therapeutic agent, the additional therapeutic agent and compound 1 or a salt thereof (or a crystalline form, hydrate, or solvate thereof) may act synergistically. Thus, the amount of additional therapeutic agent in such compositions will be less than that required in a monotherapy employing only that therapeutic agent. In such compositions, the additional therapeutic agent may be administered at a dose of between 0.01-100mg/kg body weight/day.

The amount of additional therapeutic agent present in the compositions of the present disclosure will not exceed the amount typically administered in compositions comprising the therapeutic agent as the only active agent. Preferably, the amount of additional therapeutic agent in the presently disclosed compositions will be in the range of about 50% to 100% of the amount typically present in compositions comprising that agent as the sole therapeutically active agent.

In some embodiments, the present disclosure provides a medicament comprising compound 1 or a salt thereof (or a crystalline form, hydrate, or solvate thereof) and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

In some embodiments, the present disclosure provides the use of compound 1 or a salt thereof (or a crystalline form, hydrate, or solvate thereof) in the manufacture of a medicament for the treatment of a neurological and/or psychiatric disease or disorder.

Examples

Example 1: preparation of salts of Compound 1

The free base of compound 1 (500mg) was dissolved in MeOH (34 mL). The solution was divided into 33 vials (yielding compound 1 on a 15mg scale). The appropriate counter ion (0.95 equiv.) was added to each vial and dissolved with the screening solvents listed in table 1. The solution was heated at 60 ℃ for 1h and then allowed to cool undisturbed at room temperature. Each vial was opened and allowed to stand at room temperature (slow evaporation). In several cases, acetone or EtOAc additive was added to the vial and allowed to stand at room temperature, allowing slow evaporation. The results of the solvent screening are shown in table 1 below. In addition, some experiments were performed on a larger scale, as shown in table 1.

TABLE 1 solvent screening

Example 2 Synthesis of free base

Saturated sodium bicarbonate water (15ml) and water (5ml) were added to compound 1 hydrochloride salt (600 mg). The solution was extracted with chloroform (15mL, 3 times). The organic extracts were washed with brine (20ml) and evaporated. The free base of compound 1 was isolated as an oil (about 500 mg).

EXAMPLE 3 Compound 1 hydrochloride form HA

The XRPD spectrum of compound 1 hydrochloride salt HA is provided in fig. 1 (fig. 1) and the corresponding peak data is provided in table 2 below.

TABLE 2 XRPD peak data for HA as hydrochloride salt of Compound 1

The DSC thermogram of form HA is shown in figure 2 (figure 2). The thermogram is characterized by endothermic peaks at about 99 ℃ and about 187 ℃. Figure 3 (figure 3) shows a thermogravimetric analysis (TGA) thermogram of form HA. Figure 4 (figure 4) shows the Dynamic Vapor Sorption (DVS) isotherm of form HA.

EXAMPLE 4 Compound 1 hydrochloride form HB

The XRPD spectrum of compound 1 hydrochloride salt HB is provided in fig. 5 (fig. 5) and the corresponding peak data is provided in table 3 below.

TABLE 3 XRPD peak data for compound 1 hydrochloride form HB

Fig. 6 (fig. 6) shows the Dynamic Vapor Sorption (DVS) isotherm for form HB.

EXAMPLE 5 Compound 1 phosphate

The XRPD spectrum of compound 1 phosphate is provided in fig. 7 (fig. 7) and the corresponding peak data is provided in table 4 below.

TABLE 4 XRPD Peak data for Compound 1 phosphate

The DSC thermogram of compound 1 phosphate is shown in figure 8 (figure 8). The thermogram is characterized by an endothermic peak at a temperature of about 213 ℃. Figure 9 (figure 9) shows a thermogravimetric analysis (TGA) thermogram of compound 1 phosphate. Figure 10 (figure 10) shows the Dynamic Vapor Sorption (DVS) isotherm of compound 1 phosphate.

EXAMPLE 6 Compound 1L-tartrate form LA

The XRPD spectrum of compound 1 form LA is provided in fig. 11 (fig. 11) and the corresponding peak data is provided in table 5 below.

TABLE 5 XRPD peak data for compound 1 levotartrate form LA

The DSC thermogram for form LA is shown in fig. 12 (fig. 12). The thermogram is characterized by endothermic peaks at about 89C and about 138 ℃. Figure 13 (figure 13) shows a thermogravimetric analysis (TGA) thermogram of compound 1 levotartrate form LA. Fig. 14 (fig. 14) shows a Dynamic Vapor Sorption (DVS) isotherm for form LA.

EXAMPLE 7 Compound 1L-tartrate form LB

The XRPD spectrum of compound 1, levotartrate form LB is provided in figure 15 (figure 15) and the corresponding peak data is provided in table 6 below.

TABLE 6 XRPD peak data for compound 1L-tartrate form LB

Fig. 16 (fig. 16) shows a Dynamic Vapor Sorption (DVS) isotherm for form LB.

Example 8 Compound 1L-tartrate form LC

The XRPD spectrum of compound 1 levotartrate form LC is provided in fig. 17 (fig. 17) and the corresponding peak data is provided in table 7 below.

TABLE 7 XRPD peak data for L-tartrate form LC of Compound 1

The DSC thermogram for form LC is shown in fig. 18 (fig. 18). The thermogram is characterized by an endothermic peak at a temperature of about 137 ℃. Figure 19 (figure 19) shows a thermogravimetric analysis (TGA) thermogram of compound 1 levotartrate form LC. Fig. 20 (fig. 20) shows a Dynamic Vapor Sorption (DVS) isotherm for form LC.

EXAMPLE 9 Compound 1D-tartrate

The XRPD spectrum of compound 1 d-tartrate is provided in fig. 22 (fig. 22) and the corresponding peak data is provided in table 8 below.

TABLE 8 XRPD peak data for compound 1D-tartrate

The DSC thermogram of the d-tartrate salt of compound 1 is shown in figure 23 (figure 23). The thermogram is characterized by endothermic peaks at about 76 ℃ and about 153 ℃. Figure 23 (figure 23) shows a thermogravimetric analysis (TGA) thermogram of compound 1 d-tartrate. Figure 24 (figure 24) shows the Dynamic Vapor Sorption (DVS) isotherm of compound 1 d-tartrate.

EXAMPLE 10 Compound 1 fumarate salt form FA

The XRPD spectrum of compound 1 fumarate FA is provided in fig. 25 (fig. 25) and the corresponding peak data is provided in table 9 below.

TABLE 9 XRPD peak data for compound 1 fumarate form FA

The DSC thermogram for form FA is shown in fig. 26 (fig. 26). The thermogram is characterized by an endothermic peak at a temperature of about 147 ℃. Figure 27 (figure 27) shows a thermogravimetric analysis (TGA) thermogram of compound 1 fumarate salt form FA. Fig. 28 (fig. 28) shows the Dynamic Vapor Sorption (DVS) isotherm for form FA.

EXAMPLE 11 Compound 1 fumarate salt form FB

The XRPD spectrum of compound 1 fumarate FB is provided in fig. 29 (fig. 29) and the corresponding peak data is provided in table 10 below.

TABLE 10 XRPD peak data for fumarate form FB of Compound 1

A DSC thermogram for form FB is shown in figure 30 (figure 30). The thermogram is characterized by endothermic peaks at a temperature of about 96 ℃, about 139 ℃ and about 146 ℃. Figure 31 (figure 31) shows a thermogravimetric analysis (TGA) thermogram of compound 1 fumarate salt form FB. Fig. 32 (fig. 32) shows a Dynamic Vapor Sorption (DVS) isotherm for form FB.

EXAMPLE 12 Compound 1 citrate salt

The XRPD spectrum of compound 1 citrate is provided in fig. 33 (fig. 33) and the corresponding peak data is provided in table 11 below.

TABLE 11 XRPD peak data for compound 1 citrate

A DSC thermogram of the citrate salt of compound 1 is shown in figure 34 (figure 34). The thermogram is characterized by an endothermic peak at a temperature of about 142 ℃. Figure 35 (figure 35) shows a thermogravimetric analysis (TGA) thermogram of the citrate salt of compound 1. Figure 36 (figure 36) shows the Dynamic Vapor Sorption (DVS) isotherm for compound 1 citrate.

EXAMPLE 13 Compound 1 succinate salt

The XRPD spectrum of compound 1 succinate salt is provided in fig. 37 (fig. 37) and the corresponding peak data is provided in table 12 below.

TABLE 12 XRPD Peak data for Compound 1 succinate

A DSC thermogram for compound 1 succinate is shown in figure 38 (figure 38). The thermogram is characterized by an endothermic peak at a temperature of about 153 ℃. Figure 39 (figure 39) shows a thermogravimetric analysis (TGA) thermogram of compound 1 succinate. Figure 40 (figure 40) shows the Dynamic Vapor Sorption (DVS) isotherm for compound 1 succinate.

EXAMPLE 14 Compound 1 glutarate

The XRPD spectrum of compound 1 glutarate salt is provided in fig. 41 (fig. 41) and the corresponding peak data is provided in table 13 below.

TABLE 13 XRPD peak data for compound 1 glutarate

Figure 42 (figure 42) shows the Dynamic Vapor Sorption (DVS) isotherm of compound 1 glutarate.

EXAMPLE 15 Compound 1L-Malate

The XRPD spectrum of compound 1 levomalate salt is provided in fig. 43 (fig. 43) and the corresponding peak data is provided in table 14 below.

TABLE 14 XRPD peak data for compound 1 levo malate

A DSC thermogram of l-malate salt of compound 1 is shown in fig. 44 (fig. 44). The thermogram is characterized by an endothermic peak at a temperature of about 82 ℃. Figure 45 (figure 45) shows a thermogravimetric analysis (TGA) thermogram of compound 1 levomalate. Figure 46 (figure 46) shows the Dynamic Vapor Sorption (DVS) isotherm of compound 1 levomalate.

EXAMPLE 16 Compound 1 benzenesulfonate

The XRPD spectrum of compound 1 benzenesulfonate is provided in fig. 47 (fig. 47) and the corresponding peak data is provided in table 15 below.

TABLE 15 XRPD peak data for compound 1 benzenesulfonate

The DSC thermogram of compound 1 benzenesulfonate is shown in fig. 48 (fig. 48). The thermogram is characterized by an endothermic peak at a temperature of about 136 ℃. Figure 49 (figure 49) shows a thermogravimetric analysis (TGA) thermogram of the benzenesulfonate salt of compound 1. Figure 50 (figure 50) shows the Dynamic Vapor Sorption (DVS) isotherm for compound 1 benzenesulfonate.

Example 17 stability Studies

Each sample was stored at 60 ℃ and 60 ℃ at 75% RH for 1 month. Each sample was measured by HPLC at 20 days and 1 month. The HPLC conditions are described below.

Column: waters XSelect CSH C18,4.6X150 mm,3

MMPPBA: : m in e water OH 5 acetonitrile mM (9: H1C) lO4(pH 3)

Wavelength: 215nm

Column temperature: 40 deg.C

Flow rate: 1mL/min

Gradient:

the stability results are shown in table 16 below.

TABLE 16 results of stability studies

The free base (amorphous) of compound 1 is unstable at 60 ℃ and 60 ℃ at 75% RH. Other salts (hydrochloride, phosphate, l-tartrate, fumarate, citrate) are stable.

Example 18 phosphate polymorph screening

Compound 1 phosphate was screened for three forms of polymorphs: solvent screening, slurry screening and rapid cooling screening. The procedure for each screening is provided below.

Screening a solvent: compound 1 phosphate (5mg) was placed in a small glass vial and solvent was added until the sample dissolved at 90 ℃ or boiling point. The maximum volume of solvent was 500. mu.L. The solution or suspension was heated for 1h, allowed to cool undisturbed overnight at room temperature, and cooled at 5 ℃ for 3 days. The non-precipitated sample was opened and allowed to stand at room temperature until dry (slow evaporation). The precipitated solid was filtered through a sintered filter plate and measured directly on the plate by XRPD.

Screening slurry: compound 1 phosphate (10mg) was placed in a small glass vial and an organic solvent mixed with water was added. The samples were then suspended at room temperature or 50 ℃ and shaken for 4 to 10 days. The suspension was filtered. The collected solid was analyzed by XRPD to determine the polymorphic form.

And (3) rapid cooling and screening: compound 1 phosphate (10mg) was dissolved at 90 ℃ or boiling point. The solution was rapidly cooled at 0 ℃. After 1h, the solution was cooled at-20 ℃ for 3 days. The precipitated crystals were filtered. The recovered solid was analyzed by XRPD to determine the polymorphic form.

Only one polymorph (compound 1 phosphate as described in example 5) was identified from the screening study (more than 75 trials).

EXAMPLE 19 Synthesis of Compound 1 and Compound 1 phosphate

Step 1.1 preparation of 1- (5-bromo-8-fluoroisochroman-1-yl) -N-methylmethanamine triflate.

A solution of 2- (2-bromo-5-fluorophenyl) ethan-1-ol (200g, 913mmol) and N-methylaminoacetaldehyde dimethylacetal (130g, 1091mmol) in dichloromethane (300mL) was cooled to 0 ℃ and trifluoromethanesulfonic acid (554g, 3691mmol) was added over 1h while maintaining the temperature below 35 ℃ with external cooling. The mixture was warmed to 30 ℃ and stirred at 30 ℃ for 23 h. The mixture was cooled to 20 ℃ and methanol (33mL), dichloromethane (1275mL) and tert-butyl methyl ether (1358mL) were added. The precipitate was collected by suction filtration. The solid was washed with a solution consisting of 1:1(v/v) dichloromethane and tert-butyl methyl ether (1830mL) and under vacuum: (A), (B), (C) and C) >28"Hg) at 45 ℃ for 21h to give 1- (5-bromo-8-fluoroisochroman-1-yl) -N-methylmethanamine triflate as a tan powder (339g, 87% yield). MS (ESI) M/z 274,276[ M + H ]]⁺；¹H-NMR(400MHz,DMSO-d₆):[ppm 8.65(br s,1H),8.54(br s,1H),7.67(dd,J＝8.80,5.28Hz,1H),7.15(dd,J＝9.98,8.80Hz,1H),5.21(dd,J＝9.78,2.35Hz,1H),4.06(dt,J＝12.03,5.92Hz,1H),3.89(dt,J＝11.93,5.18Hz,1H),3.50–3.38(m,1H),3.31(br s,1H),2.73(t,J＝5.67Hz,2H),2.64(br s,3H)；¹³C-NMR(100MHz,DMSO-d₆):[ppm 158.91,156.48,136.20,136.16,132.57,132.48,123.37,123.20,119.20,119.17,115.34,115.10,66.59,59.63,49.09,49.04,33.01,28.75,28.73。

Step 2 preparation of (R) -1- (8-fluoroisochroman-1-yl) -N-methylmethanamine (2R,3R) -2, 3-bis (benzoyloxy) -3-carboxypropionate.

1- (5-bromo-8-fluoroisochroman-1-yl) -N-methylmethanamine triflate (300g, 707mmol), palladium on activated carbon 10 wt.% (dry basis), 50% water (1.2g), methanol (1006mL) and 5 wt.% aqueous potassium carbonate (1059g) were hydrogenated at 25 ℃ under 5 bar hydrogen pressure for 1 h. The pressure was released and the solution was filtered through a 5 micron disposable polypropylene flow-through filter cartridge and the cartridge was rinsed with a solution consisting of 1:1(v/v) methanol and water (540 g). The solution was concentrated under reduced pressure to a final volume of 1200 mL. To the mixture was added tert-butyl methyl ether (893mL) and 20 wt.% aqueous potassium hydroxide solution (185 mL). The mixture was stirred at 20 ℃ for 10 minutes. The stirring was stopped and the phases were separated. The aqueous phase was extracted with tert-butyl methyl ether (649 mL). The combined organic layers were concentrated under reduced pressure to a final volume of 450 mL. SDA (especially denatured alcohol) 3A ethanol (851mL) was added to the solution. The solution was concentrated under reduced pressure to a final volume of 675 mL. The solution (solution a) is maintained for further processing. In a separate vessel, dibenzoyl-levotartaric acid (252g, 703mmol), SDA 3A ethanol (2704mL), and deionized water (69mL) were added. The mixture was heated to about 70 ℃ and solution a was added over 9 minutes, which resulted in precipitation. The mixture was stirred at about 70 ℃ for 45 minutes and then cooled to 20 ℃ over about 2.5 h. The precipitate was collected by suction filtration. The solid was washed with SDA 3A ethanol (960mL) and dried under vacuum (>28"Hg) at 45 ℃ for 17h to give (R) -1- (8-fluoroisochroman-1-yl) -N-methylmethanium (2R,3R) -2, 3-bis (benzoyloxy) -3-carboxypropionate as a white solid (181g, 46% yield).

Alternative resolving agents other than dibenzoyl-l-tartaric acid were explored, but most were found to be unsuitable or impractical for various reasons (e.g., availability, cost, performance). Such resolving agents include (R) -mandelic acid, l-tartaric acid and l-malic acid. However, it was found that N-acetyl-D-leucine provided the desired (R) -isomer in a ratio of about 91:9 and a yield of about 17%.

The optical purity of the intermediate (R) -1- (8-fluoroisochroman-1-yl) -N-methylmethanamine (2R,3R) -2, 3-bis (benzoyloxy) -3-carboxypropionate was enriched to 96.4% de by the following recrystallization procedure.

To (R) -1- (8-fluoroisochroman-1-yl) -N-methylmethanium (2R,3R) -2, 3-bis (benzoyloxy) -3-carboxypropionate (177g, 320mmol) was added methanol (3578mL) and the solution was concentrated at atmospheric pressure to a final volume of 1326mL, resulting in crystallization. The temperature of the slurry was adjusted to about 62 ℃ and stirring was continued for 20 min. The slurry was cooled to 10 ℃ over 2h and the solid was collected by suction filtration. The solid was washed with cold (10 ℃ C.) methanol (675mL) and placed under vacuum: (10 ℃ C.)>28"Hg) was dried at 45 deg.C overnight to give (R) -1- (8-fluoroisochroman-1-yl) -N-methylmethanamine (2R,3R) -2, 3-bis (benzoyloxy) -3-carboxypropionate as a white solid (136g, 77% yield). MS (ESI) M/z196[ M + H ] ]⁺；¹H-NMR(400MHz,DMSO-d₆):[ppm 8.03–7.85(m,4H),7.70–7.55(m,2H),7.54–7.43(m,4H),7.27(td,J＝7.92,6.06Hz,1H),7.11–6.89(m,2H),5.67(s,2H),5.15(dd,J＝9.98,2.93Hz,1H),3.92(ddd,J＝11.84,7.34,4.70Hz,1H),3.69(dt,J＝11.54,4.99Hz,1H),3.36–3.24(m,1H),3.22–3.04(m,1H),2.80–2.61(m,2H),2.54(s,3H)；¹³C-NMR(100MHz,DMSO-d₆):[ppm 168.21,164.89,159.56,157.13,136.87,136.82,133.37,129.60,129.23,128.88,128.80,128.65,125.10,125.07,120.58,120.43,114.57,113.07,112.87,72.47,66.71,59.65,49.22,49.17,32.62,27.28,27.26。

Step 3 preparation of (R) -1- (8-fluoroisochroman-1-yl) -N-methyl methylamine phosphate.

To a mixture of the compound (R) -1- (8-fluoroisochroman-1-yl) -N-methylmethanamine (2R,3R) -2, 3-bis (benzoyloxy) -3-carboxypropionate (75g, 135.5mmol) and tert-butyl methyl ether (223mL) was added a mixture consisting of 14 wt% aqueous potassium hydroxide (120mL) and sodium chloride (15g)And (4) forming a solution. The mixture was stirred at 23-25 ℃ for 10 minutes. The stirring was stopped and the phases were separated. The aqueous phase was extracted with tert-butyl methyl ether (2 × 78 mL). The combined organic layers were concentrated under reduced pressure to a final volume of 90 mL. The solution was cooled to about 48 ℃ and acetonitrile (288ml) was added. The solution was concentrated at atmospheric pressure to a final volume of about 210 mL. The mixture was cooled to 20 ℃ and acetonitrile (97mL) and deionized water (23mL) were added. To this was added at 20 ℃ a mixture of 87% by weight of H₃PO₄Aqueous solution (16.9g) and acetonitrile (81 mL). The product precipitated during the addition. The slurry was stirred at 20 ℃ for 3h and the solid was collected by suction filtration. The solid was washed with a solution consisting of acetonitrile (135mL) and deionized water (8mL) and heated at 55 deg.C under vacuum (C>28"Hg) was dried overnight to give (R) -1- (8-fluoroisochroman-1-yl) -N-methyl methylamine phosphate (36g, 89% yield) as a white crystalline solid, which was compound 1 phosphate characterized in example 5. MS (ESI) M/z 196[ M + H ] ]⁺；¹H-NMR(400MHz,D₂O):[ppm 7.27(td,J＝7.83,5.87Hz,1H),7.03(d,J＝7.25Hz,1H),6.97(dd,J＝10.37,8.80Hz,1H),5.25(t,J＝5.87Hz,1H),4.04(dt,J＝11.74,5.87Hz,1H),3.91–3.80(m,1H),3.47(d,J＝5.87Hz,2H)；2.83(t,J＝5.48Hz,2H),2.75(s,3H)；¹³C-NMR (100MHz, with 5% methanol-d₄D of (A)₂O):[ppm 161.09,158.67,138.10,138.07,130.51,130.42,126.19,126.16,120.28,120.13,114.37,114.17,68.33,62.15,51.39,51.34,34.05,28.38,28.35。

Step 4 recrystallisation of (R) -1- (8-fluoroisochroman-1-yl) -N-methylmethanamine phosphate using water/acetone

19.5g of the (R) -1- (8-fluoroisochroman-1-yl) -N-methylmethanamine phosphate product from step 3 were dissolved in 70g of water at 20 ℃ and then 30g of acetone were charged to the process stream to prepare a 16.3 wt% starting solution. The solution was passed through a fine filter to remove any insoluble material. 600g of acetone were then added to the solution over about 1 hour. The product crystallized out during the addition. The slurry was stirred at 20 ℃ for at least 30min and the solid was collected by suction filtration. The solid was washed with the binary solvents acetone (54g) and deionized water (6g) and dried under vacuum (>28"Hg) at 55 ℃ overnight to give (R) -1- (8-fluoroisochroman-1-yl) -N-methyl methylamine phosphate (18.1g, 93% yield) as a white crystalline solid.

Step 4 recrystallisation of (R) -1- (8-fluoroisochroman-1-yl) -N-methylmethanamine phosphate using water/acetonitrile

35.0g of the (R) -1- (8-fluoroisochroman-1-yl) -N-methylmethanamine phosphate product from step 3 was dissolved in 70g of water at 20 ℃ and then 30g of acetonitrile was charged to the process stream to prepare a 25.9 wt% starting solution. The solution was passed through a fine filter to remove any insoluble material. 600g of acetonitrile was then added to the solution over about 1 hour. The product crystallized out during the addition. The slurry was stirred at 20 ℃ for at least 30min and the solid was collected by suction filtration. The solid was washed with the binary solvent acetonitrile (90g) and deionized water (10g) and dried under vacuum (>28"Hg) at 55 ℃ overnight to give (R) -1- (8-fluoroisochroman-1-yl) -N-methyl methylamine phosphate (31.2g, 89% yield) as a white crystalline solid.

Various preferred embodiments [ A ] to [ DY ] of the present invention can be described below:

[ embodiment A ] A salt which is:

(R) -1- (8-fluoroisochroman-1-yl) -N-methyl methylamine phosphate (compound 1 phosphate);

(R) -1- (8-fluoroisochroman-1-yl) -N-methylmethanamine l-tartrate (compound 1 l-tartrate);

(R) -1- (8-fluoroisochroman-1-yl) -N-methylmethanamine d-tartrate (compound 1 d-tartrate);

(R) -1- (8-fluoroisochroman-1-yl) -N-methyl methylamine fumarate (compound 1 fumarate);

(R) -1- (8-fluoroisochroman-1-yl) -N-methyl methylamine citrate (compound 1 citrate);

(R) -1- (8-fluoroisochroman-1-yl) -N-methyl methylamine succinate (compound 1 succinate);

(R) -1- (8-fluoroisochroman-1-yl) -N-methyl methylamine glutarate (compound 1 glutarate);

(R) -1- (8-fluoroisochroman-1-yl) -N-methylmethanamine levomalate (compound 1 levomalate);

(R) -1- (8-fluoroisochroman-1-yl) -N-methylmethanemethanesulfonate (compound 1 benzenesulfonate); or

(R) -1- (8-fluoroisochroman-1-yl) -N-methylmethanamine p-toluenesulfonate (compound 1 p-toluenesulfonate); or a hydrate or solvate thereof.

Embodiment B the salt according to embodiment B above or according to other embodiments of the invention, wherein the salt is in solid form.

[ embodiment C ] the salt according to the above embodiment [ A ] or [ B ] or according to other embodiments of the invention, wherein the salt is (R) -1- (8-fluoroisochroman-1-yl) -N-methylmethanamine phosphate (Compound 1 phosphate).

Embodiment D a salt according to embodiment [ C ] above or according to other embodiments of the invention, wherein compound 1 phosphate is crystalline.

Embodiment E the salt according to embodiment [ D ] above or according to other embodiments of the invention wherein the salt has a characteristic XRPD peak expressed in 2 Θ selected from 4.6 ° ± 0.2 °, 9.1 ° ± 0.2 ° and 18.2 ° ± 0.2 °.

Embodiment F the salt according to embodiment [ D ] above or according to other embodiments of the invention, wherein the salt has at least one characteristic XRPD peak, expressed in 2 Θ, selected from 4.6 ° ± 0.2 °, 9.1 ° ± 0.2 °, 15.7 ° ± 0.2 °, 18.2 ° ± 0.2 °, 22.3 ° ± 0.2 °, 22.8 ° ± 0.2 ° and 24.8 ° ± 0.2 °.

Embodiment G the salt according to embodiment [ D ] above or according to other embodiments of the invention, wherein the salt has at least two characteristic XRPD peaks expressed in 2 Θ selected from 4.6 ° ± 0.2 °, 9.1 ° ± 0.2 °, 15.7 ° ± 0.2 °, 18.2 ° ± 0.2 °, 22.3 ° ± 0.2 °, 22.8 ° ± 0.2 ° and 24.8 ° ± 0.2 °.

Embodiment H the salt according to embodiment [ D ] above or according to other embodiments of the invention wherein the salt has at least three characteristic XRPD peaks expressed in 2 Θ selected from 4.6 ° ± 0.2 °, 9.1 ° ± 0.2 °, 15.7 ° ± 0.2 °, 18.2 ° ± 0.2 °, 22.3 ° ± 0.2 °, 22.8 ° ± 0.2 ° and 24.8 ° ± 0.2 °.

Embodiment I the salt according to any one of embodiments [ D ] to [ H ] above or according to other embodiments of the invention, wherein the salt has an XRPD pattern of characteristic peaks substantially as shown in figure 6 (figure 6).

Embodiment J the salt according to any one of embodiments [ D ] to [ I ] above or according to other embodiments of the invention, wherein the salt has an endothermic peak at a temperature of about 213 ℃.

Embodiment K the salt according to any one of embodiments [ D ] to [ J ] above or according to other embodiments of the invention, wherein the salt has a DSC thermogram substantially as depicted in figure 7 (figure 7).

Embodiment L the salt according to any one of embodiments [ D ] to [ K ] above or according to other embodiments of the invention, wherein the salt has a DVS isotherm substantially as depicted in figure 9 (figure 9).

[ embodiment M ] the salt according to the above embodiment [ A ] or [ B ] or according to other embodiments of the present invention, wherein the salt is (R) -1- (8-fluoroisochroman-1-yl) -N-methylmethanamine L-tartrate (Compound 1L-tartrate).

Embodiment N a salt according to embodiment [ M ] above or according to other embodiments of the invention, wherein compound 1, the l-tartrate salt, is crystalline.

Embodiment O the salt according to embodiment [ N ] above or according to other embodiments of the invention, having form LA.

Embodiment P a salt according to the above embodiment O or according to other embodiments of the invention, wherein form LA is selected from the group consisting of 12.1 ° ± 0.2 °, 18.1 ° ± 0.2 ° and 24.2 ° ± 0.2 ° having a characteristic XRPD peak, expressed in 2 Θ.

[ embodiment Q ] salts according to the above embodiment [ N ] or [ O ] or according to other embodiments of the invention, wherein form LA has an XRPD pattern with characteristic peaks substantially as shown in figure 10 (figure 10).

Embodiment R a salt according to embodiment [ N ] above or according to other embodiments of the invention, said salt having the form LB.

Embodiment S a salt according to embodiment [ R ] above or according to other embodiments of the invention, wherein form LB has a characteristic XRPD peak, expressed in 2 Θ, selected from 18.7 ° ± 0.2 °, 25.0 ° ± 0.2 ° and 31.4 ° ± 0.2 °.

[ embodiment T ] salts according to the above embodiment [ R ] or [ S ] or according to other embodiments of the invention, wherein form LB has an XRPD pattern with characteristic peaks substantially as shown in figure 14 (figure 14).

Embodiment U a salt according to embodiment [ N ] above or according to other embodiments of the invention, said salt having form LC.

Embodiment V a salt according to embodiment [ U ] above or according to other embodiments of the invention, wherein form LC has a characteristic XRPD peak expressed in 2 Θ selected from 12.2 ° ± 0.2 °, 16.5 ° ± 0.2 ° and 24.8 ° ± 0.2 °.

[ embodiment W ] salts according to the above embodiments [ U ] or [ V ] or according to other embodiments of the invention, wherein form LC has an XRPD pattern with characteristic peaks substantially as shown in figure 16 (figure 16).

[ embodiment X ] the salt according to the above embodiment [ A ] or [ B ] or according to other embodiments of the present invention, wherein the salt is (R) -1- (8-fluoroisochroman-1-yl) -N-methylmethanamine D-tartrate (Compound 1D-tartrate).

Embodiment Y a salt according to embodiment [ X ] above or according to other embodiments of the invention, wherein compound 1 d-tartrate is crystalline.

Embodiment Z the salt according to embodiment Y above or according to other embodiments of the invention wherein the salt has a characteristic XRPD peak expressed in 2 Θ selected from 11.9 ° ± 0.2 °, 16.9 ° ± 0.2 ° and 17.9 ° ± 0.2 °.

Embodiment AA the salt according to embodiments [ Y ] or [ Z ] above or according to other embodiments of the invention, wherein the salt has an XRPD pattern of characteristic peaks substantially as shown in figure 20 (figure 20).

[ embodiment AB ] the salt according to the above embodiment [ A ] or [ B ] or according to other embodiments of the present invention, wherein the salt is (R) -1- (8-fluoroisochroman-1-yl) -N-methylmethanemethanemetic fumarate (Compound 1, L-fumarate).

Embodiment AC a salt according to the above embodiment [ AB ] or according to other embodiments of the invention, wherein compound 1 fumarate salt is crystalline.

Embodiment AD the salt according to the above embodiment [ AC ] or according to other embodiments of the invention has the form FA.

Embodiment AE according to the above embodiment AD or according to other embodiments of the invention, wherein form FA has a characteristic XRPD peak expressed in 2 θ selected from 7.7 ° ± 0.2 °, 14.2 ° ± 0.2 ° and 15.2 ° ± 0.2 °.

[ embodiment AF ] a salt according to any of the above embodiments [ AD ] or [ AE ] or according to other embodiments of the invention, wherein form FA has an XRPD pattern with characteristic peaks substantially as shown in figure 22 (figure 22).

[ embodiment AG ] a salt according to the above embodiment [ AC ] or according to other embodiments of the invention, said salt having form FB.

Embodiment AH a salt according to the above embodiment AG or according to other embodiments of the invention wherein form FB has a characteristic XRPD peak expressed in 2 Θ selected from 6.7 ° ± 0.2 °, 13.8 ° ± 0.2 ° and 20.2 ° ± 0.2 °.

Embodiment AI a salt according to embodiments [ AG ] or [ AH ] above or according to other embodiments of the invention, wherein form FB has an XRPD pattern with characteristic peaks substantially as shown in figure 26 (figure 26).

Embodiment AJ the salt according to the above embodiment [ a ] or [ B ] or according to other embodiments of the invention, wherein the salt is (R) -1- (8-fluoroisochroman-1-yl) -N-methylmethaneme-lamine citrate (compound 1 citrate).

Embodiment AK the salt according to embodiment [ AJ ] above or according to other embodiments of the present invention, wherein compound 1 citrate is crystalline.

Embodiment AL according to the above embodiment [ AK ] or according to other embodiments of the invention, wherein said salt has a characteristic XRPD peak, expressed in 2 Θ, selected from 6.5 ° ± 0.2 °, 15.5 ° ± 0.2 ° and 20.4 ° ± 0.2 °.

Embodiment AM a salt according to any one of the above embodiments [ AK ] or [ AL ] or according to other embodiments of the invention, wherein the salt has an XRPD pattern with characteristic peaks substantially as shown in figure 30 (figure 30).

[ embodiment AN ] the salt according to the above embodiment [ A ] or [ B ] or according to other embodiments of the present invention, wherein the salt is (R) -1- (8-fluoroisochroman-1-yl) -N-methylmethanemethanemeccinate (Compound 1 succinate).

Embodiment AO a salt according to the above embodiment [ AN ] or according to other embodiments of the invention, wherein compound 1 succinate salt is crystalline.

Embodiment AP a salt according to the above embodiment [ AO ] or according to other embodiments of the invention, wherein the salt has a characteristic XRPD peak, expressed in 2 Θ, selected from 6.6 ° ± 0.2 °, 12.8 ° ± 0.2 ° and 13.9 ° ± 0.2 °.

[ embodiment AQ ] a salt according to the above embodiment [ AO ] or [ AP ] or according to other embodiments of the invention, wherein the salt has an XRPD pattern with characteristic peaks substantially as shown in figure 34 (figure 34).

[ embodiment AR ] the salt according to the above embodiment [ A ] or [ B ] or according to other embodiments of the present invention, wherein the salt is (R) -1- (8-fluoroisochroman-1-yl) -N-methylmethanemethylamine glutarate (Compound 1 glutarate).

Embodiment AS a salt according to the above embodiment [ AR ] or according to other embodiments of the invention, wherein compound 1 glutarate salt is crystalline.

Embodiment AT the salt according to the above embodiment [ AS ] or according to other embodiments of the invention, wherein the salt has a characteristic XRPD peak, expressed in 2 Θ, selected from 9.1 ° ± 0.2 °, 10.6 ° ± 0.2 ° and 18.2 ° ± 0.2 °.

[ embodiment AU ] A salt according to the above embodiment [ AS ] or [ AT ] or according to other embodiments of the invention, wherein the salt has an XRPD pattern with characteristic peaks substantially AS shown in figure 38 (figure 38).

[ embodiment AV ] the salt according to the above embodiment [ A ] or [ B ] or according to other embodiments of the present invention, wherein the salt is (R) -1- (8-fluoroisochroman-1-yl) -N-methylmethanamine levomalate (Compound 1 levomalate).

Embodiment AW a salt according to the above embodiment AV or according to other embodiments of the invention, wherein compound 1 l-malate salt is crystalline.

Embodiment AX the salt according to the above embodiment [ AW ] or according to other embodiments of the invention, wherein the salt has a characteristic XRPD peak expressed in 2 Θ selected from 13.5 ° ± 0.2 °, 18.8 ° ± 0.2 ° and 25.2 ° ± 0.2 °.

[ embodiment AY ] a salt according to the above embodiment [ AW ] or [ AX ] or according to other embodiments of the invention, wherein the salt has an XRPD pattern of characteristic peaks substantially as shown in figure 40 (figure 40).

[ embodiment AZ ] A salt according to the above embodiment [ A ] or [ B ] or according to other embodiments of the invention, wherein the salt is (R) -1- (8-fluoroisochroman-1-yl) -N-methylmethanemethanemethanemethanemethanesulfonate (Compound 1 besylate).

Embodiment BA a salt according to the above embodiment [ AZ ] or according to other embodiments of the present invention wherein compound 1 benzenesulfonate is crystalline.

Embodiment BB a salt according to the above embodiment [ BA ] or according to other embodiments of the invention, wherein the salt has a characteristic XRPD peak, expressed in 2 Θ, selected from 6.0 ° ± 0.2 °, 12.0 ° ± 0.2 ° and 24.1 ° ± 0.2 °.

Embodiment BC a salt according to the above embodiment [ BA ] or [ BB ] or according to other embodiments of the invention, wherein the salt has an XRPD pattern with characteristic peaks substantially as shown in figure 44 (figure 44).

Embodiment BD the salt according to embodiment [ a ] above or according to other embodiments of the present invention, wherein the salt is (R) -1- (8-fluoroisochroman-1-yl) -N-methylmethanemethylamine p-toluenesulfonate (compound 1 p-toluenesulfonate).

[ embodiment BE ] A salt which is:

(R) -1- (8-fluoroisochroman-1-yl) -N-methyl methylamine hydrochloride (compound 1 hydrochloride); or a hydrate or solvate thereof, wherein the salt is crystalline and HAs form HA or form HB.

Embodiment BF the salt according to the above embodiment [ BE ] or according to other embodiments of the invention HAs the form HA.

Embodiment BG a salt according to the above embodiment [ BF ] or according to other embodiments of the invention, wherein form HA HAs a characteristic XRPD peak, expressed in 2 Θ, selected from 9.4 ° ± 0.2 °, 11.4 ± 0.2 ° and 15.1 ° ± 0.2 °.

Embodiment BH a salt according to the above embodiment [ BF ] or according to other embodiments of the invention in which form HA HAs characteristic XRPD peaks expressed in 2 θ selected from 9.4 ° ± 0.2 °, 11.4 ± 0.2 °, 15.1 ° ± 0.2 °, 17.2 ° ± 0.2 ° and 17.6 ° ± 0.2 °.

Embodiment BI a salt according to the above embodiment [ BF ] or according to other embodiments of the invention, wherein form HA HAs at least one characteristic XRPD peak, expressed in 2 Θ, selected from 9.4 ° ± 0.2 °, 11.4 ° ± 0.2 °, 14.2 ° ± 0.2 °, 15.1 ° ± 0.2 °, 17.2 ° ± 0.2 °, 17.6 ° ± 0.2 ° and 27.0 ° ± 0.2 °.

Embodiment BJ a salt according to the above embodiment [ BF ], or according to other embodiments of the invention, wherein form HA HAs at least two characteristic XRPD peaks, expressed in 2 Θ, selected from 9.4 ° ± 0.2 °, 11.4 ° ± 0.2 °, 14.2 ° ± 0.2 °, 15.1 ° ± 0.2 °, 17.2 ° ± 0.2 °, 17.6 ° ± 0.2 ° and 27.0 ° ± 0.2 °.

Embodiment BK the salt according to the above embodiment [ BF ] or according to other embodiments of the invention, wherein form HA HAs at least three characteristic XRPD peaks, expressed in 2 Θ, selected from 9.4 ° ± 0.2 °, 11.4 ° ± 0.2 °, 14.2 ° ± 0.2 °, 15.1 ° ± 0.2 °, 17.2 ° ± 0.2 °, 17.6 ° ± 0.2 ° and 27.0 ° ± 0.2 °.

[ embodiment BL ] a salt according to any one of the above embodiments [ BE ] to [ BK ] or according to other embodiments of the invention, wherein form HA HAs an XRPD pattern with characteristic peaks substantially as shown in figure 1 (figure 1).

Embodiment BM the salt according to any one of embodiments [ BE ] to [ BL ] above or according to other embodiments of the invention wherein form HA HAs endothermic peaks at temperatures of about 99 ℃ and about 187 ℃.

Embodiment BN a salt according to any one of the above embodiments [ BE ] to [ BM ] or according to other embodiments of the invention, wherein form HA HAs a DSC thermogram substantially as depicted in figure 2 (figure 2).

[ embodiment BO ] a salt according to any one of the above embodiments [ BE ] to [ BN ], or according to other embodiments of the invention, wherein form HA HAs a DVS isotherm substantially as depicted in FIG. 4 (FIG. 4).

Embodiment BP the salt according to embodiment [ BE ] above or according to other embodiments of the invention, which salt has form HB.

Embodiment BQ the salt according to embodiment [ BP ] above or according to other embodiments of the invention, wherein form HB has a characteristic XRPD peak, expressed in 2 Θ, selected from 8.6 ° ± 0.2 °, 9.6 ° ± 0.2 ° and 10.3 ° ± 0.2 °.

Embodiment BR a salt according to the above embodiment [ BP ] or according to other embodiments of the invention, wherein form HB has characteristic XRPD peaks expressed in 2 θ selected from 8.6 ° ± 0.2 °, 9.6 ° ± 0.2 °, 10.3 ° ± 0.2 ° and 17.3 ° ± 0.2 °.

Embodiment BS a salt according to the above embodiment [ BP ] or according to other embodiments of the invention, wherein form HB has at least one characteristic XRPD peak, expressed in 2 Θ, selected from 8.6 ° ± 0.2 °, 9.6 ° ± 0.2 °, 10.3 ° ± 0.2 °, 12.6 ° ± 0.2 °, 14.7 ° ± 0.2 °, 17.3 ° ± 0.2 ° and 23.8 ° ± 0.2 °.

Embodiment BT a salt according to the above embodiment [ BP ] or according to other embodiments of the invention, wherein form HB has at least two characteristic XRPD peaks, expressed in 2 Θ, selected from 8.6 ° ± 0.2 °, 9.6 ° ± 0.2 °, 10.3 ° ± 0.2 °, 12.6 ° ± 0.2 °, 14.7 ° ± 0.2 °, 17.3 ° ± 0.2 ° and 23.8 ° ± 0.2 °.

Embodiment BU a salt according to the above embodiment [ BP ] or according to other embodiments of the invention, wherein form HB has at least three characteristic XRPD peaks, expressed in 2 Θ, selected from 8.6 ° ± 0.2 °, 9.6 ° ± 0.2 °, 10.3 ° ± 0.2 °, 12.6 ° ± 0.2 °, 14.7 ° ± 0.2 °, 17.3 ° ± 0.2 ° and 23.8 ° ± 0.2 °.

Embodiment BV a salt according to any one of the above embodiments [ BP ] to [ BU ], or according to other embodiments of the invention, wherein form HB has an XRPD pattern with characteristic peaks substantially as shown in figure 5 (figure 5).

Embodiment BW a pharmaceutical composition comprising a salt according to any one of the above embodiments [ a ] to [ BV ] or according to other embodiments of the invention and a pharmaceutically acceptable excipient.

[ embodiment BX ] a method for treating a neurological or psychiatric disease or disorder in a subject in need thereof, the method comprising administering to the subject an effective amount of a salt according to any one of the above embodiments [ a ] to [ BV ], or a pharmaceutical composition according to the above [ embodiment BW ] or according to other embodiments of the invention.

[ embodiment BY ] the method according to the above embodiment [ BX ] or according to other embodiments of the invention, wherein the neurological or psychiatric disease or disorder is depression, bipolar disorder, pain, schizophrenia or other psychiatric disorder, obsessive-compulsive disorder, addiction, social disorders, attention deficit hyperactivity disorder, anxiety disorders, movement disorders, epilepsy, autism, or cognitive diseases or disorders.

Embodiment BZ the method according to the above embodiment [ BX ] or according to other embodiments of the invention, wherein the neurological or psychiatric disease or disorder is depression.

Embodiment CA the method according to the above embodiment [ BZ ] or according to other embodiments of the invention, wherein the depression is Treatment Resistant Depression (TRD), Major Depressive Disorder (MDD), unipolar depression, bipolar depression, or depression associated with another disease or disorder.

Embodiment CB the method according to the above embodiment BX or according to other embodiments of the invention, wherein the neurological disease or disorder is selected from alzheimer's disease and parkinson's disease.

[ embodiment CC ] the method according to the above embodiment [ CB ] or according to a further embodiment of the invention, wherein said Alzheimer's disease is Alzheimer's disease with a challenge, a challenge of Alzheimer's disease or Alzheimer's disease with a challenge of a challenge.

[ embodiment CD ] A method of treating a subject in need thereof, the method comprising administering to the subject an effective amount of a salt according to any one of the above embodiments [ A ] to [ BV ], or a pharmaceutical composition according to the above [ embodiment BW ] or according to other embodiments of the invention.

[ embodiment CE ] A method of treating a surge associated with a neurological or psychiatric disease or disorder in a subject in need thereof, the method comprising administering to the subject an effective amount of a salt according to any one of the above embodiments [ A ] to [ BV ], or a pharmaceutical composition according to the above [ embodiment BW ] or according to other embodiments of the invention.

[ embodiment CF ] A process for preparing (R) -1- (8-fluoroisochroman-1-yl) -N-methylmethanamine phosphate (Compound 1 phosphate) having the following structure:

compound 1 phosphate the method comprises reacting (R) -1- (8-fluoroisochroman-1-yl) -N-methylmethanamine (compound 1) having the structure:

compound 1

With phosphoric acid.

Embodiment CG the process according to the above embodiment CF or according to other embodiments of the invention wherein the phosphoric acid is an aqueous solution of phosphoric acid.

Embodiment CH the process according to the above embodiment CF or according to other embodiments of the invention wherein the aqueous solution of phosphoric acid is about 80 to about 95% by weight aqueous solution of phosphoric acid.

Embodiment CI the process according to the above embodiment [ CF ] or according to other embodiments of the present invention, wherein the aqueous solution of phosphoric acid is an aqueous solution of about 87% by weight of phosphoric acid.

Embodiment CJ the process according to any one of the above embodiments [ CF ] to [ CI ] or according to other embodiments of the invention wherein the reaction of compound 1 with phosphoric acid is carried out in the presence of S1a wherein S1a is a solvent.

Embodiment CK the process according to the above embodiment [ CJ ] or according to other embodiments of the invention wherein S1a is a mixture of acetonitrile and water.

Embodiment CL the process according to the above embodiment [ CJ ] or according to other embodiments of the invention wherein S1a is a mixture of acetone and water.

Embodiment CM the process according to the above embodiment [ CJ ] or according to other embodiments of the invention wherein S1a is a polar aprotic solvent, water or a mixture thereof.

Embodiment CN the process according to any one of the above embodiments [ CF ] to [ CM ] or according to other embodiments of the invention wherein between about 1 and about 5 molar equivalents of phosphoric acid are used per molar equivalent of compound 1.

[ embodiment CO ] the process according to any one of the above embodiments [ CF ] to [ CN ] or according to other embodiments of the invention, wherein compound 1 is prepared by a process comprising reacting (R) -1- (8-fluoroisochroman-1-yl) -N-methylmethanamine dibenzoyl-levotartrate (compound 1 dibenzoyl-levotartrate) having the structure:

Compound 1 dibenzoyl-l-tartrate is reacted with B1, wherein B1 is a base.

[ embodiment CP ] A process for preparing (R) -1- (8-fluoroisochroman-1-yl) -N-methylmethanamine (Compound 1) comprising reacting (R) -1- (8-fluoroisochroman-1-yl) -N-methylmethanamine dibenzoyl-levotartrate (Compound 1 dibenzoyl-levotartrate) having the structure:

compound 1 dibenzoyl-l-tartrate is reacted with B1, wherein B1 is a base.

Embodiment CQ the method according to the above embodiment [ CO ] or [ CP ] or according to other embodiments of the invention wherein B1 is an alkali metal hydroxide base.

Embodiment CR the process according to the above embodiment [ CO ] or [ CP ] or according to other embodiments of the invention wherein B1 is potassium hydroxide.

Embodiment CS the method according to the above embodiment [ CO ] or [ CP ] or according to other embodiments of the invention, wherein B1 is an aqueous solution of potassium hydroxide.

Embodiment CT the method according to the above embodiment CS or according to other embodiments of the present invention, wherein the aqueous solution of potassium hydroxide is an aqueous solution of potassium hydroxide of about 10% to about 20% by weight.

Embodiment CU the process according to the above embodiment [ CS ] or according to other embodiments of the present invention, wherein the aqueous solution of potassium hydroxide is about 14% by weight aqueous potassium hydroxide solution.

Embodiment CV the process according to any one of the above embodiments [ CO ] to [ CU ], or according to other embodiments of the invention, wherein the reaction of compound 1 dibenzoyl-l-tartrate with the base is carried out in the presence of S2, wherein S2 is a solvent.

Embodiment CW the method according to the above embodiment [ CV ] or according to other embodiments of the invention, wherein S2 is a polar aprotic solvent.

Embodiment CX the process according to any one of the above embodiments [ CO ] to [ CW ] or according to other embodiments of the present invention, wherein about 0.5 and about 5 molar equivalents of B1 are used per molar equivalent of the compound 1 dibenzoyl-l-tartrate.

Embodiment CY the process according to any one of the above embodiments [ CO ] to [ CX ] or according to other embodiments of the present invention wherein the reaction of compound 1 dibenzoyl-l-tartrate with B1 is further carried out in the presence of sodium chloride.

Embodiment CZ the process according to any one of the above embodiments [ CO ] to [ CY ] or according to other embodiments of the invention, wherein about 1 to about 10 molar equivalents of sodium chloride are used per molar equivalent of the compound 1 dibenzoyl-l-tartrate.

[ embodiment DA ] A process for the preparation of (R) -1- (8-fluoroisochroman-1-yl) -N-methylmethanamine dibenzoyl-levotartrate (compound 1 dibenzoyl-levotartrate) which comprises reacting 1- (8-fluoroisochroman-1-yl) -N-methylmethanamine (racemic compound 1) having the structure:

the racemic compound 1 is a mixture of the compounds,

with dibenzoyl-levotartaric acid in the presence of S3, wherein S3 is a solvent.

Embodiment DB the process according to the above embodiment [ DA ] or according to other embodiments of the invention wherein S3 is a polar protic solvent.

Embodiment DC the process according to the above embodiment [ DA ] or according to other embodiments of the present invention, wherein S3 is a mixture of methanol and water.

Embodiment DD the process according to any one of the above embodiments [ DA ] to [ DC ] or according to other embodiments of the invention wherein about 1 to about 5 molar equivalents of dibenzoyl-levotartaric acid are used per molar equivalent of racemic compound 1.

Embodiment DE the process according to any one of the above embodiments [ DA ] to [ DD ] or according to other embodiments of the invention further comprises precipitating compound 1 dibenzoyl-levotartrate from a mixture comprising racemic compound 1, dibenzoyl-levotartaric acid and S3.

[ embodiment DF ] the method according to any one of the above embodiments [ DA ] to [ DE ] or according to other embodiments of the invention, further comprising isolating the compound 1 dibenzoyl-l-tartrate salt from S3a, wherein S3a is a solvent.

Embodiment DG the process according to the above embodiment [ DF ] or according to other embodiments of the present invention, wherein S3a is methanol.

[ embodiment DH ] A process according to any one of the above embodiments [ DA ] to [ DG ] or according to other embodiments of the invention, wherein 1- (8-fluoroisochroman-1-yl) -N-methylmethanamine (racemic compound 1) is prepared by a process comprising reacting a compound of formula II having the structure:

or a salt thereof, wherein X is halogen, in the presence of a metal catalyst.

[ embodiment DI ] A process according to the above embodiment [ DH ] or according to other embodiments of the invention, wherein the compound of formula II is 1- (5-bromo-8-fluoroisochroman-1-yl) -N-methylmethanamine triflate (compound 2) having the structure:

compound 2.

Embodiment DJ the process according to the above embodiment [ DH ] or [ DI ] or according to other embodiments of the invention, wherein the metal catalyst is palladium on activated carbon.

Embodiment DK a process according to any one of the above embodiments [ DH ] to [ DJ ] or according to a further embodiment of the invention, wherein the hydrogenation of the compound of formula II is carried out under a hydrogen pressure of about 2 to about 10 bar.

Embodiment DL the process according to any one of the above embodiments [ DH ] to [ DK ] or according to other embodiments of the invention, wherein the hydrogenation of the compound of formula II is carried out under a hydrogen pressure of about 5 bar.

Embodiment DM the process according to any one of the above embodiments [ DH ] to [ DL ] or according to further embodiments of the invention, wherein the hydrogenation of the compound of formula II is carried out in the presence of S4, wherein S4 is a solvent.

Embodiment DN the process according to embodiment [ DM ] above or according to other embodiments of the invention wherein S4 is a polar protic solvent.

[ embodiment DO ] A process according to any one of the above embodiments [ DH ] to [ DN ] or according to other embodiments of the invention wherein the hydrogenation of the compound of formula II is carried out in the presence of B2 wherein B2 is a solvent.

Embodiment DP the process according to the above embodiment [ DO ] or according to other embodiments of the invention wherein B2 is a carbonate base.

Embodiment DQ the method according to the above embodiment [ DO ] or according to other embodiments of the invention wherein B2 is potassium carbonate.

Embodiment DR the method according to the above embodiment [ DO ] or according to other embodiments of the invention, wherein B2 is an aqueous solution of potassium carbonate.

Embodiment DS a process according to any one of the above embodiments [ DH ] to [ DR ], or according to a further embodiment of the invention, wherein a compound of formula II is prepared by: reacting a compound of formula III having the structure:

or a salt thereof, wherein X is halogen,

with N-methylaminoacetaldehyde dimethylacetal (Compound 4) having the structure:

compound 4

In the presence of a1, wherein a1 is an acid.

[ embodiment DT ] the process according to the above embodiment [ DS ] or according to other embodiments of the invention wherein the compound of formula III is 2- (2-bromo-5-fluorophenyl) ethan-1-ol (Compound 3) having the following structure:

compound 3.

Embodiment DU the process according to the above embodiment [ DS ] or [ DT ] or according to other embodiments of the invention wherein a1 is trifluoromethanesulfonic acid.

[ embodiment DV ] the process according to any one of the above embodiments [ DS ] to [ DU ], or according to other embodiments of the invention, wherein the reaction of the compound of formula III and compound 4 is carried out in the presence of S5, wherein S5 is a solvent.

Embodiment DW the process according to embodiment [ DV ] above or according to other embodiments of the invention wherein S5 is a halogenated solvent.

Embodiment DX the process according to any one of embodiments [ DS ] to [ DW ] above or according to other embodiments of the invention, wherein about 1.2 molar equivalents of compound 4 are used per molar equivalent of the compound of formula III.

[ embodiment DY ] Compound 1 phosphate prepared by the method according to any one of the above embodiments [ CF ] through [ CO ] or according to other embodiments of the invention, wherein Compound 1 phosphate is crystalline.

Various modifications of the invention in addition to those described herein will be apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims. Each reference, including all patents, patent applications, and publications, cited in this application is hereby incorporated by reference in its entirety.